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1INTRODUCTION
Electroconvulsive therapy offers exciting subject matters 
for the human brain, clinicians and scientists
8 | Chapter 1
“Het was alsof ze feestvierde op den bodem van een diepen put,  
waaruit nooit iemand verlost werd. Soms dacht zij, dat dit op de hel leek,  
waar de verdoemden het laatste oordeel afwachten en zich verdooven door 
feestgedruisch in kunstlicht, daar Gods zon hun niet meer gegund is.”
Frederik	van	Eeden,	Van	de	koele	meren	des	doods,	1900.
“It was as if they were celebrating at the bottom of a deep well,  
from which no person would ever be redeemed.  
Sometimes she thought that this resembled hell,  
where the doomed await their final verdict and benumb themselves by feasting  
in artificial light, as they are no longer blessed with God’s sun.”
Frederik	van	Eeden,	The	Cool	Lakes	of	Death,	1900.
_____
“Depressie gaat nergens over; het is een lege archiefkast.  
Ik heb eindeloos gezocht naar een oorzaak van mijn somberheid,  
maar ik kom er gewoon niet achter.”
Mike	Boddé,	Pil,	2010.
“Depression deals with nothing; it is an empty filing cabinet.  
I have searched endlessly for a cause of my sorrow,  
but I just can’t understand it.” 
Mike	Boddé,	Pill,	2010.
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The suffering of depressed patients is enormous. It also poses an important burden 
on their significant others and on society as a whole. Clinicians are therefore being 
urged to relieve these conditions as soon as possible. To that purpose, effective 
psychotherapeutic, psychopharmacologic and other biological interventions, such 
as electroconvulsive therapy (ECT), are available. Observing a quick response to a 
course of ECT in a psychotic depressed patient is astonishing. ECT may restore the 
patient’s normal mood, but at the same time may provoke anxiety and a sense of 
shame or stigmatization. Frequently, ECT is accompanied by more or less impairing 
cognitive side effects. 
For clinicians and scientists, ECT is fascinating and raises many research questions 
concerning the effects of this treatment on the functioning of the brain. This 
thesis reports on our daily practice in which we treat severely ill depressed 
patients, while simultaneously doing clinical research. To further improve the 
understanding and the effectiveness of ECT, the electrical dose, which elicits the 
seizure activity (defined as seizure threshold [ST]), is the subject of this thesis.
1. Clinical aspects of ECT
1.1 Indications for and use of ECT in the Netherlands
In the Netherlands, the use of ECT is limited, functioning mostly as the ‘treat-
ment-of-last-resort’ for severely ill patients suffering from (psychotic and/or phar-
macotherapy resistant) depression, mania, intractable psychosis, catatonia, 
neuroleptic malignant syndrome, or delirium.1,2 Worldwide, it has been estimated 
that approximately 1 million patients receive ECT each year.3 As the incidence of 
major depressive disorder with psychotic features (an important indication for 
ECT) is about 4 in 1,000 individuals in the general population,4 an incidence rate 
of about 64,000 patients might be expected in the Netherlands annually. This 
number contrasts greatly with the actual amount: in 1999 only 328 Dutch patients 
received ECT.5 Nevertheless, ECT is a very effective biological treatment. Bilateral 
(BL) ECT is moderately more effective than right unilateral (RUL) ECT and high 
dosed ECT more effective than low dosed.6 In adults with a major depressive 
disorder, ECT is probably more effective than pharmacotherapy.6 It is also possible 
that certain depressed patients such as psychotic, catatonic, suicidal or otherwise 
life threatened patients may benefit even more from ECT than others.1 
In the Netherlands, it is mostly general and university hospitals that provide ECT. 
The procedure follows the clinical guidelines of the Netherlands Association of 
Psychiatry (‘NVvP’) on the practice of ECT.7,8 In 2010, references in the Dutch 
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national register for treatments (‘Diagnose-Behandelcombinatie Informatie 
Systeem’) revealed that ECT courses were given with a median of 9 sessions 
(interquartile range 4-15 sessions). The majority - female patients (75%) with an 
average age of 58 ± 15 years - were treated because of recurrent mood disorders 
(85%), often with psychotic features (33%).9 Although most psychiatric patients are 
diagnosed and treated for their psychiatric illnesses in facilities for mental health 
care (‘GGZ-instellingen’), only a minority of these institutions offer ECT. The 
annual use of ECT in the Netherlands had increased substantially from 1.8 per 
10,000 inhabitants in 19995 to 8.5 per 10,000 inhabitants in 2008.8 However, this 
rate is still low compared with the 14 treatments per 10,000 inhabitants in 
Scotland10 and the approximately 27 per 10,000 inhabitants in the USA.3 
1.2 Clinical practice of ECT
To be effective, ECT must induce generalized seizure activity in the brain of the 
patient by overcoming the ST.11 Effectiveness of ECT not only depends on the 
administered electrical stimulus and the induced seizure, but is also related to 
electrode placement, level of seizure generalization and the extent to which the ST 
is exceeded.1 Seizures are elicited by an electrical stimulus that is administered 
between two electrodes placed at the outside of the patient’s head. In the 
Netherlands, ECT is usually given twice a week,8 and takes place under general 
anesthesia in order to prevent awareness and distress. The patient also receives a 
muscle relaxant to prevent complications such as injuries and fractures.1,7 
Generalized seizure activity occurs only when the electrical stimulus is strong 
enough to exceed a critical threshold (i.e., the ST).12 The ST has several definitions 
in the literature. Normally, the smallest electrical stimulus dose that is necessary 
to produce a generalized seizure of at least 25-30 seconds on electroencephalo-
gram (EEG)1,13 is defined as the initial seizure threshold (IST). This definition seems 
arbitrary, however. Whether there are associations between the level of the ST and 
seizure duration on the one hand and the clinical effectiveness of ECT on the other 
hand is still a matter of debate. Moreover, experimental data to support the 
universally recommended 25-30 second minimum duration on EEG to define ST is 
lacking.1,14 Although not studied extensively, for decades it has been clinically 
known that the level of IST varies substantially among patients.14 Besides the 
anesthetic used, several other factors were described to affect the level of IST 
including gender,15 age,15,16 previous ECT treatment and concomitant medication 
use.1,17 Additionally, ST seems to increase during the course of ECT, at least in some 
patients.15,18 Recently however, this finding was not confirmed in BL ECT.19 
Underlying mechanisms explaining the initial ST level and its possible increase 
are hypothetical and need further study.
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1.3 Optimal exceeding of the ST 
For the individual patient, knowledge of the IST level seems crucial for estimating 
the proper electrical dose.20,21 It is well-known that in RUL ECT the electrical dose 
should exceed the IST substantially (e.g., 6-12 times) to be as effective as BL ECT, 
with the advantage that RUL ECT results in fewer cognitive adverse effects than BL 
ECT.22 Among ECT practitioners however, controversy exists about the optimal 
suprathreshold electrical stimulus dose and its proper determination.14,23 
Furthermore, it has been reported that the extent of the electrical dose above the 
individual IST, rather than the absolute electrical dose, was associated with 
short-term cognitive adverse effects.20 Conversely, attempting to administer the 
lowest possible dose bears the risk of a subconvulsive stimulus and consequently of 
severe bradycardia and asystole.24 
To decide on the proper electrical dose for a patient, the ‘empirical dose-titration 
method’ is used to calculate individualized stimulation above ST.25 This means 
that, under proper anesthesia and muscle relaxation, the brain is initially 
stimulated with a low electrical stimulus; if consequently no seizure of a certain 
duration occurs, re-stimulation of the brain follows according to the steps of a 
predefined titration protocol. Also, in clinical practice, ‘age-based’ methods are 
often used to estimate the electrical dose that exceeds the ST sufficiently,14,26 based 
on the assumption that increasing age raises the ST.2 Furthermore, a ‘fixed-high 
dose’ strategy has been described in which a high dose (i.e., 400 milliCoulombs) is 
always administered regardless of other factors. This procedure may probably lead 
to overdosing in a substantial number of patients and a higher rate of cognitive 
adverse effects.1 
In the literature, discussion exists about the accuracy of determining the IST using 
titration protocols.27 It was suggested that only one single pulse of electrical 
current can decrease the ST, which may lead to underestimation of the IST with 
each additional stimulus administered during the titration procedure itself.28 
Also, most titration protocols vary regarding the used pulse widths, charge rates 
and increments of stimulus dosage causing internal inconsistency of the titration 
methods.27 Therefore, studying the various factors that may determine the 
individual ST and its relation to the effectiveness and adverse effects of ECT in 
more detail is warranted. 
Before focusing on the possible determinants of the ST, some understanding of the 
basic mechanisms of normal brain functioning, as described below, is helpful. 
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2. Normal human brain functioning
2.1 Communication systems and signaling in the brain
Most of the human brain’s functions are based on the coordinated electrical and 
chemical interactions of large numbers of neurons that are distributed within and 
across different specialized brain areas (neuronal networks).29 Ordinarily, using 
their sodium-potassium exchange pump, neurons generate a negative resting 
membrane potential and employ several different types of electrical signals to 
encode and transfer information. Neurons have cell bodies (‘the soma’) with 
dendrites and an axon (see Figure 1). Neuronal membranes may become more 
depolarized (becoming less negatively charged) by the influx of positively charged 
sodium ions. This depolarization occurs locally and propagates. Consequently, 
excitation of the membrane spreads from dendrites (input zone of the neuron), 
through the membrane of the cell body, towards the axon hillox. If at the hillox a 
critical threshold of sufficient depolarization has been reached, an action 
potential, following an ‘all-or-none’ excitatory process, is sent down the axon 
(conducting zone) and passed on to the dendrites of other neurons or end organs 
(output zone). All together, around 100 billion neurons communicate with each 
other through electrical and chemical signals.
When the action potential reaches the terminals of the neurons, calcium channels 
are opened leading to the release of neurotransmitters from the presynaptic 
neuron into the synaptic cleft (chemical synapse). These neurotransmitters (such 
as the excitatory glutamate or inhibitory gamma-aminobutyric acid [GABA]) attach 
to receptors at the dendrites of postsynaptic neurons. This causes the opening of 
sodium and other channels, which results in either continued depolarization of 
these dendrites or termination of the signal. As a result, the chemical signals may 
be excitatory (leading to depolarization of receiving neurons) or inhibitory (leading 
to hyperpolarization). Besides this chemical synaptic signaling, gap junctions 
(places of intimate contact between neurons) serve as electrical synapses passing 
through the current directly between neurons.30 This direct electrical signaling 
is extraordinarily fast and such synapses may interconnect many neurons, 
facilitating synchronization among populations of neurons. 
Glia cells, known as ‘white matter’ (astrocytes, microglia cells, oligodendrocytes), 
which surround the neuronal axons, seem to be particularly important in 
maintaining electrical and chemical balance as well as setting the general tone of 
excitability in the brain.31 Glia cells can release or absorb glutamate and therefore 
excite or depress neurons.31 Glia cells cannot generate electrical impulses 
themselves and seem to communicate with each other through calcium signaling. 
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Glia cells do sense, affect and respond to changes in voltage as they absorb 
potassium ions released by neurons, drain these ions away into the bloodstream, 
and maintain proper potassium concentrations outside the neurons. These 
processes also lead to electrical charging and discharging throughout the brain. 
All together, very efficient and huge communication systems within the brain 
exist, which are disrupted when a patient has a seizure. Knowledge about the 
generation of seizure activity, its spreading through the brain and its termination 
is important for our understanding of how ECT may work.
2.2 Network dynamics in the brain
In seizure activity, as provoked by ECT, the normal network dynamics of the brain 
are disturbed. Normal activity of large populations of neurons, working together 
in huge neuronal networks, is essential for optimal brain functioning. Even in the 
Figure 1   The neuron consists of a cell body with nucleus (soma), dendrites and 
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absence of environmental and body-derived stimuli (resting state), the brain is 
perpetually active. In the human brain, most of the 100 billion (1011) neurons are 
connected locally and approximately 100-200 million axons serve to interconnect 
symmetric and asymmetric neuronal groups in the two hemispheres, forming the 
corpus callosum and the somewhat larger numbers of long-range fibers connect 
areas within the same hemispheres.32 Because of this tremendous connectivity 
and in order to generate a harmonious interplay between cortical circuits, 
excitation of neurons must be balanced with an equally effective inhibition so 
that neuronal homeostasis can be reached. Therefore, a stabilizing internal 
negative feedback control system is needed.32,33 This neuronal homeostasis is often 
accomplished by oscillations, maintained by connected interneurons which use 
GABA-ergic neurotransmission and electrical gap junctions to stabilize the (local) 
networks.32,34 Phenomena of neural network destabilization during seizure 
occurrence and propagation, as well as the network stabilization mechanisms, are 
most likely important in ECT and may partly determine the ST.  
3. Technical aspects of ECT
3.1 Seizure generation and propagation
In the case of generalized seizure activity, overly large populations of neurons 
become excited simultaneously (known as synchronization) and are insufficiently 
compensated by inhibitory interneuron systems. As neurons are anatomically 
connected in neuronal networks (e.g., through cortico-cortical and cortico-thalamo- 
cortical feedback loops), during the process of synchronization, progressive 
recruitment (known as coupling) of different connected brain areas precedes 
complete system destabilization, clinically known as generalized seizure 
activity.33,35 Seizures then result from large neuronal firing in pathological 
synchrony superimposed on the background activity, which disrupts normal 
brain function.33,34,36,37 Seizure activity appears not only to be a neuronal process 
and glia cells also seem to play an important role.31 During seizure activity, glia 
cells may release glutamate and other substances which may intensify the 
excitability of neurons, like pouring fuel on a fire.31 Furthermore, glia cells may 
stimulate synapses connecting neurons into circuits by releasing growth factors 
in response to seizure activity.31 
Seizure activity does not spread diffusely throughout the brain, but propagates 
along specific anatomic pathways.38 For example, the hippocampus is often one of 
the first regions to exhibit seizure activity because of its apparently low ST, and 
basal ganglia circuits are suggested to control cortical excitability and to regulate 
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synchronization of neuronal discharge in widespread regions of the cortex.38 Cor-
tico-cortical seizure propagation between the frontal and parietal association 
cortex, with little effect on the intervening cortical regions, may occur through 
long association fiber pathways such as the superior longitudinal fasciculus.39 
It can be hypothesized that, on the one hand, the amount of neuronal and glial 
connections will (at least partly) determine whether or not seizure activity will 
propagate through certain parts of the brain. On the other hand, a certain amount 
of connections would contribute to negative feedback systems and inhibition of 
(locally induced) seizure activity. In ECT, eliciting widespread seizure activity by 
exceeding the ST is intended. Therefore, externally administered electrical stimuli 
must induce a critical amount of synchronization in both large and connected 
brain areas, and must also overcome the inhibitory feed-back systems. 
3.2 Seizure induction and termination in ECT
Traditionally, direct electrical depolarization of large groups of neurons by the 
flow of negatively charged electrons between two ECT electrodes has been 
described as the mechanism for seizure generation in ECT. Recently, it was 
proposed that electrical stimulus pulses pass through neuronal cell membranes 
and interact with the operation of the sodium-potassium exchange pump across it. 
Presumably, with each ECT stimulus pulse the intracellular sodium levels increase, 
leading to neuronal depolarization. As these depolarized neurons depolarize 
adjacent neurons, a wave of depolarization consequently sweeps through the 
brain, known as seizure activity.28,30 In ECT, the transition to a fully generalized 
seizure is associated with maintained depolarization of the membrane potential 
and repetitive generation of action potentials (resulting in the clinically visible 
muscle spasm known as the tonic phase), followed by a period of irregular periodic 
bursts of action potentials (resulting in the clinically visible muscle contractions 
known as the clonic phase). With the final phase, the seizure ends with a relatively 
quiet and hyperpolarized membrane potential corresponding to a period known 
as post-ictal suppression.36 These three phases can be identified on the EEG during 
ECT (Figure 2).
Passing through the scalp, skull, meninges and cerebrospinal fluid (CSF) space, 
electrical stimulation leads to a local sphere of depolarized neurons beneath the 
ECT electrodes, which increases in size with more electrical current. The pattern 
of propagation of activated neurons is likely to reflect the pattern in which axons 
project through the cortex, i.e., the cortico-(thalamo-)cortical networks.40 Old 
cadaver studies using intracranial probes estimated that only 10% of the electrical 
current applied to the head reaches the brain tissue. Furthermore, the current did 
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not concentrate in one area or pathway, although with BL electrode placement the 
voltage was higher in the frontal lobes. Also, the current traversed the gray matter 
(soma and dendrites of neurons) relatively freely, but in white matter (axons 
surrounded by glia cells) the current generally followed the direction of the axons, 
concentrating in structures such as the corpus callosum, and traversing both sides 
of the brain, even when one electrode was applied to the vertex and the other to 
the parietal region (in clinical practice: placement according to d’Elia).41,42 
Figure 2   Electroencephalographic registration of seizure activity during 
 electroconvulsive therapy
Tonic phase: recruitment of neurons, transition to full seizure activity 
Clonic phase: irregular periodic bursts of action potentials 
Post-ictal suppression phase: quiet and hyperpolarized membrane potentials  
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More recently, single-photon emission computed tomography (SPECT) showed that 
BL electrode placement focally and bilaterally activated the frontotemporal and 
parietal association cortex, without affecting other brain regions; whereas in RUL 
ECT the left frontotemporal region remained relatively unaffected.43 In another 
SPECT study, increase of cerebral blood flow at induction of the ECT seizure was 
shown near the electrodes as well as in some thalamic and basal ganglia regions. 
During the seizure, thirty seconds later an increase of blood flow occurred mainly 
in the parietal and occipital lobes. These phenomena were suggested to reflect 
seizure propagation through cortico-cortical (between the frontal and parietal 
association cortex) and cortico-thalamo-cortical (descending connections from 
frontal cortex to thalamus) networks.39 
After seizure induction and propagation, ECT or the seizure itself activates mechanisms 
to terminate seizure activity and to create a period of post-ictal suppression. Seizure 
termination is unlikely to be caused by neuronal exhaustion or lack of metabolic 
substrate, but is probably the result of enhancement of the GABA-ergic neurotransmission 
during the ECT course.12 Ten minutes after one single ECT-session, a huge increase in 
serum GABA levels was shown, suggesting an acute inhibitory GABA-ergic response to 
ECT and/or seizure activity,44 although another small study found the opposite.45 Based 
on results from human and animal studies, in the literature, a “network inhibition 
hypothesis” for epilepsy was proposed. An increased cortical activity in one region 
might inhibit subcortical arousal systems, which might lead to widespread decreased 
cortical activity.46 In the post-ictal period, it was further observed that activity in the 
cerebellum continued to increase before returning to baseline. This might suggest 
inhibitory outputs from cerebellar Purkinje cells, influencing thalamico-cortical 
circuits that might contribute to seizure termination and/or post-ictal suppression in 
epilepsy,46 and possibly also in ECT. 
It is suggested that generalized and repeated seizures that terminate themselves 
and affect, in particular, prefrontal regions and thalamic structures, are essential 
for the efficacy of ECT.28 It is likely that the mechanisms through which seizures 
cure patients involve structural and functional changes at different levels of 
complexity in the human brain. A course of ECT may restore more balanced 
neuronal activity and may reorganize preexisting brain homeostasis.28 It is still a 
mystery as to which mechanisms are specifically responsible for the therapeutic 
effectiveness of ECT. For clinicians however, it is very important to apply an 
optimal beneficial electrical stimulus that will elicit a therapeutic and self-limiting 
seizure in the patient. In daily practice, there are some factors that have been 
supposed to obstruct optimal seizure induction, propagation and termination, 
and these determinants are subject to further studies.
18 | Chapter 1
4. Challenges for ECT
4.1 Obstacles in seizure induction
To reach the brain tissue effectively, the electrical stimulus must successively pass 
scalp tissue, skull, meninges, and cerebrospinal fluid (CSF), with each compartment 
(Figure 3) having a typical resistance to the passage of the stimulus.47 Because the 
human skull is highly resistant to the passage of electrical current, large-voltage 
electrical stimulation must be applied to the scalp. Most of the flow of electrons is 
lost even before it reaches the brain tissue. After passage through scalp, skull and 
dura mater, the next layer consisting of CSF (an excellent conductor) also shunts 
current away from the brain tissue. A recent computerized simulation study of 
ECT in spherical head models estimated large effects of the variations in scalp and 
skull thickness as well as in brain volume, on the levels of stimulation strength 
and excited brain volume underneath the electrodes.47 The amount of bone tissue 
and CSF in an individual patient, therefore, determines the amount of current 
reaching the brain tissue.48 Moreover, the amount of shunting of the current 
depends on the distance between the two electrodes and the use of conducting 
substances (gel, saline, but also hairspray). The clinician modulates this distance 
between the two electrodes by choosing the electrode placement (BL2, bifrontal1 or 
RUL placement according to d’Elia49). 
Interestingly, it is not common practice to evaluate skull and brain anatomy in 
patients undergoing ECT in order to decide on optimal electrode placement and 
electrical dosage. In older literature it was shown that the current density in the 
cortex immediately underneath sutures (places where the bony plates of the skull 
attach) may be three times higher than predicted.50 This suggests the possible 
importance of assessing at least some of these anatomical features in the patient. 
4.2 Obstacles in seizure propagation and termination
In ECT, seizure activity propagates through different parts of the brain following 
neuronal circuitry.39 This process is followed by seizure termination probably 
induced by inhibitory thalamico-cortical feedback circuits and GABA-ergic 
enhancement.44,46 Disease-related alterations of these anatomical connections and 
neurotransmitter systems may also interfere directly with mechanisms that 
support neuronal synchronization, seizure spreading and termination. For 
example, ischemic injuries of brain tissue, such as white matter hyperintensities, 
might cause certain cortico-(thalamo-)cortical circuits to be disconnected.51 In the 
literature, ECT has been described to be less effective in older patients who showed 
more subcortical gray matter hyperintensities on MRI and medial temporal lobe 
atrophy.52,53 Therefore, more destruction of connected neuronal circuits may lead 
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to less seizure propagation and/or less integrity of terminating negative feedback 
circuits. This may have implications for the level of the ST. 
Figure 3   A T
1
-weighted magnetic resonance imaging of the head to illustrate 
that the electrical stimulus must successively pass scalp tissue, skull, 
meninges, and cerebrospinal fluid (CSF), with each compartment 
having a typical resistance to the passage of the stimulus*
*Electrodes are shown in red and placed according to d' Elia and bifrontotemporal left. During electrical 
stimulation, the most electrons will flow between the two electrodes through the scalp without crossing 
the skull. Electrons that pass the highly resistant skull will reach the meninges and CSF space and will 
then be shunted between the electrodes due to the very low resistance of CSF. Therefore, only a small 
portion of the electrical current will excite the brain tissues and will be able to elicit seizure activity. 
Moreover, in right unilateral electrode placement, most current will excite the anterior two-third of the 
cortex ipsilateral to the electrodes, and in bifrontotemporal electrode placement the anterior frontal 
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5. Aims and outline of this thesis
In summary, during the procedure of ECT, progressively large enough groups of 
cortico-(thalamo-)cortical connected neurons, embedded in supportive glia cells, 
fire synchronously, which leads to generalized seizure activity in (certain parts of) 
the brain. Scalp, skull, blood vessels, CSF, glia cells, damaged connections between 
brain tissue and inhibitory feed-back systems have all been suggested to hamper 
this process. To our knowledge, studies are lacking, which relate ST and effectiveness of 
ECT to anatomical factors (e.g., thickness of scalp and skull, volumes of gray matter, 
white matter, and CSF), as barriers for the current to reach the brain effectively. 
Also, studies relating ST and effectiveness of ECT to cerebral pathology (e.g., white 
matter hyperintensities, cortical atrophy), as determinants of the integrity of 
neuronal networks, which may hamper seizure propagation and/or termination, 
are not yet available. This thesis outlines studies that explore predictors of ST and 
its increase during the course in patients undergoing ECT.
The aims of our study in Part 1 are to explore levels of IST in patients undergoing 
ECT and to examine clinical and anatomical determinants of the ST. In Chapter	2 
we describe the results of a meta-analysis of studies providing IST levels to 
determine common levels of IST in patients and to summarize its reported 
determinants. In Chapter	3, we study a patient with an exceptionally high IST and 
we systematically review the literature on this phenomenon, paying special 
attention to clinical and treatment characteristics as determinants of the IST. We 
also describe strategies for the management of high IST. Chapter	 4 contains a 
systematic literature review on hypotheses regarding clinical, morphological and 
functional determinants of changes in ST in older patients. 
In Part 2, we examine in a prospective, explorative cohort study the hypothesized 
determinants of IST as described in Part 1 of this thesis. Chapter	5 reports on the 
clinical characteristics influencing IST and ST change during the course of ECT. 
Correcting for the clinical variables influencing IST independently, Chapter	 6 
examines the relation between scalp and skull thickness and structural brain 
characteristics (volumes of CSF, gray matter, white matter and white matter hyper-
intensities) related to IST and ST change during the course. 
Part 3 of this thesis deals with the patients themselves. Chapter	7 reports on our 
prospective study regarding clinical, treatment and morphological predictors of 
outcome in ECT. Furthermore, catatonic patients are retrospectively examined 
regarding ECT characteristics (seizure length, used electrical dosage and post-ictal 
suppression of the EEG) and outcome (Chapter	8). In Chapter	9, we study retrospectively 
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the relationship between time-interval between sessions, electrical dose and seizure 
duration, in patients treated with continuation ECT because of treatment-resistant 
mood disorder. 
In conclusion, Chapter	10 presents a summary and general discussion of the overall 
results, limitations, and the implications of our studies for clinical practice and 
further research.   
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Abstract
Background: In electroconvulsive therapy (ECT), electrical dosage is determined 
using ‘fixed-dose’, ‘age-based’ dose, or empirical titration methods. Estimation of 
initial seizure threshold (IST) has been claimed to be imperative for suprathreshold 
dosing. This systematic review aimed to determine common levels of IST, to define 
cut-off values for high IST, and to summarize reported IST associated factors.
Methods: Medline and PsycINFO were searched from 1966 to January 2008 and 
relevant references were cross-checked. Subject headings including ECT, seizure 
threshold, dosage, and dosing were used. All articles reporting on levels of IST and/
or associated factors were included. 
Results: Of 395 potentially relevant reports, 46 studies on 70 samples concerning 
3,023 patients were selected. Nine samples (n=306 patients) without available 
standard deviation and four samples (n=275 patients) treated with mixed electrode 
placement were excluded. Meta-analysis was done on 30 unilaterally treated 
samples (n=1,326 patients) and 27 bilaterally treated samples (n=1,116 patients). In 
unilateral ECT, weighted mean of IST was 68.2 milliCoulombs (mC; 95% CI: 
63.2-73.3 mC), and in bilateral ECT 111.6 mC (95% CI: 103.7-119.4 mC). Calculated 
cut-off values for high IST were 121 mC for unilateral ECT and 221 mC for bilateral 
ECT. According to the literature, male gender and use of bilateral electrode 
placement appeared to increase IST most prominently. 
Conclusions: Calculated electrical doses for ‘suprathreshold’ right unilateral ECT 
and for ‘moderate above threshold’ bilateral ECT, using commonly reported IST 
levels, were in the same though narrower ranges as provided in ‘fixed-dose’ and 
‘half-age’ based strategies, respectively.
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Introduction
Electroconvulsive therapy (ECT) is an important treatment option for patients with 
severe, psychotic, or pharmacotherapy-resistant mood disorders.1,2 To be effective, 
seizure activity has to be elicited, and the minimal electrical stimulus in the first 
treatment session that provokes a generalized seizure of sufficient duration indicates 
the initial seizure threshold (IST).1,2 In the literature, different seizure durations 
define seizure adequacy and no systematic association has been shown between 
seizure duration and clinical improvement.1,3,4 Clinicians use different methods to 
choose the initial stimulus dose, of which ‘age-based’,4 ‘half-age based’,5 ‘fixed-high’,1,6 
and ‘empirical titration based’ dosing strategies are common. 
Controversy, however, exists about the ability of these different methods to determine 
the optimal stimulus dose and their risk-benefit ratios.4,7-10 For example, in unilateral 
ECT it has been claimed that the electrical stimulus has to exceed the IST substantially 
for optimal effectiveness (e.g., 6-12 times above IST).6,11 Moreover, seizure thresholds 
appear to vary substantially among patients,4 and factors as gender,12 age,13 previous 
ECT treatment and concomitant medication usage1,14 may influence seizure thresholds. 
Some patients show exceptionally high IST being associated with an increased risk of 
subconvulsive stimulation and unilateral ECT failure.15 
These findings may imply that basic measurement of the IST by titration protocols 
would be favorable above other methods. Others, though, stated that in the vast 
majority of patients the distribution of IST would be tightly clustered in the 50-200 
milliCoulombs (mC) range, and therefore the proper electrical dose should be 
accomplished without dose titration.4,16 Thus for clinicians, knowledge about the 
common IST level in average patients may be useful to decide on the preferred stimulus 
dosing method. Therefore, the aim of our study was to analyze studies on IST and to 
determine whether common IST levels for both unilateral and bilateral ECT could be 
possibly deduced from these data. We also wanted to define cut-off values for high IST, 
since these patients may pose a special problem for clinicians. Additionally, we aimed 
to summarize reported factors that may be associated with IST levels.
Method
This review aimed to include all published articles on IST in ECT. Medline (Pubmed, 
National Library of Medicine, http://www.ncbi.nlm.nih.gov) and PsycINFO (American 
Psychological Association 2008) were searched for articles that were published 
from 1966 to January 2008. The abstracts of the 395 retrieved articles were 
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examined for information on IST (Figure 1). Of these articles, 348 were excluded 
because they did not report on IST and one because the reported mean IST was 
extraordinarily high compared to those reported in the other studies.17 References 
Figure 1   Flow diagram of selection of reports on initial seizure threshold in ECT






- “electroconvulsive therapy” [Mesh] and “excessive stimulus” (3 hits)
- “electroconvulsive therapy” [Mesh] and “high seizure threshold” (39 hits)
- “seizures” [Mesh] and “high threshold” (200 hits)
PsycINFO:
- “dose” or “dosage” or “doses” or “dosing” and "electroconvulsive therapy"
   [Mesh] or "electroshock"[Mesh]” (150 hits)
Articles found by cross-referencing: n=3      
Reasons for exclusion:
- report was not on seizure thresholds (n=348)
- seizure thresholds were much higher than in all
  the other samples (n=1)
 
 
Included reports n=46 on 70 samples concerning 3,023 patients:
- n=34, right unilateral ECT (1,500 patients)
- n=32, bifrontotemporal ECT (1,248 patients) 
- n=4, mixed electrode placement (275 patients)      
Reasons for not entering report in analysis:
- use of both right unilateral and bilateral ECT 
  (n=4; 275 patients)
- standard deviations were not available for 
  meta-analysis (n=9; 306 patients)
Included samples in meta-analysis: n=57
- for seizure thresholds (n=57 concerning 2,442 patients):
     - n=30, right unilateral ECT (1,326 patients)
     - n=27, bifrontotemporal ECT (1,116 patients)
- for patients’ and treatments’ characteristics (n=52)*
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of the remaining 46 articles were cross-checked, and three standard works on ECT 
were examined as well.1-3 The 46 studies that were selected for further investigation 
consisted of 70 patient samples; 34 patient samples were treated with unilateral 
ECT, 32 with bilateral ECT and 4 with mixed electrode placement. Because electrode 
placement is known to have a substantial influence on seizure thresholds,13 mixed 
samples were excluded (n=4; 275 patients). Furthermore, nine samples (306 patients) 
could not be used in the meta-analysis because standard deviations of the mean 
IST were lacking. Therefore, 57 samples containing 2,442 patients were available 
for further investigation. These studies were scrutinized for: (1) patient character-
istics such as age, gender, psychiatric diagnosis, use of anticonvulsants and 
previous ECT; (2) treatment characteristics such as electrode placement, settings of 
the device (constant-current and pulse width), titration process including seizure 
duration and definition of an adequate seizure, and the anaesthetic drugs used; 
and (3) data on IST [mean and standard deviation (SD), or median and range in mC] 
in both unilateral and bilateral ECT.
Statistics
Data are presented as numbers and percentages, and means and SD or medians 
and interquartile ranges (IQR) when appropriate, using SPSS for Windows (version 
13.0). After meta-analysis of the data on mean IST with the statistical package of 
Comprehensive Meta-Analysis (version 2.0), forest plots were generated. Because 
the included studies proved to be substantially heterogeneous, random effect 
models were used. Furthermore, we defined high IST level as the upper high 95% 
bound of the mean IST, which was calculated by adding two times the SD to the 
mean IST of each patient sample. For both unilaterally and bilaterally treated 
samples the medians and IQR of these cut-off values were calculated. 
Results
Patient and treatment characteristics of the samples
Table 1 summarizes the patient and treatment characteristics of the samples 
included in the meta-analysis. Mean age of the 57 samples (n=2,442 patients) 
ranged from 29.8 to 73.8 years, and 36.9% of the patients were male. Most samples 
concerned patients with major depression (n=37; 64.9%). In 22 (38.6%) samples, also 
patients with bipolar depression were included. In most studies, seizure adequacy 
was defined as visible motor activity (35.1%) or EEG seizure activity (22.8%) with a 
duration ≥ 25 s. All studies, except one,18 described the use of ECT devices with 
constant-current and brief pulse properties. In most cases (52 samples; 91.2%), a 
barbiturate (methohexital or thiopental) was administered as anesthetic. 
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Table 1   Characteristics of patients and treatment in all the study samples  
(n=57 concerning 2,442 patients)
Mean age (± SD, range) in years 51.7 (± 9.1, 29.8-73.8)
Male* 971 (36.9%)
Psychiatric diagnosis*
   Major depression 
   Bipolar depression as well 
   Psychosis 
   Various diagnoses







   Use of anticonvulsants
   ECT in previous 6 months
42 (73.7%)
41 (71.9%)
Definition of seizure adequacy in seconds (s)*
   Visible motor seizure activity ≥ 25 s 
   EEG seizure activity ≥ 25 s 
   Visible motor seizure activity ≥ 15 s 
   Visible motor seizure activity ≥ 30 s 
   Other description 
   Not described
20 (35.1 %)
13 (22.8 %) 
11 (19.3 %)
3 (5.3 %)
2 (3.5 %)  
8 (14 %)
Settings of ECT device* 
   Constant current 0.8 Ampere (A)
   Range of used currents in studies
   Brief pulse 1.0 milliseconds (ms)






   Methohexital 
   Thiopental 
   Other anaesthetic (etomidate; propofol;
   or not specified)
   Not described




Values of IST in unilateral treated patient 
samples (n=30):
   Range of IST values
   Median IST
   Weighted mean in meta-analysis
42.7-138.9 mC
66.6 mC (IQR: 58.4-78.1 mC)
68.2 mC (95% CI: 63.2-73.3 mC)
Cut-off values for high IST in unilateral treated 
patient samples (n=30)
  Range of high IST values
  Median of high IST values
59.3-281.5 mC
120.9 mC (IQR: 104.1-163.5 mC)
Values of IST in bilateral treated patient samples 
(n=27)
   Range of IST values
   Median IST
   Weighted mean in meta-analysis
63.8-192.3 mC
107.5 mC (IQR: 94.8-130.0 mC)
111.6 mC (95% CI: 103.7-119.4 mC)
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Levels of IST (Table 1)
The means and ranges of reported IST were analyzed in two ways. Using Comprehensive 
Meta-Analysis software (random effects model), the weighted overall mean IST in 
right unilateral ECT was 68.2 mC (standard error 2.59; 95% confidence interval [CI] 
63.2-73.3 mC), and in bilateral ECT 111.6 mC (standard error 4.02; 95% CI 103.7-119.4 
mC). Figure 2 presents these findings in a forest plot. 
In the unilaterally treated samples, the means of IST ranged from 42.7 to 138.9 mC 
(median of all means 66.6 mC; IQR: 58.4-78.1 mC), and in bilaterally treated samples 
from 63.8 to 192.3 mC (median of all means 107.5 mC; IQR: 94.8-130.0 mC). The 
cut-off values for high IST in the unilaterally treated samples ranged from 59.3 to 
281.5 mC (median 120.9 mC, IQR 104.1-163.5 mC); and in the samples treated with 
bilateral ECT from 119.9 to 499.9 mC (median 221.0 mC; IQR: 161.8-285.5 mC). 
Determinants of IST
In the reviewed literature, several patient-related, treatment-related and some 
miscellaneous factors were shown or mentioned to be possibly associated with the 
level of IST (Table 2). When taking into account prospective studies only, levels of IST 
were significantly related to the following factors: gender,12 age,12 number of 
cumulative treatments,12,19 electrode placement,20 dynamic impedance,21 current 
characteristics such as stimulus train duration, frequency, pulse width, and 
amperage,22,23 and sleep deprivation.24 Male gender 12 and bilateral electrode 
placement 20 were reported to increase IST most prominently. 
Table 1   Continued
Cut-off values for high IST in bilateral treated 
patient samples (n=27)
  Range of high IST values
  Median of high IST values
119.9-499.9 mC
221.0 mC (IQR: 161.8-285.5 mC)
* Data are in numbers and percentages unless otherwise indicated; SD=standard deviation; EEG= electro-
encephalogram; IST=initial seizure threshold; IQR=interquartile ranges; mC=milliCoulombs.
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Figure 2   Forest plot of meta-analysis of initial seizure thresholds (IST) in 
 electroconvulsive therapy (n=30 right unilaterally treated samples 
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Table 2   Possible determinants for initial seizure thresholds (IST) in electrocon-
vulsive therapy (ECT)
Determinant Type of influence
Patient characteristics 
Gender* Men have much higher IST (approximately 70%) than 
women.12
Age* Moderate association, somewhat sex dependent: elderly 
men have highest IST.12
Racial diversity African-Americans may have higher IST.29
Some morphological 
characteristics
Thickness of skin and scalp bone, and higher brain 
density may raise the IST, probably due to a raise of static 
impedance.30
Longer inion-nasion distances Wider interelectrode (inion-nasion) distance may be 
associated with higher IST, especially in women.29,31
Body-mass index (BMI) In Chinese patients, higher BMI was associated with 
higher IST.32
Presence of neurodegenerative 
disorder
In dementia, there may be an additional decrease in 
neuronal excitability associated with higher IST.33
Greater medical burden Modest association with higher IST, especially in patients 
with cardiovascular diseases.25
Psychiatric diagnosis Manic patients may have lower IST than depressed 
patients.26
Use of psychotropic drugs
Anaesthetic drugs Thiopental may have a disadvantage over etomidate in 
producing seizures of adequate duration.34
Anticonvulsants Higher stimulus doses are required to overcome IST.1
Benzodiazepines Average lorazepam dosage in 48 hours before ECT was 
not associated with higher IST, but with decreased 
seizure duration.25
Barbiturates Have anticonvulsant properties.25
Neuroleptics May have an inverse effect and be associated with a lower 
IST.35
Beta-blockers May raise IST; atenolol does not pass the blood-brain 
barrier, but metoprolol and propranolol do.36
Calcium-antagonists May raise IST.37
Lidocaine Shortens seizures and may raise IST.3
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Discussion
We found that the overall mean of IST in the 30 patient samples treated with right 
unilateral ECT was 68.2 mC (95% CI 63.2-73.3 mC), whereas in the 27 patient 
samples that received bilateral ECT the overall mean was 111.6 mC (95% CI 
103.7-119.4 mC). IST might be considered as high when the electrical stimulus has 
to exceed 121 mC in unilateral ECT or 221 mC in bilateral ECT to induce a 
generalized seizure of at least 25-30 s on EEG. Of reported factors associated with 
IST levels, male gender and bilateral electrode placement predicted higher IST 
most explicitly.
Clinical relevance of these findings 
Although in the literature, IST levels were suggested to vary substantially between 
individual patients justifying the empirical titration as a more accurate dosing 
method (e.g., a 35-fold range 25), this meta-analysis showed a more narrow range of 
mean IST. The IST levels, as found in this meta-analysis, bring together the concepts 
of ‘dose-titration’, ‘fixed-dose’ and ‘half-age’ methods, which was suggested before 
by rough clinical estimations.16 After all, a calculated dose for suprathreshold 
Table 2   Continued
Determinant Type of influence
ECT characteristics 
Cumulative number of 
treatments*
Average of 65% increase in IST from first to final session 
of ECT course.12,19
Electrode placement* IST is higher in bilateral than in right unilateral ECT, and 
increased on average by 87% during bilateral treatment, 
and only 40% during right unilateral ECT.12
Dynamic impedance* Lower dynamic impedance increased IST.38
Current* Shorter stimulus train duration with same dose 
increased IST.22
Higher stimulus frequency (pulses per second) increased 
IST.22
Longer pulse width increased IST.23,39
Stimuli of 0.8 A gave higher IST than stimuli of 0.9 A.40
Miscellaneous factors 
Sleep deprivation* Decreased IST.24
Drinking alcohol May increase IST.41
* Results of prospective study
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unilateral ECT 11 using our calculated weighted mean IST (e.g., 6 x 68.2 mC ≈ 409 
mC) corresponds to the stimulus dose range as advocated in ‘fixed-dose’ methods 
(378-504 mC) for both unilateral and bilateral ECT.4 On the other hand, the found 
IST level of 111.6 mC used in ‘moderate above IST bilateral stimulus dose’ 
calculations (e.g., 1.5-2.5 x 111.6 mC ≈ 167-279 mC) suggests that the use of 
‘fixed-dose’ methods (378-504 mC 4) may result in overstimulation, and corresponds 
more to the ‘half-age’ method stimulus dose range (50-252 mC) in bilateral ECT.5    
Strengths and limitations
Although our systematic literature review is relatively complete, only cautious 
conclusions may be drawn. IST levels were collected from studies that did not 
primarily aim to examine IST and its associated factors, and the selected samples 
could not be stratified for gender or for other presumed influencing factors as 
many data on the 2,442 individuals studied were lacking. This may have influenced 
our results. For example, if samples would contain relatively more males, or more 
subjects with lower dynamic impedances, or if IST increasing current characteris-
tics (shorter stimulus train duration, higher stimulus frequency, longer pulse 
width, lower amperage) were used, the weighted mean would be higher than real. 
Furthermore, in 22 samples (38.6%) seizure thresholds were analyzed in patients 
with unipolar as well as bipolar depressive disorders together. Since it has been 
suggested that patients with bipolar disorder may have a lower seizure threshold,26 
inclusion of these patients may have decreased the overall means of IST. Also, 
patients who could not reach adequate seizure durations most probably have been 
excluded, leading to underestimation of the seizure threshold. In only one study, 
however, this was mentioned as an exclusion criterium.27 
Moreover, the lack of a standardized definition of adequate seizure duration in 
titration protocols hampered appropriate comparison of studies. In 40% of the 
studies, minimal duration of 25-30 s of ‘visible motor seizure activity’ was assumed 
to be adequate, which is rather arbitrary.1,4 In more than 19% of the studies, a 
shorter seizure duration was regarded as adequate. Limiting our meta-analysis 
though to the studies that defined an adequate seizure duration as ≥ 25 s of ‘visible 
motor seizure activity’ revealed, however, comparable weighted means of IST 
(unilateral ECT n=27; mean 68.2 mC; 95% CI 62.8-73.6 mC; bilateral ECT n=19; 
mean 107.1 mC; 95% CI 97.8-116.3 mC). Seizure duration monitoring was sometimes 
performed with the cuff method only, which is probably unreliable and might 
lead to higher estimation of IST as the seizure duration would sometimes be 
incorrectly regarded as insufficient.28 Further research on IST could be optimized 
by using standardized procedures for seizure duration monitoring and an agreed 
definition for seizure adequacy in the titration protocols. 
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Finally, the calculated levels of mean IST will probably be applicable in most 
patients, but some individuals will have lower or higher IST, which in unilateral 
ECT might result in over- or understimulation. Although some factors are known 
to influence IST, it is uncertain in what manner these must be taken into account 
in determining IST for the individual patient.  
In conclusion, based on this meta-analysis, an IST of 68.2 mC for calculation of 
suprathreshold unilateral ECT is within the stimulus dose range of  ‘fixed-dose’ 
methods. A ‘moderate above IST bilateral ECT stimulus’ dose, calculated with an 
IST of 111.6 mC, is substantially lower than the stimulus dose range of ‘fixed-dose’ 
methods but is within the ‘half-age method’ based dose range. Given the discussion 
in the literature about optimal dosing strategies, these findings support use of 
‘fixed’ and ‘half-age’ methods. Male gender and bilateral electrode placement were 
reported to increase IST most prominently, and IST exceeding 121 mC in unilateral 
ECT and 221 mC in bilateral ECT may be regarded as high. More research is needed 
to determine the relevance of factors influencing IST. 
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Abstract
Background: Seizure threshold in electroconvulsive therapy (ECT) is generally 
defined as the smallest electrical stimulus dose that produces a generalized seizure 
of at least 25 to 30 seconds on electroencephalogram. Seizure thresholds vary 
considerably among patients, and some patients have an exceptionally high initial 
seizure threshold. We describe a patient with catatonia who showed an initial 
seizure threshold exceeding 500 milliCoulombs (mC). The literature was searched 
for other reports on this phenomenon. 
Methods: A systematic review was conducted using MedLine from 1966 to January 
2008 and PsychINFO (2007), cross-referencing ECT and (excessively high) seizure 
threshold, as well as standard works on ECT. The literature was scrutinized for 
reports on high initial seizure threshold and associated demographic and clinical 
characteristics.
Results: Besides our patient, 6 articles were found reporting on 9 severely 
depressed, mostly elderly patients (aged 45-85 years; 5 males, 2 females, 2 persons 
with unknown sex) with excessive initial seizure thresholds ranging from 335 to 
896 mC, and most with cardiovascular compromise. Strategies to lower seizure 
thresholds in ECT included manipulation of stimulus parameters, adjustment of 
anesthetics, and augmentation with proconvulsant agents.
Conclusions: Because reports on exceptionally high initial seizure thresholds in 
ECT are rare, no definite conclusions can be drawn regarding its possible risk 
factors and management. However, since high initial seizure thresholds can 
complicate ECT, it is clinically important to further investigate this phenomenon.
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Introduction
In clinical practice, some patients treated with electroconvulsive therapy (ECT) 
show exceptionally high initial seizure thresholds. At the first ECT session, a high 
stimulus dose is then needed to induce a seizure of sufficient length in case a 
stimulus titration method 1 is used, or a subconvulsive stimulus is the result of the 
initial “age-based estimated dose method”. Seizure threshold in ECT is generally 
defined as the smallest electrical stimulus dose that results in a generalised 
seizure of at least 25 to 30 seconds on electroencephalogram (EEG).2,3 Seizure 
thresholds vary greatly among patients, and no consistent relationship has been 
found with the antidepressant response, except in unilateral ECT.4,5 Induction of 
any seizure activity is thought to be imperative for effectiveness of ECT,2 whereas 
it has also been reported that subconvulsive stimulation can be dangerous for the 
patient because of harmful bradycardia or asystole.6 Exceptionally high seizure 
thresholds may therefore complicate ECT, due to the increased risk of inadequate 
treatment, especially in countries where the maximum stimulus dose of ECT 
devices is limited.7
In this report we describe ECT in a catatonic patient who needed an exceptionally 
high initial stimulus dose to induce an adequate seizure. The literature was 
searched for other reports on this phenomenon paying special attention to clinical 
and treatment characteristics and to strategies for management of high initial 
seizure threshold.
Case report
A 76-year-old patient with a history of recurrent depressive disorder with psychotic 
features and personality disorder for more than 20 years was referred for ECT 
because of catatonia during the last two months. She had a history of diabetes 
mellitus type 2, myocardial infarction, and ischemic cerebral infarction; in 
addition a moderate to severe aortic stenosis and aortic insufficiency had recently 
been diagnosed. During the previous year symptoms of cognitive impairment had 
emerged, probably due to cerebral cardiovascular disease. At admission, she almost 
exclusively showed severe muscle rigidity and mutism. On the Bush-Francis 
Catatonia Rating Scale (CRS), a score of 18 (from a maximum of 69 points) was 
rated.8 The patient’s clinical condition deteriorated quickly because she could not 
eat or drink. ECT was considered to be the treatment with the least risks and the 
highest probability to achieve improvement of her condition. In line with the 
clinical diagnosis of catatonia, apart from dehydration with uremia and masked 
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anemia, no abnormalities were found in blood tests. Cerebral MRI showed generalized 
atrophy with central and peripheral liquor spaces and bilateral periventricular 
white matter lesions. No signs of infarction were found.
At the first ECT session, anesthesia was induced with 10 mg etomidate intravenously 
(IV). Because the patient had been immobile for a prolonged period muscle 
relaxation was initiated with 8 mg mivacurium IV, instead of succinylcholine, to 
inhibit release of large amounts of potassium. In addition, 0.5 mg methylatropine 
IV was given to prevent bradycardia. Metoprolol was administered to prevent 
tachycardia and hypertension; in patients with aorta stenoses the latter conditions 
are potentially fatal. Standard bilateral (bifrontotemporal) ECT was administrated 
with the Thymatron IV (constant current, 0.9 Ampère; brief pulse; Somatics, Lake 
Bluff, Ill., USA). Seizure duration was monitored by EEG and motor activity by elec-
tromyography using the cuff method.  
At the first stimulus, a dose of 223.2 milliCoulombs (mC; frequency, 70 Hz; pulse 
width, 0.25 milliseconds; stimulus duration, 7.2 seconds; static impedance, 1620 
Ω; dynamic impedance, 270 Ω) was administered. This dosage was considered to be 
well above the age-based estimated seizure threshold. However, no muscle 
contractions occurred, and no seizure activity was registered on the EEG; the 
patient continued to have a regular heart rate and normal blood pressure. After 30 
seconds, a second dose of 497.8 mC (frequency, 140 Hz; pulse width, 0.25 milli -
seconds; stimulus duration, 8 seconds; static impedance, 1460 Ω; dynamic 
impedance, 270 Ω) was given, again without any motor or EEG convulsive activity. 
While the patient was still adequately paralyzed and anesthesia was maintained, 
a third stimulus of 760.8 mC (frequency, 70 Hz; pulse width, 0.75 milliseconds; 
stimulus duration, 8 seconds; static impedance, 1350 Ω; dynamic impedance, 260 
Ω) could be given. This stimulus resulted in 22 seconds of motor activity, and 29 
seconds of EEG seizure activity. 
Because of the patient’s clinical condition, ECT was administered daily. During 
treatments, the stimulus doses and etomidate doses were kept identical resulting 
in adequate seizures with duration of motor activity ranging from 20 to 38 seconds. 
After 6 ECT sessions, the Catatonia Rating Scale score declined to 6 points, and 
after the 10th ECT session, the score was only 1 point. Clinically, the patient could 
speak, eat and drink again, and the catatonic features were no longer present. 
Unfortunately, after the 10th session, the patient suddenly developed paralysis of 
the left side of her face and mouth for several hours. After 3 days, the CT scan did 
not show infarction of the brain. However, ECT was discontinued because a 
transient ischemic attack was suspected, and it was considered that there was a 
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substantial risk of inducing more (severe) vascular incidents. The catatonia did not 
recur, and the patient was transferred back to the long-stay facility where she lived 
before admission to the hospital.
Literature search
We made a systematic search of the literature for other reports on patients with 
this phenomenon using Medline from 1966 to January 2008 and PsychINFO (2007), 
cross-referencing ECT and (excessively high) seizure threshold. The references of 
the articles found were hand searched for any additional reports. Furthermore, 
standard works on ECT were consulted.2,3,9 We were especially interested in 
demographic and clinical factors that might enhance the initial seizure threshold 
and in strategies for its prevention. The abstracts of the articles found were 
scrutinized for reports on patients with high initial seizure thresholds in ECT, 
associated demographic and clinical characteristics, and recommendations for its 
management. Articles that did not describe any patient characteristics or 
descriptions of initial seizure thresholds were excluded.
Only 6 articles reporting on 10 patients with excessive initial seizure thresholds 
were found (Table 1).7,10-14 The highest seizure threshold (3,226 mC) was described in 
a patient treated with ECT for status epilepticus,14 although ECT is normally not 
indicated in such a condition. The other 5 case reports described high initial 
seizure thresholds (ranging from 335 to 896 mC) in severely depressed, mostly 
elderly patients (age range, 45-85 years; 5 males, 2 females; in 2 patients, data on 
age and sex were lacking). In 5 patients, comorbid somatic diseases were described, 
mostly of cardiovascular origin. In the literature, several factors influencing the 
seizure threshold could be identified, of which many were present in our patient 
(see Discussion). Some of the methods reported to lower seizure thresholds are 
given in Table 2.2,12,15-24
50 | Chapter 3
Table 1   Characteristics of patients (n= 10) with exceptionally high initial 

















































10 Female 45 Major depression Hypertension; diabetes 
mellitus type 2; dialysis-










11 Male ’elderly’ Psychotic depression - BL: 672 mC





Male 85 Recurrent major 
depression
Cardiovascular diseases RUL: 896 mC
13 - - Major depression - BL: 428 mC (n=1)
- - Major depression - BL: 335 mC (n=2)
12 Male 54 Major depression - RUL: 840 mC
Male 80 Major depression - BL: 576 mC







*In milliCoulombs (mC); RUL: right unilateral electrode placement (d’Elia); BL: bifrontotemporal placement. 
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Table 2   Methods used to overcome high seizure threshold in patients  
undergoing ECT
Manipulation of stimulus parameters Reference
(Switch to, or provide) unilateral ECT d’Elia. 27
Raise the stimulus dose 
Provide longer stimulus duration with same dosage 
Lower stimulus frequency
Lower the frequency of treatments
2,17,18
Adjustments made by the anesthesiologist
Switching anesthetic (administration of etomidate is advised as first-line 
in patients with high seizure thresholds; administrating ketamine or 
combining methohexital with alfentanil may prolong seizure duration)
15
Hyperventilation before stimulation, which lowers the carbon oxide level 
thereby raising neuroexcitability
2,19
Administer antagonist (flumazenil) if concomitant benzodiazepines are used 12,20
Augmentation strategies during ECT
Caffeine augmentation significantly increases seizure duration, but does not 
decrease the seizure threshold
19
Theophiline augmentation 19
Concomitant use of an antipsychotic (chlorpromazine and clozapine have a 
relatively high seizurogenic potential).
21
Concomitant use of an antidepressant use (maprotiline, clomipramine, 
bupropion) is inconclusive
21
Augmentation strategies during ECT
If possible, advise the patient to stop using or lower the use of 
anticonvulsants, benzodiazepines (also hypnotics), and antihypertensive 
medication (e.g. beta-blockers and calcium antagonists)
2,16
Advise sleep deprivation the night before ECT 22
Advise the patient to stop drinking alcohol 23
Encourage weight loss in an obese Chinese patient 24
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Discussion
We have described bilateral ECT in a 76-year-old female catatonic patient with an 
exceptionally high initial seizure threshold. Because 2 preceding subconvulsive 
stimuli may have lowered the seizure threshold, her initial threshold might have 
been even higher.25 A literature search revealed only 10 other cases with excessively 
high initial seizure thresholds. Compared with our patient, in most other cases, 
even higher seizure thresholds had to be overcome in order to elicit an adequate 
seizure. Several factors might have played a role in the occurrence of the 
exceptionally high seizure threshold in our patient, including, higher age, 
pre-existent dementia, large medical burden (in particular of cardiovascular 
origin), dehydration, use of metoprolol before ECT, bilateral electrode placement, 
lower dynamic impedance (260-270 Ω), and higher pulse frequency (70-140 Hz). 
Malnutrition for several months may have further contributed to the excessively 
high seizure threshold of our patient. It has been shown in young rats that a low-
carbohydrate diet produces a significant increase of the seizure threshold.26 On the 
other hand, female patients generally have a lower seizure threshold than males,27 
and the stimulus parameters used in our patient (i.e., long stimulus duration and 
short pulse width) may have contributed to lowering her seizure threshold.18 
Etomidate has been recommended as the first-line anesthetic for patients with 
very high seizure thresholds.15 Because we routinely administer etomidate, 
lowering the seizure threshold by switching to another anesthetic was not an 
option with our patient. The cardiovascular condition of our patient was severely 
compromised as shown by the transient ischemic attack during the treatment 
period. Earlier, higher severity scores for cardiac illness and other forms of vascular 
diseases have been associated with higher seizure thresholds.12 Concomitant use of 
antihypertensives and antiarrhythmics may have raised the seizure threshold in 
our patient who was given metoprolol before the first ECT because of aortic stenosis 
to prevent severe tachycardia and hypertension.16,28 
In conclusion, patients with an exceptionally high seizure threshold at their first 
ECT are rare. Until now, besides our patient, very few have been reported in the 
literature. Several factors are known to raise the seizure threshold, thereby 
complicating ECT. Some of these factors might be managed clinically, with the 
aim to improve treatment and hopefully the outcome in individual patients. 
Further research may help to identify patients with exceptionally high seizure 
thresholds, to better understand their underlying causes, and to better deal with 
such phenomena.
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Abstract
Background: Electroconvulsive therapy (ECT) is effective and generally safe in 
depression. Its effectiveness and side effects are suggested to be related to the 
electrical stimulus administered relative to the seizure threshold. Since aging 
seems to raise the seizure threshold in ECT, we reviewed the literature for evidence 
correlating advanced age and seizure threshold, and for hypotheses explaining 
why seizure thresholds might raise with age.
Methods: Pubmed, PsychINFO, three standard works on ECT, and cross-references 
were searched for studies investigating seizure thresholds and/or associated 
factors in elderly depressed patients. 
Results: A total of 406 possibly relevant articles were found, of which 27 studies 
could be included. One very recently published study was included afterwards 
because of its significance. Aging was moderately associated with a raised initial 
seizure threshold with correlation coefficients ranging from 0.30 to 0.64 (P<0.05). 
Also, seizure thresholds in elderly patients were more likely to raise during the 
ECT course. Reported hypotheses for these clinical phenomena include a decrease 
of neuroexcitability, changes in morphologic and functional characteristics of the 
brain, somatic comorbidity, and concomitant medication use.
Conclusions: To optimize ECT in elderly patients, hypotheses and suggestions for 
further research are proposed regarding the moderate correlation between 
advanced age and initial seizure threshold and the rise in seizure threshold during 
the ECT course.
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Introduction
Electroconvulsive therapy (ECT) is an effective treatment for late life depression.1 
Also in other severe psychiatric conditions (e.g., catatonia, malignant neuroleptic 
syndrome, intractable psychosis, mania and delirium) ECT can be worthwhile and 
even lifesaving in elderly patients.2 In old age, treatment of depression is often 
complicated by somatic comorbidity and polypharmacy, whereas transient 
post-ictal confusion, cardiovascular problems and falls are the most serious 
side-effects of ECT.3,4 Even in patients aged >75 years, ECT is generally safe when 
carefully monitored and when its side-effects are balanced against the risks of 
untreated depression and complications of psycho-pharmacotherapy.3
Effectiveness and side-effects of ECT seem to be related to the administered 
electrical stimulus dose and electrode placement.2 The electrical stimulus must 
exceed the seizure threshold to elicit a sufficient seizure,5 whereas subconvulsive 
stimulation may cause bradycardia and asystole.6 Seizure threshold has been 
defined as the smallest electrical stimulus dose that is necessary to produce a 
generalized seizure of at least a 25-30 seconds on EEG.2 In addition, the extent of 
the electrical dose above the individual seizure threshold, rather than the absolute 
electrical dose, was suggested to be associated with short-term cognitive 
side-effects.7 For example, patients aged > 50 years who fail to respond to moder-
ate-charge right unilateral ECT, may benefit from high-charge right unilateral 
stimulation rather than from bilateral ECT, with less cognitive side-effects.8 
Although not studied extensively, it is established that seizure thresholds vary 
substantially between patients. Several factors are known to increase seizure 
threshold and in clinical practice higher seizure thresholds seem to occur more 
often in elderly patients, especially in elderly men.9-11 
To decide on the proper electrical dose for a patient, the empirical dose-titration 
method that determines the actual initial seizure threshold may be used to 
calculate individualized ‘moderate’ or ‘high above’ seizure threshold stimulation. 
In clinical practice, an ‘age-based’ method is often used to estimate the electrical 
dose that sufficiently exceeds the seizure threshold, based on the assumption that 
increasing age raises the seizure threshold.12 However, the precise relationship 
between age and age-associated factors on the one hand and seizure threshold on 
the other hand is unknown. Therefore, we reviewed the literature for evidence 
correlating advanced age and seizure threshold in depressed patients, and for 
hypotheses explaining why seizure thresholds might raise with age. 
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Method
Medline (Pubmed, National Library of Medicine, http://www.ncbi.nlm.nih.gov) and 
PsychINFO (American Psychological Association, 2007) were searched for articles 
that were published from 1966 through March 2008 (see Figure 1 for the search 
strategy). All retrieved titles and abstracts (n=406) were investigated. Studies 
exploring seizure thresholds and/or associated factors in elderly patients were 
included in this review. In addition, one important, more recently published study 
was included afterwards,13 three standard works on ECT were consulted 2,12,14 and 
their references were cross-checked to reveal relevant additional articles. 
 
Results 
For the present review, 27 studies appeared to be relevant. Of these, 13 studies 
presented data on correlations between seizure threshold and age, 3 studies compared 
younger and older age groups (of which 1 also calculated correlations), 1 study 
examined changes in seizure thresholds during the ECT course, 3 studies indirectly 
showed an increase of seizure threshold in elderly patients, and 8 studies presented 
hypotheses for an increased seizure threshold in elderly patients.    
Initial seizure threshold in relation to age
In the 13 studies investigating the correlation between seizure threshold and age, a 
total of 1,481 subjects were included. The mean age of these samples ranged from 
43.6 to 67.1 years and the absolute age from 18 to 93 years (Table 1). In all studies 
moderate significant overall correlations (r=0.30-0.64, P<0.05) between initial 
seizure thresholds and age were found,9,10,15-25 except for one unilaterally treated 
female sample (r=0.098; P>0.05),22 a bilaterally treated male sample (r=-0.47, P=0.17) 22 
and a bilaterally treated female sample (r=-0.06; P>0.05).23 After Z-transformation, 
sample size weighted average correlation coefficients were 0.42 ± 0.12 in right 
unilateral treated samples, 0.48 ± 0.07 in bilateral treated samples and 0.37 ± 0.06 
in samples treated with both electrode placements, which are moderate 
correlations. Three studies reported that the initial seizure threshold, as measured 
at the first ECT session, was almost twice as high in patients aged ≥ 65 years than 
in younger patients aged < 55 years.13,18,26 Further, being an elderly man appeared 
to be positively correlated with initial seizure threshold in right unilateral ECT 22 
and bilateral ECT.10,23
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Figure 1   Flow diagram of articles on ECT and initial and/or raise of seizure 





† search date March 2008, # one study in French10  was included because of its  relevance
* one study (counted twice) also calculated correlations
Medline:
“seizure threshold” AND “electroconvulsive therapy" [MeSH] AND "aged" [MeSH] OR "aged, 
80 and over" [MeSH] (n=79) †
PsycINFO:
"electroconvulsive shock therapy" OR “electroconvulsive shock therapy” OR “electro 
convulsive therapy” OR “electroconvulsive therapy” OR “ect” OR "electroconvulsive 
shock therapy" OR "shock therapy", limiters were age groups: “aged” (65 years & older) 
AND “very old” (85 years & older) (n=327 hits) †
Potentially relevant articles (n=406)
      
Reasons for exclusion (Medline):
- not related to age or seizure threshold (n=41)
- not in the English language (n=5) #
- only case report (n=1); on anesthesia (n=6);
  on epilepsy (n=1); on pain thresholds (n=2)
Reasons for exclusion (PsychINFO):
- not related to age or seizure threshold (n=221)
- only case reports (n=33)
- only reporting medical problems in ECT (n=30)
- only anesthesia-related matters (n=20)




- Medline: 23 articles
- PsychINFO: 17 articles (apart from those found in Medline) 
- Relevant study that was published after March 2008, added later because of its 
  significance for this review (n=1)
Articles included in review (n=41)
      
Reasons for not being included in this review: 
No correlations between age and initial seizure 
threshold were calculated and/or hypotheses 
regarding age and initial seizure threshold were 
lacking (n=14)
Articles (n=27) useful for answering the research questions : 
- Studies calculating correlation coefficients on age and initial seizure threshold (n=13)
- Studies comparing younger and older age-groups regarding initial seizure threshold (n=3*)
- Studies regarding raise of seizure threshold during the ECT course (n=1)
-Studies indirectly showing raise of seizure thresholds (n=3)
- Studies describing hypotheses regarding higher seizure thresholds in elderly patients (n=8)
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Seizure threshold during the course of ECT
Increasing age was associated with a greater likelihood that seizure threshold 
would raise during the ECT course, independently of electrode placement. For 
example, of 15 patients aged 70-89 years, 12 (80%) showed an increase in seizure 
threshold from the first to the sixth treatment session compared to 26 of 52 
patients (50%) aged < 70 years (Chi-square=8.78;df=1; P<0.003).27 More recently, 
however, age was reported not to be associated with a raise in seizure threshold 
measured after an index ECT course, comparing only bilaterally treated patients 
aged > 50 years (n=55) and ≤ 50 years (n=20).28
There are also indirect indications for the clinical phenomenon of a raise in 
seizure threshold in elderly patients. Older age was a predictor of requiring the 
maximum possible stimulus intensity during the course of ECT;29 in older patients 
more failures to elicit an adequate seizure occurred.30 Although seizure duration 
does not necessary reflect seizure threshold, in a stepwise regression analysis of 
mostly bilaterally treated subjects (n=334), higher age was found to predict failure 
or short duration of the seizure in both women and men, but only if the number 
of medical diagnoses was not taken into account.31 
Discussion
In the present review, advanced age showed a moderate correlation with initial 
seizure threshold in ECT, which is in line with studies reporting that age accounted 
for only 8-25% of the variance in initial seizure threshold.9,13,20,24,25 In addition, only 
a few studies showed seizure failure and a greater likelihood of seizure threshold 
raise during the ECT course in elderly patients. Although the use of the commonly 
practiced ‘age-based’ dosage methods, assuming increased seizure threshold in 
older patients, seems rational,32-34 the upper limit of the reviewed study samples’ 
mean age was only 67.1 years. This raises questions about the generalizability of 
these findings to the ECT practice in (very) old patients, especially taking into 
account their vulnerability for side-effects.3,4 Also, in elderly patients without 
increased seizure threshold ‘age-based’ methods may lead to overestimation of 
the seizure threshold, leading to overstimulation and possibly increased risk of 
cognitive dysfunction. On the other hand, underestimation of the seizure threshold 
may increase the risk of subconvulsive stimulation associated with cardiac 
arrhythmia (bradycardia or even asystole).6 Furthermore, a suboptimal treatment 
response may be the result in case of underestimation of the seizure threshold. 
Therefore, in right unilateral ECT electrical dosage 6-12 times above seizure 
threshold is advised for optimal effectiveness.12 Only with the ‘dose-titration’ 
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method, however, the individualized initial seizure threshold is determined at the 
first ECT session.2,12 Therewith, an optimal suprathreshold dosage may be chosen, 
and the expected effectiveness can be weighted against the risk of cognitive 
side-effects and cardiac arrhythmia.6,12 It remains unclear why increasing age 
affects seizure threshold, especially because other factors (e.g., electrode 
placement, pulse width, stimulus frequency) have been suggested to influence 
seizure threshold more than age.2 Therefore, based on the reviewed literature, 
hypotheses on the relation between increased seizure threshold in elderly patients 
and morphological, functional and clinical factors of aging are discussed below 
(see also Table 2). 
Morphological factors and decreased neuroexcitability
The aging brain undergoes several morphological changes which may contribute 
to decreased neuronal excitability and consequently higher seizure threshold in 
ECT.15,29,35 Elderly subjects show reduced brain volumes primarily affecting the 
prefrontal cortex, angulus gyrus, superior parietal gyri and hippocampus. Also, a 
general reduction of neural density (disproportionally more so in the frontal white 
matter) as well as a reduction in neuronal complexity are part of the aging process, 
thereby compromising cerebral synaptic communication.36-39 The age-related atrophy 
and decreased complexity of the brain network may increase the distance between 
ECT electrodes and cortex, which may lead to both decreased and less synchronous 
stimulation of the neurons resulting in reduced neuroexcitability.39,40
Because of the cerebral atrophy, the brain’s volume of cerebrospinal fluid (CSF) also 
increases with age.37 Furthermore, brain vessel changes and breakdown of the 
ventricular lining in old age can cause leakage of CSF into the white matter.41 It has 
been shown that, compared to controls, patients with late-life major depression 
have even larger volumes of CSF on magnetic resonance imaging (MRI).42 Electrical 
current flows easier through CSF than brain tissue.43 Consequently, increased 
volumes of CSF in elderly patients will result in more shunting of electrical 
current, also explaining higher seizure thresholds.43 The finding that elderly men 
show a more pronounced increase in CSF volumes than elderly women,44 is in line 
with the finding that elderly men have higher seizure thresholds compared to 
women.2,9
The interelectrode distance and scalp, skull and brain tissue characteristics are 
important determinants of the seizure threshold, probably also in elderly 
patients,27,43 Scalp impedance was hypothesized to increase with age which can 
imply higher seizure thresholds,45 although others did not find evidence for this 
factor.15 Anthropometric research regarding the forehead width showed a decrease 
66 | Chapter 4
of the bony and skin surface in old women (aged 81-90 years) but not in men, 
compared to youngsters.46 As a consequence, interelectrode distance as well as the 
skin-electrode interface may be relatively smaller in elderly women and thus 
contribute to lower seizure thresholds compared to elderly men.17 This is, however, 
not consistent with the fact that reduced interelectrode distances have been 
associated with increased shunting of the current through the scalp, thus 
requiring a higher stimulus intensity to elicit a seizure.43,47 
Table 2   Suggested hypotheses for morphological, functional and clinical 
factors explaining the relation between higher seizure threshold in 
electroconvulsive therapy (ECT) and aging
Morphological factors:
Atrophy - Age-related atrophy increases the distance between ECT 
electrodes and cortex.
- Age-related atrophy decreases the number of neurons that 
are stimulated or less synchronously activated. 
- Age-based decrease of neuronal density and complexity 
results in less synaptic communication.
Cerebrospinal fluid (CSF) - Increase of CSF volume results in more shunting of 
electrical current. 
- Elderly men have increased CSF volumes compared to 
women, therefore men have higher seizure thresholds.
Scalp impedance - Scalp impedance increases with age.
Interelectrode distances - Shorter interelectrode distances gives more shunting of the 
current through the scalp.
- Decrease of interelectrode distance and the skin-electrode 
interface in elderly women results in lower seizure 
threshold, compared to men.
Functional factors:




- Increased rates of subcortical WMH are associated with 
lower coherence on the quantitative electroencephalogram 
(a measure of neuronal connectivity) resulting in poorer 
neuroexcitability.
Neurotransmitters - More GABA-A receptors in the hippocampus.
- Reduction in the brain’s concentration of glutamate.
Clinical factors:
Medical illness - Higher prevalence of medical illnesses predicts higher 
seizure threshold. 
Pharmacotherapy - Concomitant medication use predicts higher seizure 
threshold.
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Functional factors and decreased neuroexcitability
Functional brain research in normal aging reveals a decrease of frontal metabolism 48 
and of activation in the prefrontal areas,36 which are especially stimulated in 
bilateral ECT 43 and may result in reduced neuronal excitability.9,35,40 Furthermore, 
synthesis, release and reuptake of different neurotransmitters change with aging, 
and inhibitory responses are increased.39,49 For example, surviving hippocampal 
neurons in aging possibly cause increased synthesis of GABA-A receptors in order 
to maintain inhibitory hippocampal circuitry,50 which may also raise the seizure 
threshold. Age-related reduction in the brain’s concentration of glutamate (an 
excitatory neurotransmitter) 36 may also result in reduced neuroexcitability. 
Nowadays, cortical excitability can be measured noninvasively using transcranial 
magnetic stimulation (TMS),51,52 but studies relating TMS to seizure threshold in 
ECT are lacking.
Late-onset depression has been associated with disruptions of fronto-striatal 
neuronal pathways due to ischemic microvascular lesions, associated with white 
matter hyperintensities (WMH) on MRI.53 These WMH are associated with low 
quantitative electroencephalographic (EEG) coherence, a measure of functional 
cerebral connectivity between brain regions and dependent upon integrity of 
white matter tracts and gray matter structures.54 Interestingly, lower interhemi-
spheric coherence in the delta frequency band on EEG measures of depressed 
patients treated with ECT has been associated with poorer treatment response.55 It 
may be hypothesized that decreased functional neuronal connectivity results in 
higher seizure threshold because a decreased number of neurons is less, or less 
synchronously, activated.40   
Clinical factors and increased seizure threshold 
Greater burden of medical illness, especially of cardiovascular origin, has been 
associated with higher initial seizure thresholds.24 As elderly depressed patients 
are at higher risk of serious medical comorbidity, including cardiovascular 
diseases,42 this clinical factor may contribute to the higher chance of increased 
seizure thresholds in older patients. Furthermore, such comorbidity often leads to 
pharmacotherapeutic treatments of which several are known to increase the 
seizure threshold, in particular anticonvulsants, benzodiazepines, beta-blockers, 
and calcium antagonists.56 Although in most studies on the relation of seizure 
threshold and age the use of psychopharmacological drugs was an exclusion 
criterion, concomitant use of non-psychotropic drugs was hardly mentioned. To 
what extent higher seizure threshold in elderly patients may be explained by 
higher prevalence of medical illnesses (e.g., cardiovascular diseases accompanied 
by white matter abnormalities) and/or concomitant medication use is not clear.
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Conclusion
The present review revealed that increasing age is moderately associated with an 
increased initial seizure threshold in ECT. Especially elderly men seem to require 
higher electrical doses, and their seizure thresholds are more likely to be raised 
during the ECT course compared to elderly women and younger patients. The 
question why aging affects seizure thresholds has received little attention. 
Reported hypotheses for the influence of increasing age on seizure threshold 
include decreased neuronal excitability, changes in morphologic (cerebral atrophy, 
increase of CSF, and of the scalp and skull thickness) and functional characteris-
tics of the brain (frontal hypometabolism, increased inhibitory responses, reduced 
EEG coherence), as well as somatic comorbidity and concomitant medication use. 
These hypotheses need to be further investigated which may lead to new strategies 
for optimizing ECT dosing, especially among frail elderly patients.
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Abstract
Background: At the start and during the course of electroconvulsive therapy 
(ECT), estimation of the seizure threshold (ST) is useful in weighing the expected 
effectiveness against the risks of side effects. Therefore, this study explores clinical 
factors predicting initial ST (IST) and levels of ST during the ECT course.
Methods: This prospective observational study included patients aged ≥ 18 years 
receiving ECT without contraindications for dosage titration. At the first and every 
sixth consecutive ECT session, ST level was measured. Using multivariate linear 
regression and multilevel models, predictors for IST and change in ST levels were 
examined. 
Results: A total of 91 patients (mean age, 59.1±15.0 years; 37% male; 97% diagnosis 
of depression) were included. In multivariable analysis, higher age (β=0.24; P=0.03) 
and bifrontotemporal (BL) electrode placement (β=0.42; P<0.001) were independent 
predictors for higher IST, explaining 49% of its variation. Also, these two variables 
independently predicted higher ST levels at different time points during the 
course. Using multilevel models, absence of a previous ECT course(s) predicted a 
steeper rise in ST during the course (P=0.03 for the interaction term time*previous 
ECT).
Limitations: The age-adjusted dose-titration method is somewhat crude, resulting 
in some measurement error. Concomitant medication use could have influenced 
ST levels. 
Conclusion: Increasing age and BL electrode placement predicted higher (I)ST, 
which should be taken into account when selecting ECT dosage. Previous ECT 
course(s) may avoid an increase in ST during the course of ECT.
5
Clinical predictors of seizure threshold | 77
Introduction
Electroconvulsive therapy (ECT) is an effective and safe treatment for depression as 
well as for other severe psychiatric conditions, such as catatonia, malignant neuroleptic 
syndrome, intractable psychosis, mania and some specific forms of delirium.1,2 To 
be effective, ECT must elicit generalized seizure activity in the brain by using an 
electrical stimulus that exceeds the seizure threshold (ST).3 Although controversy 
exists about the optimal electrical stimulus dosing strategy,4,5 there is some consensus 
that, especially in right unilateral (RUL), the stimulus should substantially exceed 
the ST.1,6,7 The initial ST (IST) has been defined as the smallest electrical dose 
needed to produce a generalized seizure of at least 25-30 s on an electroencephalo-
gram (EEG) at the first session.1,8 IST is reported to vary substantially between 
patients,4 although prospective studies are sparse.9,10 
Higher IST is associated with male gender,9,11 advanced age,9,11,12 bifrontotemporal 
(BL) electrode placement,9,13,14 lower dynamic impedance,13,15 a greater burden of 
medical illness,9 higher body mass index (BMI),9,16 and with previous ECT course(s) 
and concomitant medication use.1,9 
Because, on the one hand, the extent of the electrical dose above the IST is associated 
with more short-term cognitive side effects 17 and, on the other, subconvulsive 
stimulus administration is related to cardiac arrhythmia,18 better knowledge of 
the factors determining the individual IST would be clinically useful in weighing 
the expected effectiveness against the risks of side effects of ECT.
Over a complete treatment course, 40-100% of patients are reported to show a rise 
in  ST, and failure to reach a substantial ST increase may be a marker of lack of 
efficacy.19, 20 Moreover, in RUL ECT, a rise in ST during the course is associated with 
a significantly lower likelihood of therapeutic response; in addition, older patients 
are more likely to show ST increase and to be a non-responder.21 Apart from age, 
seizure intensity on EEG, total course duration and electrode placement, are 
suggested to determine a rise in ST.19-21 However, those disagreeing with these 
findings estimate that only 20-46% of patients would show a rise in ST during the 
course without negative consequences for the effectiveness of the treatment.1,22,23 
Hypotheses to explain the variation of IST and the change of ST during the ECT 
course in relation to clinical characteristics are sparse.24 Clinically, it will be 
helpful if patient characteristics could guide an optimal decision regarding the 
electrical stimulus, both at the start and during the course of ECT. Therefore, this 
study is a prospective investigation of clinical factors predicting IST and change of 
ST during the course of ECT. 
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Methods
Participants
All consecutive patients (from December 1, 2009, to November 15, 2011) with an 
indication for ECT at the Rijnstate Hospital (a 36-bed psychiatric facility in Arnhem, 
with a catchment area of 600,000 inhabitants) were asked to participate in this 
prospective observational study. Patients were excluded if age was < 18 years (n=0), 
no written informed consent was provided (n=5), and contraindications existed for 
dose titration (e.g., life-threatening condition of the patient, severe cardiovascular 
comorbidity; n=18). The local medical ethical committee approved the research 
protocol (trial registration number: NL24697.091.09). Written informed consent 
was obtained from all participants.
Age, gender, psychiatric disorder(s) classified according to the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) by at least two experienced 
psychiatrists, somatic comorbidity, BMI (weight/[height]2), previous ECT treatment 
(including time interval between last ECT session and current titration session), 
and concomitant medication use were documented in a standardized way. Of 
those patients who did not agree to participate or who were excluded, age, gender, 
psychiatric diagnoses (DSM-IV-TR, axis 1 and 2), and somatic comorbidity were 
registered. Only patients who were diagnosed with a well-documented personality 
disorder or who were clinically suspected to suffer from comorbid personality 
disorder were classified according to the DSM-IV-TR, axis 2.
Instruments
In the week before the first ECT (baseline), severity of the mood disorder was 
assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS), a validated 
observer-rated scale that contains 10 items (scored 1-6 per item). Maximum score 
is 60, with higher scores indicating more and a higher severity of depressive 
symptoms.25 
Cognitive functioning in the week before the first ECT (baseline) was measured 
using the Mini-Mental State Examination (MMSE). This validated instrument is 
commonly used to evaluate cognitive functioning in patients (maximum score is 
30, with lower scores indicating more cognitive dysfunction).26
Amount and severity of somatic comorbidity was rated using a modified Cumulative 
Illness Rating Scale (CIRS),27 consisting of 14 aspects of possible pathology and 
impairment of major organ systems, which are rated from 1 (no impairment to 
that organ/system) to 5 (impairment is life threatening; treatment is urgent or of 
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no avail; prognosis is grave), whose sum score ranges from 14 through 70 points.27 
The item ‘Psychiatric/Behavioral (includes depression, anxiety, agitation, psychosis, 
not dementia)’ was set at 5.
Electroconvulsive therapy and measurement seizure thresholds
ECT was administered using a constant-current (0.9 Ampère), brief-pulse (0.25 
milliseconds [ms] in RUL ECT; 0.5 ms in BL ECT) device (Thymatron IV; Somatics 
Incorporation, Lake Bluff, Illinois, USA), after intravenous induction of anesthesia 
with etomidate (1.5 mg/kg body mass), muscle paralysis with succinylcholine (0.5-1 
mg/kg body mass), and with appropriate oxygenation (100% oxygen, positive 
pressure) until the resumption of spontaneous respiration. Electrode placement 
was initially RUL, except in patients at high risk for suicidality and/or somatic 
complications, or if previous ECT had successfully been administered bilaterally. 
The decision as to whether a patient should be switched to BL during the course 
was based on the clinical judgment of the treating psychiatrist (mostly when less/
no clinical response had been reached after six RUL sessions). Treatment parameters 
(electrode placement, dynamic impedance, etomidate and succinylcholine dose, 
switch from RUL to BL during the course, and total ECT sessions of the index ECT 
course) were documented. 
ST was measured by an internationally accepted, empirical, age-adjusted, titration 
method at the 1st (IST), 6th, 12th, 18th and 24th (ST
6-12-18-24
, respectively) ECT session.7 
Consecutive measurements of ST depended on the duration of the ECT course. 
Index ECT was terminated if the patient had recovered, showed no (further) 
clinical improvement over a period of 2 weeks, or had shown no improvement at 
all after 10 BL sessions, based on the judgment of at least two experienced 
psychiatrists. If the starting stimulus dose failed to elicit a seizure of at least 20 s 
of motor activity measured with the cuff method and/or ≥ 25 s on EEG, stimulus 
charge was increased according to the titration schedule (for patients aged < 50 
years: 25.2 mC, 50.4 mC, 100.8 mC, 201.6 mC, and 403.2 mC; for patients aged ≥ 50 
years: 50.4 mC, 100.8 mC, 201.6 mC, and 403.2 mC), and the patient was restimulated 
after 30 s. After the titration session, dosage was set at 2.5 times ST for BL, and at 
six times ST for RUL treatment. Patients were treated twice weekly. During the 
titration session, if the ST was reached, and muscle relaxation and anesthesia were 
still sufficient, the patient was restimulated at a therapeutic dose in that same 
session.
Statistical analyses
Data are presented as means, standard deviations (SD) or standard errors (SE), medians 
and interquartile ranges (IQR), or numbers and percentages, when appropriate. 
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The excluded patients were compared to the study group using t-tests for age, 
MADRS score, and CIRS score, with the Χ2-test for gender, and the Mann-Whitney U 
test for the skewed MMSE score. First, descriptive statistics were applied on patient 
and treatment parameters. Differences between levels of IST and ST
6-12-18-24
 were 
calculated, and the median change in ST value per ST measurement was compared 
in the RUL and BL treated groups, using Mann-Whitney U tests. Second, to detect 
independent clinical factors predicting IST, univariate regression analyses were 
performed for all variables, followed by multivariate regression analyses selecting 
those variables that were associated with P-values < 0.10 in the univariate analyses. 
Finally, multivariate multilevel regression analyses (i.e., linear mixed models, 
adjusted for gender, age, CIRS score, MMSE score, previous ECT, electrode placement, 
dynamic impedance and succinylcholine dose) were performed to detect predictors 
of ST levels during the ECT course. Multilevel regression analysis was also used to 
analyze the association between baseline predictors and changes over time in ST 
(using appropriate interaction terms of the predictor*time; in which time was used 
as a continuous variable). In multilevel analyses, we used a compound symmetry 
covariance model with a two-level structure consisting of up to five observations 
in time (lower level) and the subject (higher level). 
All tests were two-sided with P<0.05 denoting statistical significance. SPSS for 
Windows version 17.0 (SPSS Inc., Chicago, Illinois, USA) was used for all analyses.
Results
Patient and treatment characteristics
Of the initial 114 patients, 91 indicated for ECT were included in this study. 
Excluded patients (no informed consent [n=5], contraindications for dose titration 
[n=18]) did not differ from the study group regarding mean age (t=-1.436; df=112; 
P=0.15), gender (Fisher’s exact test=0.053; df=1; P=0.51), mean MADRS score (t=0.445; 
df=99; P=0.66), median MMSE score (Mann-Whitney U test=344.5; Z=-1.88; P=0.06), 
and mean CIRS score (t=1.671; df=112; P=0.10). In the excluded group, there were 
more patients with a diagnosis of catatonia (Χ2=12.48; df=3; P=0.006).
Table 1 shows the patient and treatment characteristics. Mean age was 59.1±15.0 
years, 37% (n=34) was male, nearly all patients (97%; n=88) were depressed, and 26% 
(n=24) of them also had psychotic features. At baseline, mean MADRS score was 
36.2±8.6 and median MMSE score was 28 (IQR: 25-29). The CIRS showed a mean 
score of 22.2±3.8, and higher CIRS scores were significantly related to higher age 
(r=0.48; P<0.001). Of all patients, 31% (n=28) had undergone previous ECT course(s), 
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Table 1   Patient and treatment characteristics (n=91)
n (%); or mean ±SD*; 
or median; IQR**Patient characteristics
Male gender 34 (37.4)
Age, in years 59.1±15.0
Body Mass Index, in kg/m2 24.7; 22.7-27.3
CIRS score^ 22.0±3.8
Diagnostic category, according to axis 1 of DSM-IV-TR$ :
     Depressive disorder without psychotic features 50 (54.9)
     Depressive disorder with psychotic features 24 (26.4)
     Bipolar disorder, depressive episode 14 (15.4)
     Other disorders^^ 3 (3.3)
Documented or clinically suspected personality disorder present, 
according to axis 2 of DSM-IV-TR
27 (29.7)
MADRS*** score at baseline (n=88) 36.2±8.6
MMSE**** score at baseline (n=86) 28; 25-29
Treatment characteristics  
Had previous course(s) of ECT 28 (30.8)
Days between last ECT and index ECT (n=28) 646; 202-1393
Use of seizure threshold influencing concomitant 
pharmacotherapy:
     Benzodiazepines 54 (59.3)
     Anti-epileptics 7 (7.7)
     Antidepressants 52 (57.1)
     Antipsychotics 58 (63.7)
Electrode placement is bifrontotemporal at first titration session 28 (30.8)
Initial seizure threshold, in milliCoulombs 60.9±42.3
Dynamic impedance at first titration session, in Ω 275.5±59.5
Etomidate dose at first titration session, in mg 20; 18-22
Succinylcholine dose at first titration session, in mg 80; 75-100
Total number of ECT sessions# (n=86) 17.9±7.4
Switch from right unilateral to bifrontotemporal electrode 
placement during course## (n=63)
33 (52.4)
*Standard deviation; **Interquartile range; ^Cumulative Illness Rating Scale (modified version); $Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; ^^Schizophrenia (n=2) and 
malignant neuroleptic syndrome (n=1); ***Montgomery-Åsberg Depression Rating Scale; ****Mini-Mental 
State Examination; #Dropouts of treatment (suicide n=1; terminal illness n=1; wanted to stop n=3) excluded 
from analysis; ##Only patients started with right unilateral electrode placement were analyzed.
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with a median of 646 (IQR: 202-1,393) days between the last previous ECT session 
and the IST session. 
Mean level of IST was 60.9±42.3 mC. In patients treated with BL electrode 
placement, mean IST was on average 50 mC higher than in RUL (95.4±59.5 mC vs. 
45.6±16.8 mC; t-test=-4.35; df=28.9; P<0.001). During the ECT course, concomitant 
pharmacological drugs that might influence ST were commonly used, mostly 
antipsychotics (64%; n=58). Of all patients, 69% (n=63) were initially treated with 
RUL ECT, of whom 52% (n=33) switched to BL electrode placement during the ECT 
course. A mean of 17.9±7.4 treatments were administered during the index ECT 
course. 
Predictors for IST
Univariate regression analyses showed significant associations with higher IST of 
higher age (P<0.001), higher CIRS score (P<0.001), lower MMSE score at baseline 
(P=0.002), having had previous ECT (P=0.001), treatment with BL electrode placement 
(P<0.001), lower dynamic impedance (P=0.02), and lower dose of succinylcholine 
(P=0.005) (Table 2). Multivariable regression analysis yielded higher age (β=0.24;	
P=0.03) and BL electrode placement (β=0.42; P<0.001) as independent predictors for 
higher IST. This model explained 49% (R2=0.493) of the variation in IST.
Predicting for ST change during the ECT course
ST values were similar to IST in 78% (n=67 of 86) of the patients at the ST
6
 
measurement, in 60% (n=40 of 67) at ST
12
, in 44% (n=19 of 43) at ST
18
, and in 33% 
(n=5 of 15) at ST
24
. Table 3 presents the changes in ST over time in the RUL- and 
BL-treated groups. Mean ST levels increased during the course (t=4.797; df=231; 
P<0.001; see also Figure 1B), in patients undergoing RUL and BL ECT. Six (of 86; 7%) 
patients showed a lower ST
6
 than IST, as well as five (of 67; 7%) at the ST
12
 
measurement, three (of 43; 7%) at ST
18
, and one (of 15; 7%) at ST
24
. At the 12th session, 
a rise in ST with respect to IST occurred 40% more often in BL than in RUL electrode 
placement (53% [n=24] vs. 14% [n=3]; Fisher’s exact test=9.68;	df=1; P=0.03), with a 
median change of 25.2 (IQR: 0-50.4) mC in BL-treated patients and of zero (IQR: 0-0) 
mC in RUL-treated patients (P=0.02; Table 3). At the ST
18 
measurement, the median 
value of ST change was also higher with BL electrode placement, but with 
borderline significance (P=0.06); at ST
24
, the median value of ST change in BL 
treated patients was higher than in the RUL group, but the difference was not 
significant (P=0.34; Table 3).
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Figure 1   Adjusted mean values* of dynamic impedance and seizure threshold 
during the course of electroconvulsive therapy in patients treated 
with right unilateral or bifrontotemporal electrode placement [A, B], 
and in patients aged < 50 years (n=29) and ≥ 50 years (n=62) [C, D]
*Error bars represent standard errors and black (dotted) lines are regression lines. The size of each square 
is proportional to the number of patients. Adjusted mean values and P-values were calculated by 
multivariable regression analysis adjusted for age [for A and B], CIRS score, MMSE score at baseline, 
previous ECT and electrode placement [for C and D], dynamic impedance, and succinylcholine dose.
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Using multilevel linear models, higher 
age (β=0.28; P=0.009) and BL electrode 
placement (β=0.35; P<0.001) were 
independent predictors for higher ST 
during the course (Table 2). Mean 
dynamic impedance decreased during 
the course (t=-5.031; df=217; P<0.001), 
and lower dynamic impedance showed 
borderline significance (β=-0.11; P=0.06) 
for being a predictor of higher ST 
during the course. Figure 1 shows 
that, during the ECT course, adjusted 
mean values of dynamic impedance 
decreased and were significantly lower 
in BL-treated compared with RUL- 
treated patients (P<0.001; Figure 1A) 
and also that adjusted mean values of ST 
increased for both electrode placements 
and were significantly higher in patients 
treated with BL electrode placement 
compared with those treated with RUL 
(P<0.001; Figure 1B). Comparing patients 
aged < 50 years and ≥ 50 years, no 
difference was found regarding adjusted 
mean values of dynamic impedance 
during the course (Figure 1C). In patients 
aged ≥ 50 years, adjusted mean values of 
ST (Figure 1D) showed a steeper increase 
during the ECT course than in patients 
aged < 50 years (P=0.02), illustrating the 
strong linear association with age as a 
continuous variable (Table 2).
Multivariate multilevel models in which 
age, CIRS score at baseline, MMSE score 
at baseline, electrode placement, dynamic 
impedance and succinylcholine dose 
were entered showed an independent 
interaction term only for having had 
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value of ST (t=2.188; df=217; P=0.03). Figure 2 shows that patients with previous ECT 
course(s) had less/no rise in ST during the course and that the absence of previous 
ECT treatment predicted a steeper rise in ST.
Figure 2   Adjusted mean values* of seizure threshold during the course of 
 electroconvulsive therapy (ECT) in patients with no previous ECT 
(n=63), and in patients with previous ECT course(s) (n=28)
* Error bars represent standard errors and the black (dotted) line is the regression line. The size of each 
square is proportional to the number of patients. Adjusted mean values and the P-value for interaction 
(i.e. time*previous ECT) was calculated by multivariable regression analysis adjusted for age, CIRS score, 
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Discussion
In this prospective, observational study in patients treated with ECT, higher IST 
was predicted by a higher age and BL electrode placement. During the ECT course 
there was a rise in ST, but not in all patients. A rise in ST occurred more often in 
patients treated with BL electrode placement and in those having had more ECT 
sessions. During the course, higher age and BL electrode placement also predicted 
higher ST levels. At the same time, having had previous ECT course(s) was associated 
with an absence of ST increase and, therefore, seems to avoid any rise in ST.
Predictors of IST and ST levels during the course
In internationally accepted guidelines, beside dosage-titration methods, age-based 
dosing strategies are being mentioned for use in clinical practice.7 Our study seems 
to justify the use of these age-based strategies, because age was an important 
predictor of IST and rise in ST during the course of ECT. CIRS score, dynamic 
impedance, lower MMSE at baseline, and succinylcholine dose were no longer 
independently associated with (I)ST, as they may all be critically dependent on age. 
Although it remains unclear why higher age is associated with higher (I)ST, several 
factors of morphological brain maturation related to age are hypothesized to 
influence ST.24 For example, advanced age was related to both increased scalp 
impedance and cerebral atrophy. Furthermore, in elderly patients less functional 
connectivity between brain areas (due to neuronal damage) was suggested to result 
in less seizure propagation.33 Also, an ECT-induced shift of the brains inhibitory 
(GABA) versus excitatory (glutamate) potency has been suggested to explain ST 
increase during the course.22,33 Therefore, it is important to study these possible 
morphological and functional determinants prospectively.24 
In accordance with other studies,9,11,13-15,20,21,28 we also found that BL electrode 
placement predicted higher ST levels during the ECT course and more often 
showed a rise in ST compared to RUL-treated patients. The higher ST in case of BL 
electrode placement might be related to differences in current pathways; that is, 
in BL ECT, there is a greater interelectrode distance than in RUL ECT, probably 
resulting in more shunting of current through the scalp which might require a 
higher electrical dosage to elicit seizure activity.29 Moreover, due to the presence of 
hair and the difficulty of keeping two electrodes coupled to the scalp, the 
impedance to the passage of current might be higher and more variable with RUL 
than with BL electrode placement, probably resulting in a higher ST.29
5
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Dynamic impedance is the resistance observed between the electrodes, during the 
passage of the electrical stimulus, and mainly depends on electrode-skin interface 
(e.g., hair, conductive gel), skull thickness and electrode placement.29 A lower 
dynamic impedance is associated with BL electrode placement and with a higher 
IST, and the dynamic impedance was found to decrease during the ECT course.13,20 
It has been hypothesized that dynamic impedance would decrease due to electro-
chemical changes of the electrode-scalp interface during the ECT course.20 
However, it is more likely that the higher electrical stimulation, due to ST increase 
later in the ECT course, would have resulted in lower dynamic impedance, that is, 
because the passage of relatively high intensity electrical stimuli resulted in much 
lower impedance values than the passage of lower intensity stimuli.29 Our study 
supports these earlier findings, since lower dynamic impedance was associated 
with higher IST in univariate regression analysis, and the adjusted mean dynamic 
impedance values decreased during the ECT course. Also, lower dynamic 
impedance proved to be an independent predictor for higher ST levels during the 
ECT course, and dynamic impedance was lower in BL-treated compared with that 
in RUL-treated patients. 
The use of concomitant pharmacological drugs may have both increased (e.g., anti-
epileptics and benzodiazepines) and decreased (e.g., tricyclic antidepressants and 
antipsychotics) the level of IST. However, our univariate regression analyses 
showed no significant effect of the use of medication on IST level. This might be 
because, in most of our patients, medications with both ST increasing (benzo-
diazepines, anti-epileptics) and ST decreasing (antidepressants, antipsychotics) 
properties were administered simultaneously, so that no specific influence could 
be established. Also, the anticonvulsive properties of the anesthetics may have had 
a stronger influence on ST, thereby masking the influence of concomitant 
medication, as also reported by others.30 
Predictors of ST increase during the course
ST is reported to increase in ≤ 20-90% of patients during a course of ECT, probably 
due to an induced shift of the brain’s inhibitory versus excitatory potency.19-22,31 
Accordingly, in the present study, mean ST levels increased during the course in 
≤ 67% of our patients. Although the median change of ST at the consecutive ST 
measurement points was higher with BL than with RUL electrode placement, in 
the multilevel models the interaction term of time*electrode placement was not 
significant. 
Having undergone a previous course of ECT a considerable time before the index 
ECT (median: 646 days; IQR: 202-1395 days) was independently associated with the 
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absence of ST increase during the treatment course. Although the mean IST level 
of patients who underwent ECT for the first time was similar to that of patients 
having undergone previous ECT, first-time patients showed a rise in ST during the 
further ECT course, as also reported by others.28 However, another study suggested 
that prior ECT course(s) resulted in higher IST in future ECT, but only in male 
patients.32 In summary, previous ECT might preclude an increase of ST during the 
ECT course, suggesting long-term adaptation of the brain after earlier ECT. 
Alternatively, the association may have been confounded by the characteristic of 
suffering from chronic or remitting depression, being reflected in the previous 
ECT course; these latter patients might have a lower tendency for a rise in ST 
during the ECT course.
Clinical implications
In the present study, a rise in ST occurred in a substantial proportion of patients 
underpinning the rationale to take age into account in ECT dosing strategies. Also, 
because comparison of BL and RUL ECT revealed that on average 50 mC higher IST 
can be expected with BL ECT, and ST increase during ECT might occur up to 40% 
more often, electrode placement should be taken into account when selecting the 
dose of the first and subsequent ECT sessions. Furthermore, patients treated earlier 
with ECT might be a specific clinical group. Clinicians should be aware of the fact 
that previous ECT course(s) might predict ST stability during the course. This 
might imply that, in these patients, less electrical dose adjustments are required 
during the ECT course, which might also prevent cognitive side effects. 
Study limitations
Several potential limitations need to be addressed. First, for ECT, ST is determined 
by several physical stimulus characteristics (e.g., pulse width, frequency, current 
strength) and by the minimum seizure duration selected to be sufficient in the 
titration procedure. In earlier studies, different settings and definitions have been 
used,1,33  thus hampering comparison of our estimated ST levels with those of 
others. Furthermore, our ECT device controls charge delivery by frequency, 
stimulus train duration and setting of the pulse width, resulting in changes of 
these parameters when delivering higher charges.1 This might have influenced the 
measurements of IST and ST levels, although the changes were the same for those 
patients who needed higher charges. Second, our ST levels were determined by a 
somewhat crude method, because the titration protocol consisted of steps of ≥ 25 
mC. Using an ECT device that offers the possibility to increase the dose with (very 
low) steps might have refined the titration procedure, but this method would 
probably be limited due to the maximum length of anesthesia and muscle paralysis. 
Furthermore, we used an age-based adjustment in our titration protocol,13 which 
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may have led to some bias and circularity, as such adjustment may explain (in 
part) the higher ST levels in older patients. Finally, almost all of our patients used 
concomitant medication during the ECT procedure. 
In conclusion, in 91 prospectively examined, mostly depressed and older patients 
treated with ECT, age and electrode placement independently predicted IST and ST 
levels during the course. Some patients showed a persistent rise in ST at the 
consecutive measurement points. However, having had previous ECT course(s) 
predicted an absence of ST increase during the ECT course, independent of age and 
electrode placement. Future studies should explore whether or not these factors 
adversely affect treatment response.
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Abstract
Background: In electroconvulsive therapy (ECT), the electrical current must pass 
the scalp, skull, cerebrospinal fluid (CSF) and brain tissues, to sufficiently exceed 
the seizure threshold (ST). 
Objective: To investigate the relationship between these anatomical strata of the 
head and the level of the ST, in both right unilateral (RUL) and bifrontotemporal 
(BL) ECT.
Methods: Observational prospective study among 74 mainly depressed patients. 
STs were measured at the 1st (initial ST), 6th, 12th, 18th and 24th session. MRI scans 
were acquired before the 1st session. Scalp and skull thickness at electrode sites 
were measured on T
2
-weighted images. Volumes of intracranial space (ICV), CSF, 
gray and white matter, and white matter hyperintensities were estimated using 
whole brain isovoxel T
1
-weighted images. Separate multivariate regression analyses 
for RUL (n=55) and BL (n=19) treated groups were used to estimate the predictive 
values of the MRI variables. 
Results: The patients had a mean age of 57.7±14.8 years, and 39% were men. After 
adjustment for age, gender and ICV, CSF volume strongly and independently 
predicted initial ST in both RUL (β=0.31; P=0.049) and BL ECT (β=0.64; P=0.007). 
Using multilevel regression analysis, CSF volume was associated with ST during 
the remaining RUL ECT course (β=0.20; P=0.02). 
Conclusions: Taking into account the limitations in the titration method and MRI 
analysis, volume of CSF strongly and independently predicted initial ST. Therefore, 
the exclusive use of age-based ECT dosing methods may result in suboptimal 
electrical stimulus dosage in patients with CSF volumes that are not within the 
average range.
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Introduction
Electroconvulsive therapy (ECT) is a fast, effective and safe treatment with remission 
rates up to 80% in cases of severe depression.1-3 Generalized seizure activity is 
elicited at several consecutive ECT sessions.4 Seizure activity will only be achieved 
when the patient’s seizure threshold (ST) is exceeded by a flow of electrical current.5 
The initial ST (IST), as measured at the first ECT session, varies among patients over 
a forty-fold range,6 with higher age and bifrontotemporal (BL) electrode placement 
as reported predictors of higher IST.7-9  Also, ST has been shown to change during 
the course, at least in some patients.10-12 For optimal ECT effectiveness, the electrical 
dosage must be substantially increased above the ST, especially in right unilateral 
(RUL) ECT.13,14 Because of the presumed increase in ST, consecutive adjustment of 
electrical dosage during the ECT course has been advised.12,15 In daily clinical 
practice, age-based dosing methods are frequently used to determine the proper 
initial electrical dose.15,16 Alternatively, a stimulus titration method is advised to 
estimate an individualized electrical dose.6,17 
The electrical stimulus must excite sufficient volumes of brain tissue to elicit seizure 
activity, and is determined by several parameters, e.g., pulse amplitude, shape, 
pulse width, train frequency, directionality, polarity and stimulus duration.18 
Higher electrical dosages (i.e., a higher number of pulses) activate larger brain 
regions.5,19,20 Moreover, electrical currents will not move in a straight line between 
the electrodes, but traverse the tissues proportional to its resistances.5,19 To reach 
brain tissue effectively, the electrical stimulus must successively pass through 
scalp, skull, meninges, and cerebrospinal fluid (CSF), with each compartment 
(Figure 1) having a typical resistance to the passage of the electrical stimulus.5,19 
The skull has a high electrical resistance and gray matter has less resistance, 
whereas CSF conducts current very well due to the high concentration of free ions 
in this aqueous solution,5,19 Consequently, the stimulus dose determines whether 
the power of the electrical current is sufficient to pass through the different 
compartments to reach the essential brain tissue. 
Electrode placement and head anatomy determine the electric field distribution in the 
brain.18 The pathway of the electrical current depends on the electrode proximity 
to skull foramina, sutures and eye cavities, as well as on brain surface morphology 
with varying amounts of surrounding CSF.21,22 In RUL application, the distance 
between the electrodes is much shorter than in BL, resulting in a more evenly 
distributed electrical stimulus across the anterior cortex and increased shunting of 
current.5,21,23 Therefore, electrode placement plays an important role in determining 
the spatial distribution of the ECT-induced electric field and, consequently, the ST 
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level. RUL electrodes (positioned more closely together) cause more shunting in the 
scalp and produce more focal and weaker electric fields within the brain. Therefore, 
in RUL ECT, more electrical pulses are needed to elicit seizure activity than in BL 
ECT,18,19 Additionally, after local seizure induction in areas directly beneath the 
electrodes, cortico-(thalamico-)cortical propagation is required to further spread 
the seizure.24 This propagation may be hampered by interruption of these circuits, 
for instance, due to cerebral lesions such as white matter hyperintensities (WMH). 
In clinical studies, subcortico-frontal lesions predicted less effective ECT.25-27 
Therefore, information on the relevance of each barrier for the electrical stimulus 
to excite brain tissue effectively, as well as for the seizure to propagate sufficiently, 
seems important in order to optimize ECT in an individual patient.
However, prospective studies on the relationship between anatomical characteristics 
on magnetic resonance imaging (MRI) of the head on the one hand, and IST and ST 
change on the other, are sparse.28 Therefore, this prospective study explores the 
influence of head anatomy on IST and ST during the ECT course.
Figure 1   Magnetic resonance imaging (MRI)* of scalp, skull, cerebrospinal fluid 
(CSF), gray matter, white matter and white matter hyperintensities 
related to right unilateral (RUL) and bifrontotemporal (BL) electrode 
placement in electroconvulsive therapy
*T
1
-weighted MRI of the head in gray colors of a patient showing the highest volume of CSF. Voxels 
representing CSF are colored blue, gray matter voxels are yellow, white matter is green, and areas 
underneath the voxels that might be detected as white matter hyperintensities are colored red. Gray 
triangles represent electrode placement sites. RUL means 3 cm right of the sagittal midline on the vertex 
and 3 cm above the midline between the right meatus acusticus externa and lateral angle of the right 
orbita. BL means 3 cm above the midline between the meatus acusticus externa and lateral angle of the 
orbita, right and left frontotemporal, respectively.
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Methods and materials
Participants and clinical data acquisition
In this observational prospective study, all consecutive patients indicated for ECT 
in Rijnstate Hospital (Arnhem, the Netherlands, a 36-bed psychiatric facility with 
a catchment area of 600,000 inhabitants), from December 1 2009 until November 
15 2011, were asked to participate. Patients were excluded in case of age < 18 years, 
absence of written informed consent, and a contraindication for dose titration 
(e.g., life-threatening condition, severe cardiovascular comorbidity) or for MRI. 
Within two weeks before the first ECT session, an MRI of the head was made. 
Patient characteristics were extracted from the medical chart. At baseline, severity 
of depression was measured using the Montgomery-Åsberg Depression Rating 
Scale (MADRS) 29 and cognitive functioning using the Mini-Mental State 
Examination (MMSE) 30, both within one week before the start of ECT. Amount and 
severity of somatic comorbidity was rated using a modified Cumulative Illness 
Rating Scale (CIRS) 31. The Medical Ethical committee approved the study protocol, 
and written informed consent was obtained from all participants. 
Patient and clinical characteristics of the study population are described in detail 
elsewhere.7 In short, higher age (β=0.24; P=0.03) and BL electrode placement 
(β=0.42; P<0.001) independently predicted higher IST.7 During the ECT course, 
concomitant medications, including psychopharmacological agents, were continued 
in a similar dosage, and did not predict the level of IST.7 
Electroconvulsive therapy and measurement of ST
ECT was administered using a constant-current (0.9 Ampère), brief-pulse (0.25 
milliseconds [ms] in RUL and 0.5 ms in BL electrode placement) device (Thymatron 
IV; Somatics Incorporation, Lake Bluff, Illinois, USA), after induction of anesthesia 
with intravenous etomidate (1.5 mg/kg body mass), muscle paralysis with 
intravenous succinylcholine (0.5-1 mg/kg body mass), and with appropriate 
oxygenation until the resumption of spontaneous respiration. Electrode placement 
was initially RUL, except in patients at high risk for suicidality and/or somatic 
complications, or if previous ECT had successfully been administered bilaterally. 
STs were measured at the 1st, 6th, 12th, 18th and 24th ECT session, in which the latter 
measurements depended on the duration of the course. The same age-adjusted 
titration schedule was used at each titration session;15 patients aged < 50 years 
started with 25.2 milliCoulombs (mC) and older patients with 50.4 mC. If the first 
stimulus dose failed to elicit a seizure of at least 20 s of motor activity measured 
with the cuff method and/or ≥ 25 s on the electroencephalogram, the stimulus 
charge was doubled according to the titration schedule (see Appendix 1 for the 
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independent stimulus parameters), and the patient was re-stimulated after 30 s. To 
become therapeutic, the consecutive electrical dosage was set at 6 times ST in RUL 
ECT and at 2.5 times ST in BL ECT. Patients were treated twice weekly. At the 
titration session, if the ST was reached and the levels of muscle relaxation and 
sedation were still appropriate, the patient was re-stimulated at a therapeutic dose 
also in this session.
MRI data acquisition
Imaging was performed on a 1.5 Tesla Philips Medical Instruments (Best, the 
Netherlands) MRI scanner, using a 16-channel SENSE receive head coil. The 




W) turbo field echo 
MRI (sequence parameters: repetition time = 7.6 ms; echo time = 3.5 ms; flip angle 





spin echo MRI (sequence parameters: repetition time = 4803 ms; echo time = 100 
ms; flip angle = 90°; 24 transverse slices; in plane voxel resolution = 0.60x0.76 mm; 
slice thickness = 5 mm; slice gap = 1 mm), and a FLuid Attenuated Inverse Recovery 
(FLAIR) image (sequence parameters: repetition time = 8000 ms; echo time = 140 
ms; flip angle = 90°; 26 coronal slices; in plane voxel resolution = 0.9x1.1 mm; slice 
thickness = 5 mm; slice gap = 1 mm).
Measurement of scalp and skull thickness
Since the flow of current through the skull is mostly normal to the surface and 
occurs in the vicinity of the electrodes due to the low conductivity of the skull,5,18 
skull thickness was measured at the electrode placement sites. Furthermore, it 
was considered that scalp thickness measured under the electrodes was 
representative for individual scalp thickness around the head. On T
2
W images, two 
independent raters (BART, TWFP) measured the thicknesses in millimetres (mm) 
at the RUL (i.e., 3 cm right of the sagittal midline on the vertex according to d’Elia 
32 and 3 cm above the midline between the right meatus acusticus externa and 
lateral angle of the right orbita) and at the BL electrode placement sites (i.e., 3 cm 
above the midline between the meatus acusticus externa and lateral angle of the 
orbita, right and left frontotemporal, respectively). Interclass coefficients (ICCs) 
between the raters ranged from 0.6-0.7. Means of the scalp and skull thickness, as 
measured by the two raters, were calculated for the three localisations (vertex, 
right and left frontotemporal).
Structural MRI analysis
All analyses were performed using the Oxford Centre for Functional MRI of the 
Brain (FMRIB) Software Library (FSL) tools (http://www.fmrib.ox.ac.uk/fsl/). Prior to 
analysis, all raw data were visually checked for the presence of (motion) artifacts.
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Brain extraction. 
For each subject, T
1
W and FLAIR volumes were brain-extracted (BETv2.1, manually 
selected individual fractional intensity thresholds).
Mask. 
For each subject, a FLAIR-based mask of WMH was created by manually delineating 
WMH on all coronal slices in FSL view.
Registration. 
For each subject, linear transformation parameters from FLAIR native space to 
T
1
W native space were estimated (FLIRTv5.5) and applied to the FLAIR-based mask 
of WMH, resulting in one T
1
W-compatible probability mask that was then 
thresholded and binarized (automatically calculated individual thresholds to 




W was segmented into partial volume maps of total CSF, 
total gray matter and total white matter (FASTv4.1). White matter that was 
erroneously classified as gray matter due to the presence of WMH (as WMH appear 
hypo-intense on T
1
W) was identified using the T
1
W-compatible WMH mask, 
subtracted from the total gray matter segmentation and added to the total white 
matter segmentation. All segmentations were visually inspected; no problems 
occurred during the analysis.
Volumes. 
Volumes of total CSF, total gray and white matter, total WMH, and total intracranial 
volume (ICV) were calculated by multiplying the number of voxels within each 
partial volume map by the mean value of all voxels within each partial volume 
map, then multiplied by the voxel volume (1.1x1.1x1.1 mm) and, finally, divided by 
1000 to obtain volumes in milliliters (mL).
Analysis of data
Data are presented as means ± standard deviations (SD) and ranges, medians and 
interquartile ranges (IQR), or numbers and percentages when appropriate. 
Normally distributed continuous variables (age and MADRS score) between the 
included/excluded groups were compared using t-tests, non-normally distributed 
continuous variables (CIRS score and MMSE score) using Mann-Whitney U tests, 
and categorical variables (gender and diagnosis) were compared using Chi-square 
tests. Descriptive statistics were used to describe the clinical and MRI characteris-
tics. Mean composite scores for the three localizations of scalp and skull thickness 
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were calculated. Z-scores were obtained for all appropriate variables. Continuous 
clinical and MRI variables for RUL and BL electrode placement were compared 
using t-tests, non-normally distributed continuous variables using Mann-Whitney 
U tests, and categorical variables using Chi-square tests.   
Because of the assumed differences between RUL and BL current distributions and 
used pulse widths,5,33 preliminary analyses were performed, showing a significant 
interaction term (CSF*RUL/BL; P<0.001). Therefore, regression analyses were 
performed for RUL and BL groups separately. First, multivariate regression 
analyses, adjusted for age, gender and ICV, were done using the z-scores of the six 
compartments (composite mean scalp and skull thickness, and total volumes of 
CSF, gray matter, white matter and WMH, respectively) as separate independent 
variables, to find variables showing P<0.10 as possible predictor of the dependent 
variable IST. Preliminary analyses were conducted to ensure no violation of the 
assumptions of normality, linearity, multicollinearity and homoscedasticity. 
Hence, because of collinearity between both gray and white matter volumes and 
ICV (tolerance<0.1 and variance inflation factor [VIF] value>10), the latter was 
excluded in the next multivariate analyses. Then, multivariate regression analyses 
were done with IST as dependent variable and age, gender and all MRI variables 
showing P<0.10 as independent factors. Finally, multivariate regression analyses 
were repeated for the ST
6-12-18-24 
measured during the ECT course (if available), and 
combined in a multilevel regression analysis (i.e., mixed linear analysis) entering 
only the previously identified independent predictors of IST, as well as age, gender 
and ICV. All tests were two-sided with P<0.05 denoting statistical significance; 
SPSS for Windows (version 18.0) was used for all analyses.
Results
Participants, clinical and anatomical MRI characteristics
Complete MRI datasets were obtained for 77 patients. Due to excessive motion 
artifacts on the T
1
W images, another three subjects had to be excluded, yielding a 
final sample of 74 patients from the 114 patients indicated for ECT (Figure 2). The 
excluded patients did not differ from the study group regarding mean age (P=0.82), 
gender (P=0.56) and mean MADRS score (P=0.55), but excluded patients had a 
higher median CIRS score (P=0.003), a lower median MMSE score (P=0.02), and 
more often had psychotic depression (P=0.03) and catatonia (P=0.003).
Mean age of the study population was 57.7±14.8 (range: 22-93) years, with 39% men 
(n=29) (Table 1). The median CIRS score was 21 (IQR: 19-23). Of all patients, 99% 
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(n=73) suffered from a mood disorder and most patients used a constant dose 
of concomitant medication. During the index ECT course, an average of 18.1±7.2 
(range: 6-38) ECT sessions was administered to 69 patients who completed the 
course. Anatomical characteristics of the patients are also summarized in Table 1. 
Patients treated with RUL (n=55) and BL (n=19) electrode placement did not differ 
from each other, except for their mean level of IST (45.4±17.8 mC in RUL and 
87.5±52.0 mC in BL; P<0.001), as was expected.
Figure 2   Flow diagram showing the patient selection process
*Magnetic Resonance Imaging
114 patients indicated 
for electroconvulsive therapy (ECT)
23 (20.2%) patients excluded:
0 Age < 18 years
7 Emergency ECT
9 Contraindication for dosage titration
2 Contraindication for undergoing MRI *
5 No informed consent
 
91 included patients
17 (18.7%) No MRI data:
14 Incomplete MRI data-set
3 Motion artifacts
74 patients included 
in the analyses: 
74 with baseline data
70 with 6th titration session
54 with 12th titration session
36 with 18th titration session
11 with 24th titration session



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































106 | Chapter 6
Anatomical characteristics and ST
Table 2 shows the results of the regression analyses. Because total ICV may 
confound volumes of CSF and brain structures measured, the influence of ICV on 
the level of IST was analyzed first with univariate regression analysis and showed 
no association (in RUL β=-0.14, P=0.31; in BL β=0.08, P=0.73). In both RUL and BL 
groups, the volume of CSF was positively associated with IST (Table 2). Because of 
Table 2   Data on regression analyses to detect independent anatomical 
 characteristics on magnetic resonance imaging predicting the variation 
of seizure threshold (ST) in 74 patients undergoing right unilateral 
(RUL) and bifrontotemporal (BL) electroconvulsive therapy (ECT).
Index-scores in RUL ECT Correlates of initial ST 
(n=55)*
 Multivariate correlates 
of initial ST** (n=55)
 β-coefficient P-value  β-coefficient P-value
Age 0.41 0.002 0.29 0.03
Gender -0.03 0.82 -0.07 0.69
Thickness of the scalp 0.24 0.08 0.19 0.14
Thickness of the skull 0.21 0.11
Volume of total cerebrospinal fluid 0.47 0.02 0.31 0.049
Volume of total gray matter -0.56 0.15
Volume of total white matter -0.74 0.07 -0.30 0.10
Volume of total white matter 
hyperintensities
0.11 0.50
Index-scores in BL ECT Correlates of initial ST 
(n=19)*
 Multivariate correlates 
of initial ST** (n=19)
 β-coefficient P-value  β-coefficient P-value
Age 0.64 0.003 0.33 0.24
Gender -0.02 0.94 -0.14 0.49
Thickness of the scalp 0.02 0.94
Thickness of the skull -0.08 0.71
Volume of total cerebrospinal fluid 0.67 0.03 0.64 0.007
Volume of total gray matter -0.89 0.08 -0.05 0.84
Volume of total white matter -0.66 0.26
Volume of total white matter 
hyperintensities
-0.02 0.96
*All six anatomical structures were adjusted for age, gender and intracranial volume (ICV). **Multivariate 
regression analysis only for variables showing P<0.10 at first regression analysis, adjusted for age and 
gender, and not for ICV due to multicollinearity.
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multicollinearity with gray and white matter volumes, ICV was not entered into 
the multivariate analyses. After entering all variables showing P<0.10 in the first 
step of our regression analyses, only the volume of CSF was an independent 
predictor of the level of IST, in both RUL and BL treated patients (β=0.31; P=0.049 
and β=0.64; P=0.007, respectively; see Table 2). In an additional confirmatory 
analysis, in which age, gender and ICV were entered into the model, the strong 
predictive value of CSF volume persisted in RUL and BL ECT (β=0.47, P=0.02 and 
β=0.67, P=0.03, respectively) (Figure 3). 
Figure 3   Mean values of initial seizure threshold in milliCoulombs (mC;  
with error bars representing standard errors) according to categories 
of volumes of cerebrospinal fluid in milliliters (mL) in patients 
undergoing either bifrontotemporal (BL) or right unilateral (RUL) 
 electroconvulsive therapy *
* The dotted lines represent the regression lines. The size of each square is proportional to the number of 
patients. Mean values are adjusted for age, gender and volume of intracranial space. Beta-coefficients and 
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Bifrontotemporal (BL) electrode placement (n=19; β=0.67; P=0.031)
Right unilateral (RUL) electrode placement (n=55; β=0.47; P=0.016)
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Subsequently, entering the CSF volume into the linear mixed model and using 
ST
6-12-18-24
 as dependent variables, thereby adjusting for age, gender and ICV, a 
significant association was found with the consecutive ST levels during the RUL 
ECT course (β=0.20; P=0.02). In the BL treated group, the positive association 
appeared to be similar in strength, although not significant (β=0.23; P=0.24). 
Discussion
In this observational prospective study, the total volume of CSF appeared to be the 
only independent and strong morphological predictor of IST in both RUL and BL 
ECT. This relationship persisted after adjustment for age, gender and ICV, and 
showed an even stronger association with BL than with RUL electrode placement. 
Although this relation has previously been hypothesized 28 and was estimated in 
computer models,19 this prospective study is (to our knowledge) the first to 
demonstrate an important role for CSF volume on the level of IST. 
The fact that CSF volume predicted the IST can be explained by its biophysical 
properties. CSF is a relatively cell-free, low-protein ultrafiltrate of blood, and 
contains an abundant amount of ions.34 As a good electric conductor19, CSF may 
serve as a spherical conducting shell (as a Faraday cage) that reduces the size of the 
ECT-induced electric field inside the brain. A weaker and more focal electrical 
field, in case of more surrounding CSF, has to be pulsed more times to trigger a 
seizure.18,19 Therefore, in our patients with a relatively increased CSF volume, 
during titration with fixed current amplitude and pulse width, the number of 
electrical pulses probably had to be increased. 
Different electrical shunting patterns were expected in RUL and BL electrode 
placement,5,21 as was confirmed by the significant interaction term CSF*RUL/BL. In 
BL ECT, the relationship between CSF volume and IST was much stronger than in 
RUL ECT. Possibly, a larger distance between BL placed electrodes, and enhanced 
electrical shunting through more CSF, resulted in higher IST levels than in RUL 
placement. On the other hand, the larger 0.5 ms pulse width used in BL placement, 
which may show higher ST than with 0.25 ms used in RUL,33 may have confounded 
the results. 
Anatomical differences and disruptions of current pathways are suggested to 
explain variations of ST in patients.23,28,35-37 In a recent computerized simulation 
study of ECT in spherical head models, a 15% decrease in volume of gray and white 
matter (corresponding to an increase of CSF volume of 116% and 113%, in the male 
and female model, respectively), led to a 55% decrease of stimulated gray matter 
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volume and about a 36% decrease of the stimulation strength and, thereby, to a 
higher ST.19 Our clinical results seem to be in accordance with these computer 
model calculations, as higher volumes of CSF predicted higher IST. Furthermore, 
large effects of scalp and skull thickness on stimulation strength and excited 
brain volume were estimated in the computer models.19 In detail, the RUL ECT 
model showed that lower scalp thickness resulted in stronger stimulation strength 
and larger stimulated brain volume with, consequently, lower ST. At the same 
time, higher skull thickness resulted in weaker stimulation strength, smaller 
excited brain volume and higher ST.19 However, in our clinical study, these modeled 
influences on IST could not be confirmed, probably because in the computer model 
thicknesses were used derived from the literature, which probably did not exactly 
match ours at the electrode placement sites. Also, due to the sites that we selected 
for thickness measurement, the influence of the inferior portions of the head was 
not taken into account, which may explain the very weak univariate correlations 
between ST and scalp and skull thickness for BL electrode placement compared to 
RUL. Moreover, our MRI estimates of scalp and skull thicknesses were hampered 
by measurement differences between the raters, which could have weakened the 
influence of these variables in the regression models. Furthermore, we hypothesized 
that a higher IST is due to more white matter disruptions in neuronal circuitry; 
however, no predictive value of the total WMH volume on IST could be determined, 
possibly due to some important methodological limitations, which we discuss 
below. 
It is remarkable that, in our study, the influence of CSF volume on IST was 
independent of age and gender, because older people often show increased CSF 
volume due to cortical atrophy,38 especially men.39 In our data, age is indeed 
correlated with CSF volume (r=0.26; P=0.03), and men show higher mean CSF 
volumes than women (P<0.001; data not shown), supporting the clinical experience 
of higher ST in older men.2 It is noteworthy that age and gender did not limit the 
strong associations between CSF volume and IST. However, increased CSF volume, 
due to cortical atrophy, is not determined exclusively by age and gender. Cortical 
atrophy has also been associated with (amongst other parameters) hereditary 
factors, starvation, neurodegenerative and cerebrovascular diseases, alcohol abuse 
and the use of certain medications (e.g., lithium).40 Moreover, compared to normal 
controls, larger CSF volumes have been demonstrated in patients suffering from 
major depression.41 These risk factors for increased atrophy and increased CSF 
volume were present in our study patients.
During the ECT course, in 18-67% of our patients the ST levels increased with a 
median of 25-50 mC versus IST, mostly with BL treatment.7 The CSF volume also 
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predicted the consecutive ST levels during the ECT course, although only reached 
significance in RUL ECT, most likely due to the limited sample size of the BL treated 
group. However, the estimated standardized associations were lower (βs were 0.2 
[ST
6-12-18-24
]  instead of 0.3 and 0.6 [IST], in RUL and BL ECT, respectively). Since it is 
very unlikely that the CSF volume changed significantly during the ECT course, 
other ECT-related factors may have emerged as more dominant determinants of 
the consecutive ST levels.7 For instance, consecutive ECT sessions may have 
decreased neuroexcitability through an increase of the inhibitory (e.g., gamma-
aminobutyric acid) and/or a decrease of the excitatory (e.g., glutamate) neurotrans-
mitter systems.10,21     
Clinical implications
Our study provides new information for clinicians to estimate the proper ECT 
dose. Our results suggest that, in patients with higher CSF volumes on MRI scans, 
a higher electrical stimulus dose may be needed to elicit therapeutic seizures. 
Current age-based dosing methods do not take CSF volumes into account,2 and age 
explained only 8-25% of the IST variance.28 Therefore, with age-based methods, 
younger patients with increased CSF volumes may be treated with ineffectively 
low electrical doses, and older patients with less than average brain atrophy may 
be overdosed and, consequently, prone to more cognitive side-effects. 
Study limitations
The most critical limitation in this study is probably our very crude and 
age-adjusted ST titration method. Substantial steps of 25-100 mC were used, which 
undoubtedly led to overestimation of ST in several patients.7,33,42 Moreover, our 
pulse widths differed between the two electrode placements, which could have 
resulted in higher ST levels in the BL group, compared to the RUL treated patients.33 
Also, our dosage increments were accompanied by higher stimulus frequencies 
and durations (and change in pulse width at the final step in RUL ECT), which will 
have had considerable impact on the level of ST. Possibly, more discrete predictors 
of ST (e.g., anatomical factors) were not detected due to the crudeness of our 
measurements. Furthermore, age probably confounded the anatomical variables 
and choice of electrode placement, because of (severe) somatic comorbidity and/or 
pre-existing cognitive functioning. Despite these limitations, CSF volume was an 
important predictor of ST. Replication of this finding, using a more precise and 
age-neutral titration method, is definitely needed. 
Another important limitation is the FSL program used to determine brain tissue 
volumes. The brain extraction tool limited outer-brain CSF estimates causing a 
systematic error with underestimation of the CSF volume.43 Furthermore, the 
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segmentation process did not always adequately distinguish between CSF and 
brain tissue, and the registration processes had appointed some voxels to wrong 
structures, leading to erroneous calculations of the volumes. For example, Figure 
1 shows that the CSF space between the superficial cortex and the skull was 
occasionally poorly segmented and that parts of the skull and CSF were assigned 
to white matter and gray matter. These errors most probably biased the effect 
estimates towards the null hypothesis implying that the predictive value of CSF 
volume on (I)ST may be even higher. 
Several other potential limitations need to be addressed. Of the 114 potential 
participants, only 74 had complete head MRI datasets; moreover, compared with 
the study population, the excluded patients differed in clinical diagnosis, somatic 
comorbidity and cognitive functioning. Also, in the literature different titration 
methods are used, which limits comparison of our estimated ST levels with others. 
In our study, titration took place under anesthesia with etomidate, an anesthetic 
that has been associated with lower ST than propofol.44 Therefore, our results can 
not be generalized to patients anesthetized with other anesthetics. Furthermore, 
usage of constant doses of concomitant medication during the ECT course could 
have influenced the ST. Although we did not show such association in our 
preliminary clinical study,7 confounding of our results cannot be excluded. 
Finally, measurement of scalp and skull thickness by the two independent raters 
showed ICCs of only moderate strength (0.6-0.7), suggesting a measurement error 
which could have led to an underestimation of the true relationships in our 
regression analyses (type II error). Nevertheless, using the mean of these two raters 
reduced some of this measurement error (by a factor of 1.4) as compared to using 
one rating alone. Especially with RUL ECT, more shunting of current through the 
thicker layers of scalp tissue was expected to predict higher IST; however, in the 
multivariable model the effect was of moderate strength and only tended toward 
significance (β=0.24; P=0.08). 
In conclusion, in this observational prospective study, taking into account the 
methodological limitations, CSF volume predicted the level of IST in ECT, besides 
the well-known predictors of age and electrode placement. Moreover, during the 
RUL ECT course, higher STs were predicted by higher CSF volume. Therefore, it is 
important to take into account that, when exclusively age-based dosing methods 
are used, less effective electrical stimuli may be administered in younger patients 
with increased CSF volumes and overdosing may occur in older patients with 
average CSF volumes. Additional studies relating CSF volume to IST and the clinical 
efficacy of ECT are needed before firm conclusions can be drawn.
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Appendix 1
Independent electrical stimulus parameters in the titration schedule using a constant 































































































Right unilateral 5* 25.2 0.25 10 5.60
10 50.4 0.25 20 5.60
20 100.8 0.25 30 7.47
40 201.6 0.25 60 7.47
80 403.2 0.5 60 7.47
Bifrontotemporal 5* 25.2 0.5 10 2.80
10 50.4 0.5 10 5.60
20 100.8 0.5 20 5.60
40 201.6 0.5 30 7.47
 80 403.2 0.5 60 7.47
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Abstract
Background: Baseline predictors of effectiveness and cognitive adverse effects of 
electroconvulsive therapy (ECT) were prospectively examined. 
Methods: Before and after ECT, the Montgomery-Åsberg Depression Rating Scale 
(MADRS) and Mini-Mental State Examination (MMSE) were assessed. Before ECT, a 
magnetic resonance imaging of the head was performed. Outcome predictors were 
investigated using multivariable regression analyses.  
Results: Of 83 patients (mean age ± SD, 59.2±15.3 years; 39% men), 28% had a 
psychotic depressive disorder, 16% had a bipolar depression, 30% had had previous 
ECT course(s), and 66% used concomitant antipsychotics. Presence of psychotic 
depression (β=-0.25; P=0.04) and	 having had previous ECT (β=-0.35; P=0.003) 
predicted lower post-ECT MADRS score. Baseline magnetic resonance imaging 
characteristics were not predictive of post-ECT MADRS and MMSE scores. The use 
of concomitant antipsychotics predicted a lower post-ECT MMSE score (β=-0.21; 
P=0.02), whereas presence of bipolar depression at baseline predicted higher 
post-ECT MMSE score (β=0.23; P=0.01). The post-ECT MADRS score seemed to be a 
confounder for the post-ECT MMSE score (β=-0.20; P=0.02). 
Conclusions: Effectiveness of ECT was better in the patients with a baseline 
psychotic depression and those who had had ECT before. Cognitive outcome was 
better in patients with baseline bipolar depression but worse in those who used 
antipsychotics during ECT and those who showed more persistent depressive 
symptoms after ECT.
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Introduction
Electroconvulsive therapy (ECT) is a fast, effective and safe treatment for severe 
pharmacotherapy-resistant depression and shows remission rates up to 80%.1-3 
Occurrence of particularly memory disturbances during and after a course of ECT 
is a main adverse effect and may limit acceptance and use of this treatment.2 
During a course of ECT, consecutive seizures are elicited by administering an 
electrical stimulus above the seizure threshold (ST) under generalized anaesthesia, 
muscle relaxation, and continuous oxygen supply.2 
Many attempts have been made to determine whether certain patient, treatment 
and brain anatomical characteristics may predict effectiveness and cognitive 
adverse effects of ECT.2,4,5 Effectiveness of ECT was studied in relation to the type 
and specific symptoms of depression. It was shown that depression with 
disturbances in vegetative functions, psychomotor retardation, psychotic features, 
and shorter duration of the current episode was associated with a more positive 
outcome of ECT.4,6,7 In addition, older patients,8,9 patients with catatonic symptoms,4 
and patients without a comorbid borderline personality disorder had a better 
outcome of ECT.10 The presence of bipolar depression was examined as a factor of 
influence for effectiveness in ECT but has not been shown a consistent predictor of 
outcome,7,11,12 Effectiveness of ECT has also been associated with certain (technical) 
aspects of the treatment itself. Having been treated with ECT before predicted 
better outcome of ECT,7 as well as treatment with higher electrical stimulus dosage 
above the ST3 and concomitant nortriptyline use during the ECT course.13 Bifronto-
temporal (BL) electrode placement was shown to be equally effective to right 
unilateral ECT (RUL), if appropriate attention was paid to the technical aspects of 
dosing.2,14 Regarding brain anatomical predictors of ECT effectiveness, measured 
with the Montgomery-Åsberg Depression Rating Scale (MADRS), a poorer response 
was suggested by increased amounts of subcorticofrontal gray matter hyperinten-
sities15 and by the presence of medial temporal lobe atrophy.16
Predictors of post-ECT cognitive adverse effects have more scarcely been studied.17,18 
Poorer pre-treatment global cognitive functioning, assessed with the Mini-Mental 
State Examination (MMSE) 19, seemed to be a strong predictor of persistent 
retrograde amnesia after ECT.17,20 Furthermore, advanced age showed a robust 
association with greater memory deficits after a course of ECT,21 but on the other 
hand, several studies showed an improvement of cognitive functioning after 
ECT.18,22 Regarding technical treatment characteristics, administering more BL 
ECT sessions (but not RUL) during the treatment course predicted more cognitive 
adverse effects, as well as electrical stimulation with longer pulse widths and 
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treating patients in higher frequencies (e.g., 3 times a week compared to 2 
times).21,23 From an anatomical point of view, less hippocampal volume on magnetic 
resonance imaging (MRI) of the head was associated with poorer ECT-related 
memory outcomes in one small study,24 but this result has not been replicated in 
studies associating anatomical head MRI characteristics and possible cognitive 
adverse effects of ECT. In this prospective study, we investigated in 83 patients 
undergoing ECT whether certain patient, (technical) treatment, and anatomical 
head MRI characteristics were predictive of effectiveness and cognitive adverse 
effects of ECT.
Materials and methods
Patients, demographic and clinical data acquisition
All consecutive patients indicated for ECT in Rijnstate Hospital (Arnhem, the 
Netherlands, a 36-beds psychiatric facility with a catchment area of 600,000 
inhabitants), from December 1, 2009, until November 15, 2011, were asked to 
participate in a prospective MRI study relating anatomical and functional 
parameters and seizure threshold (trail registration number: NL24697.091.09).25 
Patients were excluded if age was younger than 18 years, no written informed 
consent was provided, or contraindications existed for dose titration (e.g., life-
threatening condition of the patient, severe cardiovascular comorbidity) or for 
MRI (e.g., metals in the body, claustrophobic reactions, patients’ inability to lie still 
in the scanner). Within 2 weeks before the first ECT session, a head MRI was 
obtained. The medical ethical committee of the hospital approved the study 
protocol, and written informed consent was obtained from all participants. 
Patient and head MRI characteristics of the study population are described in 
more detail elsewhere.26 In this present open observational study, the relation 
between baseline characteristics and prospectively obtained outcome measures 
were analyzed. 
Psychometric instruments
Severity of depression was scored by a trained research nurse (O.B.H.) in the week 
before the first ECT (baseline) and within 1 week after the last ECT session using 
the MADRS, a validated observer-rated scale that contains 10 items (scored 1-6 per 
item), with the sum score ranging from 0 to 60 and higher scores indicating more 
and a higher severity of depressive symptoms.27 
Cognitive functioning at baseline and within 1 week after the last ECT session was 
assessed using the MMSE, a commonly used validated instrument to evaluate 
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cognitive functioning, with the total score ranging from 0 to 30, and lower scores 
indicating more cognitive dysfunction.19
Amount and severity of somatic comorbidity at baseline were rated using a 
modified Cumulative Illness Rating Scale (CIRS), consisting of 14 aspects of possible 
pathology and impairment of major organ systems, which are rated from 1 (no 
impairment to that organ/system) to 5 (impairment is life-threatening; treatment 
is urgent or of no avail; prognosis is grave), ranging from 14 to 70. The item 
‘Psychiatric/Behavioral (includes depression, anxiety, agitation, psychosis, not 
dementia)’ was set at 5.28
Electroconvulsive therapy and measurement of ST
Electroconvulsive therapy was administered using a constant-current (0.9 
Ampère), brief-pulse (0.25 milliseconds [ms] in RUL and 0.5 ms in BL ECT) device 
(maximum output, 1008 milliCoulombs [mC]; Thymatron IV; Somatics Incorporation, 
Lake Bluff, Illinois, USA) after induction of anesthesia intravenously with etomidate 
(1.5 mg/kg body mass), muscle paralysis with succinylcholine (0.5-1 mg/kg body 
mass) intravenously, and with appropriate oxygenation (100% oxygen, positive 
pressure) until the resumption of spontaneous respiration. Electrode placement 
was started RUL, except in patients at high risk for suicidality and/or somatic 
complications, or if previous ECT had successfully been administered bilaterally. 
Initial ST (IST) was measured at the 1st ECT session by an empirical titration 
method.4 If the starting stimulus dose failed to elicit a seizure of at least 20 seconds 
of motor activity measured with the cuff method and/or 25 seconds or longer on 
electroencephalogram, stimulus charge was increased according to the titration 
schedule (for patients younger than 50 years: 25.2 mC, 50.4 mC, 100.8 mC, 201.6 
mC, and 403.2 mC; for patients aged 50 years and older: 50.4 mC, 100.8 mC, 201.6 
mC, and 403.2 mC), and the patient was restimulated after 30 seconds. At the 
second session, dosage was set at 6 times the IST in RUL ECT and at 2.5 times the 
IST for BL treatment. The patients were treated twice weekly. Right unilateral 
electrode placement was changed into BL during the ECT course, based on the 
clinical decision of experienced psychiatrists, mostly if the patient did not show 
(enough) improvement after 6 RUL sessions. If at the titration session the ST was 
reached and there was still sufficient sedation and muscle relaxation, the patient 
was restimulated at a therapeutic dose also in this session.
Magnetic Resonance Imaging data acquisition to explore 
anatomical characteristics
More details of the MRI data acquisition and analyses are described elsewhere.25 
Imaging was performed on a 1.5 Tesla Philips Medical Instruments (Best, the 
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Netherlands) MRI scanner. The scanning protocol included a high-resolution 
T
1
-weighted image and a FLuid Attenuated Inverse Recovery (FLAIR) image. 
Structural MRI analyses were performed using the Oxford Centre for Functional 
MRI of the Brain Software Library (FSL) tools (http://www.fmrib.ox.ac.uk/fsl/). After 
visually checking for the presence of (motion) artifacts, brains were extracted and 
masks for white matter hyperintensities (WMH) were created manually using 
FLAIR. Each brain-extracted T
1
-weighted image was segmented into partial volume 
maps of total cerebrospinal fluid (CSF), total gray matter and total white matter, 
and total WMH. All segmentations were visually inspected and showed no 
problems during the analysis. Volumes of total CSF, total gray and white matter, 
and total WMH were obtained in milliliters (mL).
Analysis of data
Data are presented as means ± standard deviations (SD), medians and interquartile 
ranges (IQR), or numbers and percentages when appropriate. Differences between 
the in- and excluded group were compared using t-tests for normally distributed 
variables (age and MADRS score), Mann-Whitney U tests for non-normally 
distributed continuous variables (CIRS score and baseline MMSE score), and 
chi-square tests for categorical variables (sex and diagnosis categories). Main 
outcome was effectiveness of ECT as determined by the post-ECT MADRS score. 
Response to ECT was defined as 50% or greater decrease of the MADRS score after 
the ECT course compared to baseline, and complete remission as the MADRS score 
10 or less at endpoint. In addition, cognitive functioning as determined by the 
MMSE score after the ECT course was a main outcome variable. 
Several groups were compared using (paired and unpaired) t-tests for continuous 
variables, and Wilcoxon signed ranks tests and Mann-Whitney U tests for 
nonnormally distributed variables. To explore whether patient, treatment and 
anatomical characteristics were predictive of ECT effectiveness and cognition 
after ECT, first univariate regression analyses, adjusted for the baseline MADRS 
scores and MMSE scores, respectively, were performed with the post-ECT MADRS 
and MMSE scores as dependent variables. Because the distribution of the MMSE 
scores were negatively skewed (because of the ceiling effect of 30), they were 
natural log transformed (i.e., -ln[31-MMSE score]) to obtain a near-normal 
distribution.29 Patients’ characteristics (sex, age, CIRS score, diagnostic categories), 
treatment characteristics (previous ECT course[s], use of concomitant pharmaco-
therapy and the level of IST), and anatomical characteristics (z-scores of total 
volumes of CSF, gray matter, white matter and WMH, respectively) were entered as 
independent variables. The variable ‘level of IST’ was adjusted for age and electrode 
placement because of their known associations.26 Preliminary analyses were 
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conducted to ensure no violation of the assumptions of normality, linearity, multi-
collinearity and homoscedasticity. Next, only variables showing P<0.10 in these 
univariate analyses were entered in an overall multivariate analysis, adjusted for 
age, sex and baseline MADRS and MMSE scores, to explore whether they were 
independent predictors for the post-ECT MADRS and MMSE scores. In the 
multivariable analysis of post-ECT MMSE score, adjustment for electrode placement 
at the first ECT session was performed as well because the level of IST was entered 
as independent variable and is confounded by electrode placement.26 All tests were 
two-sided, with P<0.05 denoting statistical significance, and were analyzed using 
SPSS for Windows (version 18.0; SPSS Inc., Chicago, Illinous, USA).
Results
Patient, treatment and anatomical MRI characteristics
Of 114 patients indicated for ECT, 18 had to be excluded and 5 patients did not 
give written informed consent (Figure 1). Some baseline (n=2) and post-ECT 
measurements (n=5) of MADRS and MMSE scores were missing, one patient did not 
have a mood disorder, and in 14 head MRI scans, different settings of scanning 
parameters had been used. Therefore, of 83 (73%) patients, the patients’ and 
treatment characteristics could be entered in the analyses, and of 69 (61%) patients, 
the anatomical MRI characteristics could be entered in the analyses. The excluded 
patients did not differ from the study group regarding mean age (P=0.20), sex 
(P=0.66), and mean MADRS score at baseline (P=0.56), although the excluded group 
of patients showed lower median MMSE score at baseline (P=0.03), higher median 
CIRS score (P=0.02), and comprised catatonic patients (P<0.001).
In Table 1, patient (n=83), treatment (n=83) and anatomical (n=69) characteristics 
are summarized. Mean age ± SD was 59.2±15.3 years, 39% was composed of men 
(n=32), and median CIRS score was 21 (IQR, 20-23). All patients were depressed (16% 
[n=13] bipolar depression), and most of them used concomitant medications 
(antipsychotics in 66% [n=55]). Thirty percent (n=25) had had ECT. Initial ST was 
62.2±44.8 mC, 30% (n=25) of the patients started the ECT course with BL electrode 
placement, and 37% (n=31) switched electrode placement from initially RUL to BL 
during the course. 
Outcome of ECT
In total, a mean ± SD of 17.4±7.4 ECT sessions was administered to the patients 
during a completed ECT course (Table 2). Patients who changed electrode placement 
(n=31) from RUL to BL during the ECT course were treated with more sessions 
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(P<0.001). After the ECT course, in the total group, the mean MADRS score was 
significantly lower than pre-ECT (P<0.001) and decreased with mean ± SD of 
22.8±12.7 points. Patients who started ECT with RUL (n=27) and BL (n=25) electrode 
placement, as well as patients who changed from RUL in BL during the ECT course 
(n=31) showed significantly lower MADRS scores after ECT. Moreover, patients who 
changed electrode placement showed a significantly higher mean post-ECT MADRS 
score than those who did not change. 
The bipolar depressed patients (n=13) showed a higher median post-ECT MMSE 
score (30; IQR, 28.5-30) than the unipolar patients (n=70; median 28; IQR, 26.8-29; 
Mann-Whitney U Test, 620.5; n=83; P=0.03), but did not differ regarding mean age 
(P=0.44), MADRS score at baseline (P=0.70) and after ECT (P=0.70), MMSE score at 
baseline (P=0.97), IST level (P=0.75), electrode placement (P=0.75), and mean total 
Figure 1   Flow diagram showing the patient selection process
MRI=magnetic resonance imaging
114 patients indicated 
for electroconvulsive therapy (ECT)
23 (20.2%) patients excluded:
0 Age < 18 years
7 Emergency ECT
9 Contraindication for dosage titration
2 Contraindication for undergoing MRI
5 No informed consent
 
91 included patients
7 (7.7%) No complete MADRS and MMSE data
1 (1.1%) No mood disorder
83 patients in data analyses 
on clinical predictors
69 patients in data analyses 
on MRI predictors
14 (16.9) Inconsistent MRI settings
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Table 1   Patient, treatment and anatomical characteristics at baseline of 
patients (n=83) treated with electroconvulsive therapy (ECT)
Mean ±SD*; n (%); or 
median; IQR**Patients’ characteristics
Male gender 32 (38.6)
Age, in years 59.2±15.3
Modified Cumulative Illness Rating Scale score 21; 20-23
Diagnostic category, according to axis 1 of DSM-IV-TR^:
     Depressive disorder without psychotic features 47 (56.6)
     Depressive disorder with psychotic features 23 (27.7)
     Bipolar disorder, depressive episode 13 (15.7)
MADRS*** score at baseline 36.1±8.6
MMSE**** score at baseline 28; 26-29
Treatment characteristics  
Had ECT before 25 (30.1)
Use of seizure threshold influencing concomitant 
pharmacotherapy:
     Benzodiazepines 51 (61.4)
     Anti-epileptics 7 (8.4)
     Antidepressants 50 (60.2)
     Antipsychotics 55 (66.3)
Electrode placement is bifrontotemporal at first titration session 25 (30.1)
Initial seizure threshold, in milliCoulombs 62.2±44.8
Anatomical MRI# characteristics, in milliliters (n=69)  
Intracranial volume, including cerebrospinal fluid 1458±142
Total volume of cerebrospinal fluid 376±45
Total volume of gray matter 538±61
Total volume white matter 544±62
Total volume of white matter hyperintensities 3.0; 1.1-9.8
*standard deviation; **interquartile range; ^Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision; ***Montgomery-Åsberg Depression Rating Scale; ****Mini-Mental State Examination; 
#Magnetic Resonance Imaging. 
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ECT sessions (P=0.81). In addition, bipolar patients used concomitant antiepileptics 
more often (P=0.01) and antidepressants less often (P=0.02) compared to unipolar 
depressed patients. 
Seventy percent (n=57) of the patients responded to ECT, and 48% (n=40) reached 
complete remission. In the total group, median post-ECT MMSE score was 29 (IQR, 
27-30) and did not differ from the pre-ECT median MMSE score (P=0.11). In RUL- 
treated patients, the post-ECT median MMSE score was significantly higher than 
before ECT (P=0.02).   
Predictors of post-ECT MADRS score
Using the multivariate regression analysis, with adjustment for age, sex and 
baseline MADRS score (Table 3), thereby entering only variables with P<0.1 at the 
first univariate analyses, lower post-ECT MADRS score (meaning better effectiveness) 
was independently predicted by a diagnosis of depressive disorder with psychotic 
features (β=-0.25; P=0.04; Figure 2A) and having had previous ECT course(s) (β=-0.35; 
P=0.003; Figure 2A). Baseline MMSE score was not associated with post-ECT MADRS 
score (P=0.55). None of the anatomical MRI characteristics were individually 
predictive of the post-ECT MADRS score and therefore not entered into the final 
multivariate analysis.
Predictors of post-ECT MMSE score
As expected, post-ECT MADRS was inversely associated with the post-ECT MMSE 
score (β=-0.20; P=0.02). Adjusted for age and sex, a higher baseline MMSE score was 
associated with a higher post-ECT MMSE score (β=0.55; P<0.001; Figure 2B). Using 
multivariable regression analysis (Table 4), with adjustment for age, sex, electrode 
placement and baseline MMSE, thereby entering only variables with P<0.1 at the 
first univariate analyses, higher post-ECT MMSE score (meaning better cognitive 
functioning) was independently predicted by having a bipolar depression at 
baseline (β=0.23; P=0.01; Figure 2B). Concomitant antipsychotics use during the 
ECT course was an independent predictor of a lower post-ECT MMSE score (β=-0.21; 
P=0.02; Figure 2B), meaning more cognitive dysfunction. In a sensitivity analysis, 
we additionally adjusted for the pre- and post-ECT MADRS scores, yielding similar 
results. The post-ECT MADRS score seemed to be a confounder for the post-ECT 
MMSE score (β=-0.20; P=0.02).
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Table 3   Multivariate regression analyses to detect baseline patient, treatment 
and anatomical predictors of the Montgomery-Åsberg Depression Rating 
Scale (MADRS) score after electroconvulsive therapy (ECT) in 83 patients
Univariate correlates 
of MADRS score at 
endpoint, adjusted 
for MADRS score at 
baseline
Multivariate correlates 
of MADRS at endpoint, 
only variable with 
P<0.1 in univariate 
analyses and adjusted 
for MADRS score at 
baseline, age and sex
Patient variables β-coefficient P-value  β-coefficient P-value
Male gender 0.07 0.57 0.01 0.93
Age -0.12 0.30 0.04 0.71
Cumulative Illness Rating Scale score 0.08 0.50
Diagnostic category, according to 
axis 1 of DSM-IV-TR$ :
Depressive disorder with psychotic 
features
-0.23 0.06 -0.25 0.04
Bipolar disorder, depressive episode -0.11 0.35 -0.06 0.60
MMSE* score at baseline 0.07 0.55
Treatment characteristics      
Had ECT before -0.33 0.002 -0.35 0.003






Initial seizure threshold -0.15^ 0.33
Z-scores of anatomical MRI characteristics (n=69)
Intracranial volume, including 
cerebrospinal fluid 
0.05 0.69
Volume of total cerebrospinal fluid 0.02 0.90
Volume of gray matter 0.12 0.35
Volume of white matter -0.10 0.92
Volume of white matter 
hyperintensities
-0.02 0.85
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; *Mini-Mental State 
Examination  (lnMMSE at baseline was used in analyses); ^also adjusted for electrode placement
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Figure 2   Relationship between 83 patients who underwent electroconvulsive 
therapy (ECT), and (A) scores on the Montgomery-Åsberg Depression 
Rating Scale (MADRS) and (B) Mini-Mental State Examination (MMSE), 
with their baseline scores, diagnostic category, previous treatment 
with ECT and concomitant use of antipsychotics, respectively * 
*Data are presented as adjusted means by ANCOVA, adjusted for (A) sex, age, baseline MADRS score, 
diagnostic category, and previous ECT, and (B) age, baseline MMSE score, diagnostic categories, IST level, 
and the use of antipsychotics when appropriate. The size of each square is proportional to the number of 
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Table 4   Multivariate regression analyses to detect baseline patient, treatment 
and anatomical predictors of the score of the Mini-Mental State 
Examination (MMSE)* 
Univariate correlates 
of MMSE score at 
endpoint, adjusted for 
MMSE score at baseline
Multivariate correlates 
of MMSE score at 
endpoint, showing 
P<0.1 in univariate 
analyses and adjusted 
for MMSE at baseline, 
age, sex and electrode 
placement
Patient variables β-coefficient P-value  β-coefficient P-value
Male gender 0.07 0.43 0.07 0.40
Age -0.13 0.20 -0.18 0.09
Cumulative Illness Rating Scale score -0.04 0.67
Diagnostic category, according to 
axis 1 of DSM-IV-TR^ :
Depressive disorder with psychotic 
features
-0.07$ 0.50 0.003 0.98
Bipolar disorder, depressive episode 0.22$ 0.02 0.23 0.01
MADRS** score at baseline 0.15 0.10
Treatment characteristics      
Had ECT before -0.03 0.75





Antipsychotics -0.12 0.048 -0.21 0.02
Initial seizure threshold 0.27$$ 0.03 0.20 0.09
Z-scores of anatomical MRI characteristics (n=69)
Intracranial volume, including 
cerebrospinal fluid 
0.16 0.14
Volume of total cerebrospinal fluid 0.16 0.12
Volume of gray matter 0.11 0.31
Volume of white matter 0.13 0.23
Volume of white matter 
hyperintensities
-0.15 0.15
*MMSE scores were transformed in lnMMSE scores owing to nonnormally distribution;**Montgomery-
Åsberg Depression Rating Scale;  ^Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision; $also adjusted for MADRS score at endpoint; $$also adjusted for known confounders  
(age and electrode placement)
7
Patient, treatment and MRI predictors of ECT outcome | 133
Discussion
As has been shown before, our prospective study demonstrated that having had ECT 
before and presence of psychotic depression at baseline were independent predictors 
of increased effectiveness of ECT. Furthermore, we found that concomitant 
use of antipsychotics predicted poorer cognitive outcome, whereas a baseline bipolar 
depression predicted better cognitive outcome after ECT. These findings remained 
when we additionally adjusted for the severity of residual depressive symptoms.
In line with earlier results,7 having had ECT course(s) before was a predictor of 
increased effectiveness. This finding is most probably due to confounding by 
indication, as a previously positive ECT outcome will increase the chance of being 
treated with ECT again. In addition, our results confirm earlier findings regarding 
enhanced effectiveness of ECT in psychotic depressed patients6 but did not support 
the previously reported positive association with higher age and concomitant use 
of antidepressants.8,9,13 Data about the length of the current depressive episode 
were not available in a standardized manner and could therefore not be related to 
effectiveness of treatment. Electroconvulsive therapy was equally effective with 
regard to depression in bipolar and unipolar patients, as was shown before.30 
Compared to other studies, the average number of total ECT sessions in our study 
was high.2 A possible reason for this is that the use of ultra-brief pulse width in the 
larger group of initially RUL-treated patients caused the longer treatment duration 
compared to brief pulse BL-treated patients.23,31 
None of the anatomical head MRI scan variables were predictive of effectiveness of 
ECT, which contrasts with earlier studies showing poorer outcome of treatment 
(with antidepressants) in patients with more subcortical gray matter hyperintensi-
ties and increased CSF volume.15,32-34 Because we did not determine separate 
volumes of the hippocampus and medial temporal lobes, no further comparison 
with the literature can be made.16,24 
In clinical practice, cognitive impairment is no contraindication for ECT.4 Indeed, 
in our study, the baseline MMSE score was not associated with effectiveness of ECT, 
meaning that poorer cognitive functioning before ECT did not predict worse 
effectiveness. Otherwise, a higher MMSE score at baseline strongly predicted 
better post-ECT cognitive functioning, as has been reported before.17,20 In the 
patients exclusively treated with RUL (using stimuli with ultrabrief pulse width) 
ECT, the median post-ECT MMSE score was one point higher than before ECT, 
which matches with earlier findings showing less cognitive adverse effects with 
ultrabrief RUL ECT.23 That a higher post-ECT MADRS score was associated with a 
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lower post-ECT MMSE score was probably due to the presence of (residual) depressive 
symptoms that are associated with (persistent) memory impairment.35,36 Moreover, 
due to less clinical response, more total ECT sessions were administered (a median 
of 21 sessions [IQR, 15.5-24.5] in the group of patients who showed less than 50% 
decrease of post-ECT MADRS score, compared to a median of 15 sessions [IQR, 
10-21] in those who decreased by 50% or greater; P=0.02), as well as more often 
occurrence of electrode placement switch to BL (68% [n=17] in patients showing 
less than 50% decrease of post-ECT MADRS score, compared to 23% [n=13] in the 
better outcome group; P<0.001), which factors both may have led to a lower 
post-ECT MMSE score.21 
A diagnosis of bipolar depression unexpectedly predicted better post-ECT cognitive 
function which, as far as we know, has not been reported before. Besides, the more 
often use of concomitant antiepileptics and less often use of antidepressants, no 
differences between the bipolar and unipolar depressed patients were found; 
especially not regarding the expected predictors of the post-MMSE score age, use 
of BL electrode placement, and duration of the ECT course.21,23 Presence of bipolar 
disorder and the use of lithium and antiepileptics were associated with more 
cognitive impairment.37 This remarkable finding is new and should be replicated 
before drawing further conclusions.   
Although psychotic depression predicted better effectiveness of ECT, the consequent 
use of antipsychotics during the ECT course predicted more cognitive dysfunction. 
An explanation for this result may be that patients who use antipsychotics during 
the ECT course might be a distinct group with more severe depression and a 
probably higher risk for cognitive adverse effects. In addition, the presence of 
persisting psychotic features or (postictal) delirium may have been the reason for 
the continuing use of antipsychotics during the ECT course. In general, anticholin-
ergic activity of psychotropic medications negatively affects cognitive functioning, 
especially in older adults,38 which may have been another cause of poorer post-ECT 
cognitive functioning in our study. In addition, antipsychotic medication may 
have slightly decreased the patients’ ST compared to nonusers (without being 
noticed because of the rather crude titration protocol), resulting in administration 
of electrical stimuli a little too well above the ST.39 Because not the absolute 
electrical stimulus dose but the dose relatively exceeding the ST was suggested to 
predict cognitive adverse effects of ECT,40 this may explain more cognitive 
dysfunction in ECT patients using concomitant antipsychotics. On the other hand, 
in a few randomized controlled trials no differences were shown in memory 
effects of ECT between patients with and without concomitant antipsychotics use, 
but these studies included mainly patients with schizophrenia.41,42  
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Several limitations should be addressed. First, of the 114 patients only, 83 patients 
(and for the MRI analyses, 69 patients) could be included, limiting the generaliz-
ability of our results to all ECT patients because the more cognitively impaired, 
the more severely somatically ill and the catatonic patients were excluded. Second, 
mood disorders were classified according to the Diagnostic	and	Statistical	Manual	of	
Mental	 Disorders,	 Fourth	 Edition,	 Text	 Revision by at least 2 clinically experienced 
psychiatrists but not confirmed using a standardized diagnostic instrument, 
which might have led to less accurate ascertainment of the diagnosis. Third, two 
thirds of the patients used concomitant psychotropic medication during the ECT 
course, as was decided on clinical grounds (e.g., to avoid withdrawal symptoms, to 
reduce psychosis or postictal delirium, or for sedation). Because this concomitant 
use was only registered for the overall type of medication without controlling for 
the clinical indication, analysis of the effects of specific types of (antipsychotic) 
medications and dosage was not possible. Fourth, the MMSE was used to evaluate 
global cognitive functioning before and after ECT and that we did not examined 
retrograde amnesia, which is a cognitive dysfunction of more concern in ECT.17 
Finally, the automatic FSL process to estimate the volumes of CSF, gray and white 
matter, and WMH also had several limitations, which are described elsewhere in 
more detail;25 in short, imperfections in the registration and segmentation process 
may have led to some measurement and systematic error in establishing the 
separate volumes.
In conclusion, this prospective, observational study confirmed that psychotic 
depressed patients and those who were previously treated with ECT responded 
better to ECT. Unexpectedly, having a bipolar depression predicted better cognitive 
function after ECT, whereas the use of antipsychotics during ECT and the presence 
of more persistent depressive symptoms following ECT were associated with a 
poorer cognitive outcome.
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Abstract
Background: Electroconvulsive therapy (ECT) has been described as an effective 
treatment option for catatonia in retrospective case series. We aimed to investigate 
treatment characteristics and outcome of patients with catatonia who were treated 
with ECT.
Methods: The medical records of 27 patients with catatonia treated with ECT 
(between 1991 and 2009) were scrutinized for clinical and treatment characteris-
tics. Outcomes were measured using the Clinical Global Impression - Improvement 
(CGI-I) scale. Patients who improved (defined as CGI-I scores ‘very much’ or ‘much 
improved’) were compared with those who did not improve (defined as a CGI-I 
score ‘no change’ or ‘very much worse’). 
Results: Mean age of all patients was 49 ± 19 years, of whom fifteen (56%) were 
female. Of all patients, 13 (48%) had a diagnosis of a mood disorder and 12 (44%) of 
a psychotic disorder. ECT was mostly started after ineffective pharmacotherapy 
(n=23; 85%) within 2 to 3 months after catatonia had been diagnosed. In total, 16 
(59%) patients improved. Improvement was significantly associated with younger 
age (P=0.05), presence of autonomic dysregulation at baseline (P=0.02), especially 
higher body temperature (P=0.02), daily ECT during the first treatment week (n=15 
[56%]; P=0.03), longer duration of electroencephalogram seizure activity at last 
ECT-session (P=0.04), and less morbidity in the year after ECT (P=0.03). Three of the 
11 non-improved patients died in the year after ECT compared with none of the 
improved patients.  
Conclusions: Most of our patients with catatonia benefited from ECT, especially 
younger patients with autonomic dysregulation. Daily administration of ECT may 
be more effective, whereas longer duration of seizure activity at the final 
ECT-session was related to better response to ECT.
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Introduction
Catatonia is characterized by motor abnormalities including rigidity, catalepsy, 
waxy flexibility, mutism, stupor, negativism, posturing, stereotypy, echophenomena, 
and mannerisms. Catatonia is closely associated with the presence of mood 
disorders, psychotic disorders and toxic states.1 The estimated prevalence of 
catatonia among psychiatric inpatients is reported to range from 8 to 38%; this 
wide range is possibly due to difficult differential diagnosis from other disorders.2 
Catatonic patients are at risk of severe complications, such as pneumonia, 
decubitus, malnutrition, dehydration, contractures and thrombosis. Moreover, 
patients who experienced malignant variant of catatonia (lethal catatonia or 
neuroleptic malignant syndrome) show autonomic instability with hyperthermia, 
tachycardia or bradycardia, hypertension or hypotension, tachypnea, diaphoresis, 
and cardiac arrhythmia, whereas a high percentage of them ultimately die.1 In 
case reports and case series, benzodiazepines and electroconvulsive therapy (ECT) 
are described as effective treatment options for catatonia. However, data from 
randomized clinical trials on the effectiveness of these treatments are not 
available,3 and large clinical studies are sparse. Therefore, this retrospective study 
describes patients with catatonia who were treated with ECT.  
Method
The medical records of all patients treated with ECT (n=285) at the Rijnstate Hospital 
(a large teaching hospital in Arnhem, the Netherlands) in the period 1991 to 2009 
were retrospectively examined. Of the 27 patients who had a diagnosis of (severe) 
catatonia, the medical records were scrutinized regarding 3 sets of variables: 
1. Patient characteristics, including sex, age, psychiatric diagnosis (according to 
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), 4 medical 
comorbidity, and severity of catatonia with the Clinical Global Impression for 
Severity (CGI-S) scale.5 Earlier treated patients (1991-2001; n=4) were rated using 
the CGI-S retrospectively from the medical charts by 2 independent psychiatrists; 
all other 23 patients were rated by the treating psychiatrists before and after 
treatment. Furthermore, the presence of autonomic dysfunctions was determined 
according to the presence of hyperthermia (body temperature ≥ 38° Celsius), 
tachycardia or bradycardia (≥ 100 or ≤ 60 beats per minute, respectively), 
hypo tension or hypertension (systolic blood pressure, ≤ 90 or ≥ 140 mm Hg), 
tachypnea (≥ 20 breaths per minute), diaphoresis, and/or cardiac arrhythmia. 
Severe catatonia was defined as, next to catatonia, autonomic dysfunctions and/
or alterations of consciousness being presence; 
142 | Chapter 8
2. Treatment characteristics, including first treatment of catatonia, time interval 
before any treatment and before ECT, and characteristics of ECT; and
3. Outcome characteristics, including outcome as assessed with the Clinical Global 
Impression for Improvement (CGI-I)5 scale and morbidity and mortality in the 
year after ECT.
Statistical analysis
Categorical data are presented as numbers and percentages and continuous 
variables as mean ± SD values or medians with interquartile ranges (IQR) when 
appropriate. Improved patients (defined according to the CGI-I as those rated as 
‘very much’ or ‘much improved’) were compared with nonimproved patients 
(defined according to the CGI-I as those rated as ‘no change’, ‘minimally’, ‘much’, 
or ‘very much worse’) using the c2 and Fisher exact tests for frequencies and 
independent t-tests for normally distributed continuous variables. The SPSS for 
Windows version 13.0 (SPSS Inc, Chicago, Illinois) was used for all analyses, and 
the level of significance was set at P ≤ 0.05.
Results
Patient characteristics
Table 1 presents the demographic and clinical characteristics of all patients with 
catatonia who were treated with ECT. In 15 patients (56%), autonomic dysregulation 
was present. At baseline, one third (n=9) of the patients were scored on the CGI-S as 
‘extremely ill’, almost half (n=13) as ‘severely ill’, and the remainder (n=5 [19%]) as 
‘markedly ill’  
Treatment characteristics
The treatment characteristics of the patients with catatonia are summarized in 
Table 2. Treatment started on average within 18 ± 40 days after onset of the first 
symptoms of catatonia. Nineteen (70%) patients were initially treated with benzo-
diazepines. Mean time interval before ECT was 62 ± 97 days after onset of catatonia. 
Bifrontotemporally electrode placement (93%) was almost exclusively used, and a 
mean of 15 ± 10 ECT sessions was given. During the first week of treatment, daily 
ECT was given to 15 (56%) of the 27 patients. After 2 weeks, 15 (56%) patients still 
received ECT (of which 4 daily), and in 12 (44%) patients, ECT had been discontinued. 
All patients were treated with a constant current (0.9 Ampère) and brief pulse 
(0.5-1 millisecond) ECT device (Thymatron DgX and later Thymatron IV, Somatics 
Inc., Lake Bluff, Illinois, USA). Mean administered electrical stimulus at the first 
ECT session was 214 ± 113 milliCoulombs (mC), mean motor seizure duration (as 
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Table 1   Baseline characteristics of the study population (n=27)*
Demographic characteristics
Female
Age in years (mean ± SD†, range)
15 (56)
49.1 ± 19.2, 19-84
Clinical characteristics
Psychiatric diagnosis# 
     Psychotic disorder
            Schizophrenia
            Psychotic disorder not otherwise specified
     Mood disorder
            Depressive disorder, without psychotic features
            Depressive disorder, with psychotic features
            Bipolar disorder
     Alcohol and substance abuse
     Mental retardation/autistic disorder 
  Somatic comorbidity# 
     Cardiovascular
     Neurological, including related to catatonia (n=4)
     Any abnormality cerebral CT/MRI†
     Infectious disease
12 (44)
      10 (37)
       2 (7)
13 (48)
       3 (11)
       3 (11)




       2 (7)
      10 (37)
       8 (33)
       3 (11)
   Catatonia characteristics
Presence of autonomic dysfunction# 
       Hyperthermia (≥  38° Celsius)
       Highest temperature (°Celcius); mean ± SD, range††
       Cardiac arrhythmia§
       Hypotension and/or hypertension$$
       Excessive transpiration and/or saliva production
15 (56)
9 (33)





				Not, borderline, mildly, or moderately ill
    Markedly ill
    Severely ill





*Data are presented in numbers and percentages unless otherwise mentioned; †Standard deviation; 
#More than one answer possible; †For 3 patients cerebral computerized tomography (CT) or magnetic 
resonance imaging (MRI) was missing and ‘any abnormality’ was defined as presence of white matter 
lesions (n=3), cerebral infarction (n=1), hematoma (n=1) or other (n=3); ††In Fahrenheit (F); mean ± SD, 
range = 100˚F ± 34˚F; 96.8-104˚F;  §Tachycardia was defined as more than 100 and bradycardia as less than 
60 beats per minute; $$Hypotension was defined as a systolic blood pressure ≤ 90 mmHg and hypertension 
as a systolic blood pressure ≥ 140 mmHg. 
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measured with the cuff method at the nonparalyzed limb) was 49 ± 35 seconds, 
and mean EEG seizure activity was 68 ± 47 seconds. Because of lack of seizure 
adequacy, at the first ECT session, restimulation was required to 9 (39%) patients. 
Table 2   Treatment characteristics of the study population (n=27)*
Pre-treatment
Benzodiazepines
Lorazepam in mg‡ at first treatment per 24 hours†
Bromocriptine, amantadine, or other drug
19 (70)
6.3 (± 5, 1-20)
4 (15) 
Time interval before catatonia treatment in days†
Before any treatment other than ECT (n=22)
Before ECT (n=24)
17.9 (± 40.3, 1-175) 




Unilateral according to d’Elia
Not described




Age-based method in unilateral ECT
Not described
Re-stimulation necessary at first session (n=23)
Total ECT sessions (n=25)†














14.6 (± 10.3, 1-34)
1st week    2nd week  3rd week
15 (56)  7 (39) 4 (27)
2 (7) 4 (22) 1 (7)
4 (15) 1 (6) 2 (13)
6 (22) 6 (33) 8 (53)
Electrical dose in milliCoulombs† 
Seizure activity in seconds†   
Motor seizure activity (cuff method)
EEG seizure activity
Post-ictal suppression index in %†
first ECT last ECT
session (n=22) session (n=21)
214 (±113, 50-504) 471 (± 241, 101-1008)
49 (± 35, 24-64) 33 (± 24, 15-49)
68 (± 47, 37-97) 47 (± 31, 22-72)
81 (± 29, 0-98)# 72 (± 32, 0-97)##
*Data are presented in numbers and percentages and n=27 unless otherwise mentioned; ‡ mg = milligram; 
†Mean (± standard deviation -SD-, range); §constant current (0.9 Ampère) and brief pulse (pulse width 0.5-1 
ms) device; # n=14;## n=15. 
8
ECT characteristics and outcome in catatonia | 145
At the final ECT session, mean administered electrical stimulus was 471 ± 241 mC, 
mean motor seizure duration was 33 ± 24 seconds, and mean EEG seizure duration 
was 47 ± 31 seconds.   
Differences between improved and nonimproved patients
As assessed with the CGI-I, 16 (59%) of the 27 patients improved, of whom 11 (41%) 
showed ‘very much’ and 5 (19%) ‘much’ improvement. Ten patients (37%) showed 
‘no change’ and one patient (4%) scored ‘very much worse’ on the CGI-I. In the year 
after ECT, 14 (58%) patients experienced morbidities (cognitive dysfunction [n=7], 
cardiovascular [n=3], neurological [n=3], infectious [n=2], other [n=5]), and 3 (12%) 
patients died of pneumonia, of whom 2 after ineffective ECT. 







Age, mean ± standard deviation (SD), in years
Autonomic dysfunction present
Highest body temperature during catatonia^ 
Any abnormality cerebral CT/MRI^^
Mean time interval before ECT (in days)
ECT frequency in first week
      Daily
      Interval 1 day
      Interval 2 days
      Other
Mean duration seizure activity ± SD at last  
ECT-session, in seconds
       Motor seizure activity
       EEG seizure activity
Morbidity in year after ECT present 





































°CGI-I=Clinical Global Impression-Improvement consisting of 7 items ranging from ‘very much improved’ 
to ‘very much worse’; data are presented in numbers and percentages unless otherwise mentioned; ^In 
˚Celcius ± SD; ^^For 3 patients cerebral computerized tomography (CT) or magnetic resonance imaging 
(MRI) was missing; *t=-2.078;df=21.283; **Fisher’s exact test=6.014;df=1; ***t=2.620;df=22.840; ****not 
significant; *****Χ2=9.271;df=3; #t=2.370;df=17.127; ##t=2.252;df=18.000; ### Χ2=7.059; df=2; ####Fisher’s exact 
test=2.536; df=1.
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Table 3 shows the significant differences between the patients who improved 
(n=16) and those who did not (n=11). Improvement was significantly related with 
younger age (P=0.05), presence of autonomic dysregulation at baseline (P=0.02), 
especially higher body temperature (P=0.02), daily ECT during the first treatment 
week (n=15 [56%]; P=0.03), longer duration of motor and EEG seizure activity at the 
final ECT session (P=0.03 and P=0.04, respectively), and less morbidity in the year 
after ECT (P=0.03).
Discussion
Retrospective evaluation of the 27 patients with catatonia who were treated with 
ECT revealed that more than 50% of the patients recovered completely. Improved 
patients were younger and more often showed autonomic dysregulation at 
baseline. Especially increased highest body temperature was correlated with a 
better outcome. ECT was mostly started after unsuccessful treatment with benzo-
diazepines, mainly within 2 to 3 months after onset of catatonia. The patients 
were treated with a mean of 15 ECT sessions (mostly administered bifronto-
temporally) and, in the first week of treatment, mostly provided daily. Improved 
patients had a longer duration of seizure activity at the final ECT session, and 
showed less morbidity in the year after ECT. 
The finding that 59% of our patients with catatonia benefited from treatment with 
ECT is not in line with 3 other studies showing higher effectiveness of ECT in 47 
(85%) of 55 patients,6 7 (88%) of 8 patients,7 and 26 (93%) of 28 patients8 with 
catatonia. However, these latter studies differed from ours in that their patients 
were more often woman8 and more often with a diagnosis of a primary mood 
disorder.7-9 Comparable with our study, others have reported successful ECT after 
failure of benzodiazepine treatment of catatonia, with all patients nonresponsive 
to benzodiazepines (4 of 28 patients10, and 9 of 18 patients11) responding to ECT 
within 1 week. Because our patients were treated with ECT after a mean time 
interval of 2 months, treatment delay may have negatively influenced treatment 
response in our group. Another retrospective study also reported that patients 
with catatonia who had been exposed to antipsychotics before ECT seemed less 
responsive to ECT.6 In the present study, 40% (n=12) of the patients experienced a 
primary psychotic disorder and 32% (n=9) had used antipsychotics just before ECT, 
which may have resulted in decreased effectiveness compared with other studies. 
Furthermore, 32% (n=9) of our patients with catatonia experienced neurological 
comorbidity; these patients may be less responsive to ECT than other forms of 
catatonia.12 
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In addition, our data indicate a physician-related delay of at least 2 months before 
starting ECT for catatonia. Although the mean time interval before ECT among the 
improved patients was much less than that among the nonimproved group, this 
difference did not reach statistical significance. The results also show that, 
particularly, patients with autonomic dysregulation may benefit from ECT. These 
findings emphasize the importance of prompt, accurate diagnosis and treatment 
of catatonia. Moreover, particularly in the case of autonomic dysregulation, ECT 
should be considered as first-line treatment. Although our nonimproved patients 
were older, ECT remains an important treatment option because some of our older 
patients with severe catatonia recovered completely. 
Our finding that the improved patients had more often received daily ECT sessions 
in the first week may be clinically relevant. In practice guidelines,13 no explicit 
advice is given about the frequency of ECT in severely ill patients. Although the 
risk of cognitive adverse effects is reported in higher ECT frequency,14 these adverse 
effects must be balanced against the risks of morbidity and mortality due to 
catatonia. Therefore, we believe that good clinical practice entails that, initially, 
daily ECT should be given for severely ill patients until remission of autonomic 
dysfunctions.    
Although not statistically different from the improved patients, the nonimproved 
patients were treated with a lower total mean number of ECT sessions. It is 
therefore possible that the nonimproved patients were treated less persistently 
with ECT. The finding that longer duration of seizure activity at the final ECT 
session seemed to be related to better outcome was in line with our clinical 
impression that in several patients, seizure adequacy improved simultaneously 
with the clinical condition of the patient during the ECT course (e.g., lower 
electrical dosage needed to elicit longer seizure activity, more adequate seizure 
expression on EEG, and higher post-ictal suppression index). This leads to several 
interesting questions, for example, how do seizure characteristics predict the 
effectiveness of ECT in catatonia, and is there any influence of the natural course 
of catatonia on brain activity and seizure threshold? Although hard to realize in 
clinical practice, prospective examination of this clinical impression may help to 
further elucidate catatonia and its underlying cerebral dysfunctions.   
The retrospective design of our study does not allow to draw firm conclusions. In 
addition, the diagnoses were made without using standard diagnostic instruments 
or catatonia rating scales; however, they were made by experienced psychiatrists 
with all relevant information at their disposal. Furthermore, the clinical outcome 
was standardized using the CGI-I. Because patients with catatonia are infrequently 
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seen in clinical practice, retrospective studies may be valuable in allowing to share 
practice-based knowledge on the treatment of catatonia. 
In conclusion, in the present study, ECT was mostly an effective treatment option 
for catatonia, especially in younger patients with autonomic dysregulation. Daily 
administration of ECT in the first treatment week seemed to be more effective for 
catatonia. Treatment procedures were comparable to those in patients with more 
common indications for ECT, and longer duration of seizure activity at the final 
ECT session was related to better outcome. In the present study, the physician’s 
delay in starting ECT indicates the importance of prompt, accurate diagnosis and 
treatment.
8
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Abstract
Background: To examine patient and treatment characteristics in continuation 
electroconvulsive therapy (c-ECT), defined as prolonged treatment with ECT with 
a maximum frequency of once a week to prevent relapse.
Methods: Medical charts of 50 patients (mean age, 59 years; 74% were female) 
undergoing c-ECT were examined retrospectively for patient and treatment char-
acteristics. Electrical stimulus dosage, seizure duration, and post-ictal suppression 
indices between the first and the last 4 ECT sessions were compared, and their 
associations with the time interval between c-ECT sessions were analyzed. 
Results: Almost all patients (n=46; 92%) experienced recurrent medication- 
resistant mood disorders. During a median c-ECT period of 393 days (interquartile 
rate, 211-677 days), the frequency of c-ECT ranged from once a week (n=15; 30%) to 
once every 4 to 6 weeks (n=17; 34%), and ECT was administered almost exclusively 
bifrontotemporally (n=46, 92%). The mean time interval between consecutive 
c-ECT sessions was 19 (SD ± 11) days. The number of days between c-ECT sessions 
correlated positively with median seizure duration (motor activity: r=0.390, 
P=0.005; electroencephalographic activity: r=0.351, P=0.013). 
Conclusions: In 50 patients with long-standing, recurrent, medication-resistant 
mood disorders who were treated with c-ECT, increased time interval between 
consecutive c-ECT sessions was correlated with increased seizure duration. Whether 
bifrontotemporal c-ECT requires a lower frequency to sustain remission compared 
with unilateral c-ECT needs further investigation.
9
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Introduction
In patients with depression, electroconvulsive therapy (ECT) is effective in the short 
term, but without further prophylactic treatment, relapse rates are high.1 In some 
highly medication-resistant patients, continuation ECT (c-ECT) is the only treatment 
option for lasting relief of severe depression and for prevention of relapse.2,3 The 
cumulative probability of survival without relapse or recurrence of depression at 5 
years was 73% for patients treated with c-ECT and 18% for patients treated with 
antidepressants alone.4 Others found a modest effectiveness for c-ECT that was 
comparable to continuation pharmacotherapy in preventing relapse of depression 
and superior in effectiveness compared to a historical placebo control group.5 
To provide effective ECT, the charge needed to elicit a seizure must exceed the 
seizure threshold and, in right unilateral electrode placement, be even substantially 
more (e.g., 6-12 times) than the seizure threshold.6 Because the seizure threshold 
seems to increase during a course of ECT (albeit not in all patients), it is suggested 
to make adjustments towards higher electrical stimulation during the ECT 
course.2,7 Seizure duration, however, was shown to decrease during a course, even 
after administration of higher electrical stimuli.8-10 According to the anticonvulsant 
hypothesis of the mechanisms of action of ECT, increase of seizure threshold and 
decrease of seizure duration may be markers of anticonvulsant brain processes 
that are thought to promote and sustain remission of depression.11 They may, 
however, also be the outcome of changes in brain neurophysiology that accompany 
remission.11 For example, compared to nonresponders, responders to ECT had a 
larger seizure threshold increase during the course,10,11 although not consistently.12,13 
Seizure threshold seemed to return to previous baseline values within a few weeks 
to months after completing ECT.11,14,15 
When the time interval between ECT sessions exceeded 60 days, seizure durations 
were shown to increase again, which corresponds to the decrease of the seizure 
threshold or loss of anticonvulsive action of ECT.8 Furthermore, in case of a rapid 
decrease of seizure threshold with greater spacing of the c-ECT sessions, electrical 
dosage might be in excess of what is needed to sustain remission, because the 
dosages used at the end of the index ECT are often continued in c-ECT.11 However, 
others reported no increase in seizure duration with an increase in time interval 
during c-ECT.16
Research on c-ECT is sparse, and the time interval between sessions seems 
important for management of c-ECT. Therefore, this retrospective cohort study 
examines possible correlates of the time interval between c-ECT sessions on the 
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one hand and patients’ and treatment characteristics, such as seizure duration 
and the amount of post-ictal suppression (PIS) on the electroencephalography 
(EEG), on the other. As also suggested by others,10 we hypothesized that the longer 
the time interval between c-ECT sessions (a) the longer the seizure duration and (b) 
the smaller the amount of PIS.
Methods
Subjects
During the period 1997 to June 2009, all patients treated with c-ECT at the Rijnstate 
Hospital (a 600-bed general teaching hospital; n=18) and the University Medical 
Center Utrecht (n=32; 1,042 beds) were included in the study. We defined c-ECT as 
treatment with ECT at a maximum frequency of once a week to sustain remission 
of depression, following an index ECT course of twice a week. The patients’ charac-
teristics (sex, age, psychiatric diagnosis, length of illness before index ECT, severity 
of depression, and severity of somatic comorbidity) were retrieved from their 
medical records. Psychiatric diagnosis, as assessed by experienced psychiatrists, 
was classified according to the Diagnostic	and	Statistical	Manual	of	Mental	Disorders,	
Fourth	Edition.17 Depression severity was measured using the Hamilton Depression 
Rating Scale (HDRS).18 The HDRS at the start of the index ECT and at the end of the 
c-ECT (or the last available HDRS of the c-ECT period) were used. The severity of 
somatic comorbidity was assessed using the modified Cumulative Illness Rating 
Scale (CIRS).19   
Data on the initial 4 sessions of the index ECT and the last 4 sessions of the c-ECT 
were collected from the patient medical records. The initial seizure threshold was 
recorded, if present, in milliCoulombs (mC). From the first and the last 4 ECT 
sessions, the mean electrical stimulus dosage in mC, the median dosage of the 
used anesthetic (in milligrams [mg]), the median of seizure duration (measured as 
motor activity at the cuffed limb, and seizure activity on the EEG, in seconds [s]), 
and the median of PIS (in percentage [%]) were calculated. Furthermore, the time 
interval between consecutive c-ECT sessions, the number of previous sessions, and 
the electrode placement (right unilateral according to d’Elia or bifrontotemporal) 
were noted.
ECT and measurement of seizure threshold
ECT was administered using the Thymatron IV (Somatics Incorporation, Lake 
Bluff, Illinois, USA), after induction of anesthesia intravenously with etomidate 
(1.5 mg/kg body mass) or methohexital sodium (1-1.5 mg/kg) and muscle paralysis 
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with succinylcholine (0.5-1 mg/kg body mass) intravenously and with appropriate 
oxygenation (100% oxygen, positive pressure) until the resumption of spontaneous 
respiration. EEG parameters were recorded and calculated by the Thymatron IV 
device, which provided the PIS in %. 
The initial seizure threshold at the first ECT session was measured by an empirical 
titration method according to the guidelines of the American Psychiatric 
Association.3 If the starting stimulus dose failed to elicit a seizure of at least 20 
seconds’ duration measured with the cuff method, stimulus charge was increased 
according to the titration schedule (for patients aged < 50 years: 5%, 10%, 20%, 40%, 
and 80%; for patients aged ≥ 50 years: 10%, 20%, 40%, and 80%), and the patient was 
restimulated after 30 seconds. At the second session, the dosage was set at 2.5-times 
seizure threshold for bifrontotemporal treatment and at 6-times seizure threshold 
for unilateral treatment. Dosage was adjusted during the course of the ECT to 
maintain seizure duration of at least 20 seconds as measured with the cuff method. 
The patients were treated twice weekly. The experienced clinicians decided to 
reduce the treatment frequency when a maximum response had been reached or 
a plateau in response occurred. First, ECT was administered once a week, followed 
by once in 2 weeks, once in 3 weeks, and so on, and each reduction in frequency 
was based on clinical judgments.3 When patients showed signs of relapse, after 
reevaluation of the psychiatric diagnosis and other treatment options, the ECT 
frequency was increased and tapered when a plateau was reached again.
Statistical analysis
Data were analyzed using SPSS for Windows, version 15 (SPSS Inc., Chicago, Illinois, 
USA), calculating frequencies and percentages for categorical variables, and mean 
and standard deviation (SD) values or median values and interquartile rates (IQRs) 
for continuous variables. Furthermore, from the first 4 index ECT sessions and the 
last 4 c-ECT-sessions, the mean (± SD) used electrical stimulus dosage, and the 
median and IQR of the seizure duration and the PIS were calculated. Data of the 4 
sessions were used to prevent influence of single outliers or missing data. 
For comparison of the first 4 and the last 4 ECT sessions, paired t-tests were used 
for normally distributed continuous variables (mean of the first and last 4 electrical 
stimuli) and Wilcoxon signed rank tests were used for nonnormally distributed 
continuous variables (median of the first and last 4 seizure durations, PIS values, 
and dosage of anesthetics). Possible correlations between the first index ECT 
sessions and the last c-ECT-sessions and between the time interval of consecutive 
c-ECT sessions on the one hand and patients’ and treatment characteristics on the 
other were calculated using Pearsons’ correlation coefficients, and Spearman’s rho 
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in case of nonnormally distributed variables. The time interval of right unilateral 
c-ECT (n=4) was compared with that of the bifrontotemporal c-ECT (n=46) with the 
Mann-Whitney U-test. Level of significance was P ≤ 0.05. 
Results
Patients’ characteristics
The demographic and clinical characteristics of the 50 patients are summarized 
in Table 1. Most patients were female (n=37; 74%) and the mean age (± SD) was 59 ± 
14 years. Almost all patients (n=46; 92%) were experiencing a medication-resistant 
mood disorder, mostly recurrent (n=43; 86%). The median illness duration was 10 
years (IQR, 4-18.5 years). The mean HDRS at the start of the index ECT was 23 ± 8 
points (n=30) and 10 ± 7 points at the last c-ECT sessions or end of treatment (n=29; 
paired t-test=5.542; df=26; P<0.0001). The mean CIRS score regarding somatic 
comorbidity remained unchanged.
Treatment characteristics
Table 2 summarizes the treatment characteristics of the 50 patients treated with 
c-ECT. Most of them were treated with ambulatory c-ECT  (n=47; 94%). The ECT was 
administered mostly bifrontotemporally (n=46; 92%), and in most cases, 
methohexital (n=29; 58%) or etomidate (n=19; 38%) were used as an anesthetic. 
Dosages of anesthetics at the first and last 4 sessions showed no significant 
differences. The median initial seizure threshold, which was measured in 40 
patients, was 63 mC (IQR, 49-151 mC). 
The mean time intervals between the 2 ECT sessions were 19 ± 11 days; in the bifronto-
temporal c-ECT a median of 20 days (IQR, 7-28 days; n=46), and in right unilateral 
c-ECT a median of 14 days (IQR, 7-26.5 days; n=4; Mann Whitney U-test=81.000; 
Z=-0.395; P=0.72). At the last 4 c-ECT-sessions, 15 patients (30%) were treated once a 
week and 17 patients (34%) with time intervals exceeding once every three weeks. 
A median of 28 (IQR, 16-59) ECT sessions was administered during a median c-ECT 
period of 393 days (IQR, 211-676 days). 
Comparison of first index ECT and last c-ECT sessions and their 
correlations
Table 3 shows that at the start of the index ECT, the mean values of the mean 
values of electrical stimulus dosage were 167.3 ± 120.6 mC and 360.7 ± 255.9 mC in 
the first 4 and last 4 c-ECT sessions, respectively. These mean values differed 
significantly (paired t-test -5.479; df=49; P<0.001) and also correlated significantly 
9
Retrospective study of continuation electroconvulsive therapy in 50 patients | 157
and positively (Pearson’s correlation coefficient, 0.287; P=0.043). In the first 4 index 
ECT sessions, the median values of the median values of motor and EEG seizure 
activity duration were 36 seconds (IQR, 32-49 seconds) and 59 seconds (IQR, 44-73 
seconds), respectively. In the last 4 c-ECT-sessions, the median values of the median 
values of motor and EEG seizure activity duration were 38 seconds (IQR, 28-47 
seconds) and 52 seconds (IQR, 40-66 seconds), respectively. These median values 
between the first 4 and last 4 sessions did not differ significantly, but the median 
of EEG duration in the first 4 sessions correlated significantly and positively with 
Table 1   Characteristics of patients (n=50) treated with continuation electro-
convulsive therapy (c-ECT) *
Sex
    Male
    Female
13 (26) 
37 (74)
Current age, mean ± standard deviation (SD); range, in years 59.3 ± 14.2; 20-85
Psychiatric diagnosis












Psychotic features present 13 (26)
Severity of depressive symptoms according to the HDRS$ 




Duration of disease before index ECT, median; IQR#, in years 10; 4-18.5
Severity of somatic comorbidity at start of the index ECT, measured 
with CIRS$$, mean ± SD (n=47)
21.0 ± 2.6
Indication for continuation ECT
  Psychopharmacological drugs resistant
  Psychopharmacological drugs contraindicated
  Patients’ preference





*Data are presented in numbers with percentages unless otherwise specified; #Interquartile range; 
$Hamilton Depression Rating Scale is a validated, observer-rated scale to measure severity and change of 
depressive symptoms, ranging from 0-54;¶Paired t-test=5.542; df=26; P<0.0001; $$Modified Cumulative 
Illness Rating Scale is a validated, observer-rated scale to measure severity of illnesses, ranging from 
14-70.
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the median EEG duration in the last 4 sessions (Spearman r=0.294, P=0.043). The 
median values of the PIS of the first 4 (90%; IQR, 85-95%) and the last 4 (94%; IQR, 
89-96%) sessions differed significantly (Wilcoxon signed ranks test; Z=-2.327; 
P=0.02) and were also significantly and positively correlated (Spearman r=0.470; 
P=0.001).
Correlation of the time interval between consecutive ECT sessions 
and patients’ and treatment characteristics
A higher number of days between c-ECT sessions correlated moderately but 
significantly with increased median duration of motor seizure activity (Spearman 
r=0.390; P=0.005) and with increased median duration of EEG seizure activity 
(Spearman r=0.351; P=0.013) as assessed during the last 4 c-ECT sessions (Figure 1). 
Table 2   Treatment characteristics of patients (n=50) treated with continuation 
ECT (c-ECT) *
Type of ECT, duration and treatment setting:
Mean number of days between two c-ECT sessions ± SD#
     in	right	unilateral	c-ECT	(n=4)
					in	bifrontotemporal	c-ECT	(n=46)	
Total number of c-ECT sessions, median; IQR#
Duration of c-ECT period, median; IQR, in days
ECT provided ambulatory
19.3 ± 11.2
   15.8 ± 10.5




Characteristics of c-ECT and anesthesia:
Bifrontotemporal electrode placement
Right unilateral electrode placement according to d’ Elia
Initial seizure threshold (n=40), median; IQR, in mC#
Use of etomidate, median dose and IQR, in mg#
Use of methohexital, median dose and IQR, in mg




19 (39); 20; 18-20¶
29 (59); 105; 72.5-127.5¶¶
1 (2); 20; 20-20
Most recent frequency of c-ECT: 
Once a week
Once every two weeks
Once every three weeks
Once every four weeks
Once every five weeks   







*Data are presented in numbers with percentages unless otherwise specified; #IQR=Interquartile range; 
SD=standard deviation; mC=milliCoulombs; mg= milligrams; ¶Median dose of etomidate at index-ECT 
was 20 mg (IQR, 19-20 mg); Wilcoxon Signed Ranks test revealed no difference compared with dose at 
c-ECT, Z=-1.394, P=0.16; ¶¶Median dose of methohexital at index-ECT was 110 mg (IQR, 78.8-150 mg); 
Wilcoxon Signed Ranks test revealed no difference compared with dose at c-ECT, Z=-0.631, P=0.53.
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The median PIS of the last c-ECT sessions showed no significant correlation with 
the time interval (Spearman r= -2.39; P=0.095). Higher patient age correlated 
moderately with higher initial seizure thresholds (Spearman r=0.504; P=0.001), 
with increased mean of the used electrical dosage of the last 4 c-ECT sessions 
(Pearson r=0.301; P=0.033) but not significantly with the median values of motor or 
EEG seizure duration. 
Table 3   Comparison of treatment characteristics in 50 patients treated with 
electroconvulsive therapy (ECT), calculated from the first 4 index ECT 
sessions and the last 4 continuation (c-ECT) sessions, and their 
correlations
At first 4 index  
ECT sessions 
At last 4  
c-ECT sessions
Mean stimulus dose ± SD* of, in mC*
Median duration of motor seizure activity; IQR*,  
in seconds
Median duration of EEG seizure activity; IQR,  
in seconds









*IQR=Interquartile range; SD=standard deviation; mC=milliCoulombs; #paired t=-5.479; df=49; P<0.0001; 
higher used electrical dosages at index ECT correlated with higher dosage at c-ECT, Pearson’s correlation 
coefficient 0.287; P=0.043; †Wilcoxon Signed Ranks Test showed no significant difference, P=0.589; no 
significant correlations between duration of motor seizure activity between index ECT and c-ECT, 
Spearman r=0.263, P=0.074; ††Wilcoxon Signed Ranks Test showed no significant difference, P=0.589; 
longer duration of EEG seizure activity at index ECT correlated with longer EEG seizure activity duration 
at c-ECT, Spearman r=0.294, P=0.043; ¶Wilcoxon Signed Ranks Test: Z=-2.327; P=0.02; higher PIS at index 
ECT correlated with higher PIS at c-ECT, Spearman r=0.470; P=0.001.
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Discussion
In this retrospective study among 50 patients who were treated with c-ECT, the 
frequency of c-ECT ranged from once a week to once every 4 to 6 weeks, whereas 
the mean time interval between consecutive c-ECT sessions was 19 days. A median 
of 28 ECT sessions was administered during the entire c-ECT period of a median of 
393 days. Compared with the baseline, the HDRS scores seemed to be decreased in 
c-ECT, which indicates the ability of c-ECT to sustain remission of depression. The 
electrical stimulus dosage increased significantly between the start of the index 
ECT and the 4 last sessions of c-ECT, and higher electrical dosage at index ECT was 
associated with higher electrical dosage administered in c-ECT. In addition, an 
increased time interval between consecutive c-ECT sessions correlated moderately 
with increased seizure duration but not with PIS, a parameter for seizure adequacy 
in ECT. 
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The association we found between increased seizure duration and increased time 
interval of c-ECT is in accordance with another study that showed increased 
seizure duration when time intervals exceeded 60 days; the latter authors 
suggested that the increase of seizure duration was a sign of decreased seizure 
threshold or loss of anticonvulsive action.8 In our study, however, seizure duration 
increased when the time interval was less than 60 days. 
In a comparable retrospective study among 41 patients (mean age, 63 years; 76% 
were female) undergoing c-ECT predominantly because of a mood disorder, 
patients were treated almost exclusively with right unilateral c-ECT; the time 
interval of treatments was mostly once every 2 weeks (n=10), and no patient was 
treated less than once every 3 weeks.20 In our study, the patients were almost 
exclusively treated bifrontotemporally, the median time interval was 20 days, and 
17 patients (34%) were treated with time intervals longer than once every 3 weeks. 
These differences might signify that the optimal time interval in bifrontotempo-
ral c-ECT is longer compared to right unilateral c-ECT. 
Seizure threshold increase is greater in bilateral index ECT than with unilateral 
ECT,21 and it has been suggested that seizure threshold would rapidly decline with 
greater spacing of c-ECT-sessions.11 In the present study, it was not possible to verify 
this decline because we did not measure seizure thresholds during the c-ECT 
period. Therefore, we cannot exclude that the electrical dosage was in excess of 
that which was needed to sustain remission. For this reason, some authors suggest 
repeated measurements of seizure threshold during ECT,11 particularly after 2 
months of treatment.8 
Because our study was retrospective, the results must be interpreted with caution, 
as various confounders (such as concomitant medication use or substance abuse) 
might have influenced seizure thresholds, electrical stimulus dosage used, seizure 
duration, and PIS. In addition, because patients’ electrical stimulus dosage during 
index-ECT and c-ECT was individualized and did not follow standard protocols, the 
increased electrical dosage at c-ECT is difficult to interpret.  
In conclusion, in the present study, electrical stimulus dosage in c-ECT was higher 
compared with index ECT. An increased time interval between consecutive c-ECT 
sessions correlated moderately with increased motor and EEG seizure duration, 
possibly indicating a decrease of seizure threshold or loss of anticonvulsive action 
when time intervals between c-ECT sessions increase. Further research is needed 
to determine whether bifrontotemporal c-ECT requires a lower frequency to 
sustain remission compared to unilateral c-ECT. 
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Electroconvulsive therapy (ECT) may greatly improve the lives of patients suffering 
from severe, disabling and life-threatening psychiatric diseases such as depression 
and catatonia. For decades it has been known that the efficacy of ECT is derived 
from an induced generalized seizure.1 However, under normal conditions the 
human brain is well-prepared to obstruct the spreading of uncontrolled, synchronous 
neuronal electrical signals, which characterizes seizure activity. Accordingly, 
seizure activity only develops when the ECT stimulus is capable of exceeding the 
brain’s seizure threshold (ST). The processes underlying seizure provocation, 
propagation and termination are exciting subject matters that may teach us more 
about the functioning of the brain and the pathophysiology of severe diseases 
including mood disorders and epilepsy. 
In the literature, the supposed working mechanisms of ECT and its several relevant 
technical aspects have been described. With respect to treatment effectiveness 
and (cognitive) adverse effects, there is still an ongoing debate about the most 
favorable electrode placement, electrical dosage, time interval between sessions 
and the optimal electrical stimulus parameters.2,3 While in ECT the goal is to 
excite large enough populations of neurons by direct electrical stimulation, it is 
necessary to overcome the resistance presented by the scalp and skull. Studies on 
how the electrical current finds its way to and through the brain are sparse. 
Investigations about the conditional working mechanisms for seizure provocation, 
propagation and termination in ECT and the barriers in these processes are also 
limited. This thesis explored various clinical and anatomical characteristics of the 
head and brain that may influence the ST as well as the outcome of ECT in patients. 
1. Summary of the main results
In Part 1, we first aimed to establish common levels of the initial ST (IST) in patients 
undergoing ECT. We were also interested in the determinants of ST levels. In our 
meta-analysis (Chapter	 2), we found a weighted overall mean level of IST of 68.2 
milliCoulombs (mC) (95% confidence interval [CI]: 63.2-73.3 mC) in right unilateral 
(RUL) and of 116.6 mC (95% CI: 103.7-119.4 mC) in bifrontotemporal (BL) ECT. With 
these results, we demonstrated that the average ranges of IST levels differed 
between RUL and BL electrode placement. Also, by using our established weighted 
IST means, the calculated ranges of the therapeutic stimulus doses in RUL and BL 
ECT appeared within the ranges of the ‘fixed-dose’ method in RUL and the ‘half-age’ 
method in BL ECT. Therefore, when using these formula-based methods, an 
electrical dosage can be administered to elicit an adequate seizure for most of the 
patients. However, there is considerable variation between patients, implying that 
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some patients are initially treated with a suboptimal electrical stimulus dosage, 
which can induce unnecessary adverse effects.
Based on literature reviews (Chapter	3	and	4), we subsequently determined several 
(established or proposed) clinical, brain anatomical and functional determinants 
of the IST and the ST during the ECT course. Clinically, a higher ST level was 
associated with advanced age, male gender, presence of comorbid medical illnesses, 
use of BL electrode placement, cumulative number of treatment sessions, lower 
dynamic impedance, and concomitant use of certain psychotropic and non-psy-
chotropic drugs. Anatomical factors such as increased scalp impedance, increased 
amount of cerebral atrophy, decreased neuronal density, increased neuronal 
damage marked by white matter hyperintensities (WMH; causing less functional 
connectivity between brain areas) and increased cerebrospinal fluid (CSF) volume 
were suggested to be associated with a higher ST. The following three functional 
brain characteristics can also be proposed to explain a higher ST. Firstly, a 
decreased metabolism in the brain’s prefrontal areas is proposed to explain higher 
ST. Secondly, an increased sensitivity to GABA through higher expression of 
GABA-receptors in the brain and thirdly, reduced concentrations of, or sensitivity 
to, glutamate in the brain can explain a higher ST.
In Part 2, we examined which patient, treatment and anatomical MRI characteris-
tics predicted the IST levels and the ST during the ECT course. This prospective 
clinical study was conducted including 91 patients with serious depression who 
were undergoing ECT (Chapter	5). Our study demonstrated that a higher age and BL 
electrode placement were independent predictors for a higher IST as well as for 
higher ST levels at different time points during the ECT course. Furthermore, the 
absence of a previous ECT course appeared to predict a steeper ST increase during 
the course, which finding - to our knowledge - has not been reported before. In 
accordance with the results of this study, we defined age and BL electrode 
placement as confounders in our subsequent MRI study. This study investigated 
the relationship between the IST and head and brain morphological characteris-
tics in 74 of the 91 patients.
In this MRI study (Chapter	6), after adjusting for age and gender, we found that the 
volume of CSF independently predicted the IST in RUL as well as in BL ECT, which 
– as far as we know – has not been reported before. In BL ECT, this relationship was 
much stronger than in RUL ECT. Moreover, the CSF volume predicted the 
consecutive ST levels during the ECT course in RUL ECT. These findings seem to 
support the hypothesis that more brain CSF leads to increased shunting of 
electrical current. This increased shunting makes the electrical field, which is 
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required to trigger seizure activity, weaker and more localized. This may result in 
a consequently higher ST.
In Part 3, we conducted an investigation with 83 patients in order to ascertain 
whether clinical, anatomical and treatment characteristics predicted their 
post-ECT scores of the Montgomery-Åsberg Depression Rating Scale (MADRS) and 
the Mini-Mental State Examination (MMSE) (Chapter	7). We demonstrated that the 
presence of psychotic depression and previous ECT exposure predicted a better 
outcome on the post-ECT MADRS score. Furthermore, the presence of bipolar 
depression at baseline predicted a better cognitive outcome, whereas the use of 
concomitant antipsychotics predicted a worse cognitive outcome. Baseline head 
MRI morphological characteristics were not predictive for post-ECT MADRS and 
MMSE scores.
In the above-mentioned prospective studies, we examined the ST in a common ECT 
population consisting of mostly pharmacotherapy resistant and/or psychotic 
depressed patients. Continuing these studies, we explored the characteristics of 
the ST in two special patient populations, including patients with catatonia and 
patients treated with continuation-ECT (c-ECT). In a retrospective study of 27 
patients with catatonia (Chapter	 8), we established that characteristics such as 
younger age, presence of autonomic dysregulation (especially fever) at baseline, 
daily ECT during the first treatment week, longer duration of the EEG seizure 
activity at the last ECT session, and less morbidity in the year after ECT were 
significantly associated with better clinical improvement. In these catatonic 
patients, quite often the ST was higher than expected and it was noticed, quite 
serendipitously, that the EEG improved simultaneously with the patients’ clinical 
condition. This may suggest that (pathophysiological mechanisms of) catatonia 
also affected the ST.
In our retrospective study of 50 patients treated with c-ECT (Chapter	9), we showed 
that an increased time-interval between consecutive c-ECT sessions correlated 
moderately with increased seizure duration, but not with increased post-ictal 
suppression on the EEG. In the literature, shorter seizure duration was related to a 
higher suprathreshold electrical stimulation,2,3 and the ST was supposed to 
decrease within a short period of time to the previous baseline level, at least in 
some patients.7 Therefore, when the time-interval between c-ECT sessions increases, 
a decrease of the ST or loss of anticonvulsant action was suggested.6 
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2.  Validity and generalizability of the results  
of our studies
Our studies may generate various methodological concerns regarding patient 
selection, study design (retrospective versus prospective), psychiatric diagnosis, 
technical confounders of the ST titration procedure, and limitations in the 
computerized analyses of the structural and functional MRI datasets. All these 
factors may have compromised to some extent the validity of the data and the 
generalizability of our results.
2.1 Selection bias and study design
In our studies, the included patients formed highly selected samples of the whole 
group of depressed patients. Therefore, diagnosing and treating patients with ECT 
in a large general teaching hospital such as Rijnstate in Arnhem (the Netherlands) 
may have induced bias in our studies. It is likely that the most somatically 
compromised ECT patients were treated in a general hospital like ours and not in 
ECT facilities with fewer somatic care capabilities. Several of these patients could 
be included in our prospective study (29 out of 91 patients [32%] showed a modified 
Cumulative Illness Rating Scale score ≥ 23). It is likely that in other ECT studies 
patients with various somatic illnesses were also included. However, in recent 
large multicenter ECT studies, the somatic conditions of the included patients 
were not described.15,16 Therefore, it is unclear whether our included patient 
population is representative for the entire population of ECT patients. This may 
have implications for the generalizability of our results and thus for the external 
validity with respect to future ECT patients. It is important, therefore, that our 
findings are replicated in different patient samples.
Some potential study patients had to be excluded from our prospective studies, 
mostly because they could not be exposed to the titration process due to their poor 
physical condition, extreme agitation that made adequate MRI scanning 
impossible, and/or inability to provide informed consent. As such, our findings 
cannot automatically be generalized to these somatically compromised and/or 
agitated patient groups. Our study group did however consist of severely depressed 
patients (mean MADRS score at baseline was high, showing 36.2±8.4 points), of 
whom 35% (n=31) also had psychotic features. This indicates that our prospective 
study group (Chapters	 5-7) represents a common population of studied ECT 
patients.2,8,15,16 In contrast, our retrospectively studied groups of catatonic (Chapter	
8) and c-ECT (Chapter	 9) patients were highly selected samples. This allows for 
inferences that are internally valid for this specific group of patients. Fortunately, 
in clinical practice, these patients rarely appear. They often show specific charac-
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teristics including persistent treatment-resistance, severe somatic comorbidity, 
concomitant benzodiazepines use, and treatment with different ECT session 
frequencies. Therefore, our findings may not necessarily apply to other more 
mildly somatically ill and depressed patients. 
It was further observed that almost all patients used concomitant medication 
during the ECT course. When treating severely ill patients in daily practice, it is 
virtually impossible to taper off all medication before ECT, especially regarding 
essential drugs for physical problems. To taper off all psychopharmacological 
drugs would also carry the risk of increased suffering to the patient. Although for 
some drugs, the effect on neuroexcitability in animal studies has been identified, 
it is not known how these medications might affect the ST in patients undergoing 
ECT. In our prospective observational studies on ST levels during the ECT course, 
all medication was continued unchanged during both the treatment period, as 
well as the titration protocol. However, the generalization of our results to patient 
populations who are drug-naive or who have been weaned off medication before 
ECT is likely to be limited.
2.2 Validity of psychiatric diagnoses
A limitation of our study may be that no standard diagnostic instruments (e.g., 
Structured Clinical Interview for DSM Disorders, or Mini-International Neuro-
psychiatric Interview) were used for formal psychiatric diagnosis according to 
DSM-IV-TR criteria. Patients had been referred for ECT from different treatment 
centers in the Netherlands and several psychiatrists had performed the mental 
status examinations of the patients and confirmed the psychiatric diagnosis for 
which ECT was indicated. We were also able to rate the Dutch version of the 
MADRS,9,10 in 91% of the study patients, thereby confirming and scoring the 
severity of the depressive symptoms. Based on this rating, we could ascertain that 
all our patients indeed suffered from a clinical diagnosis of depression. Regarding 
our retrospective studies, the diagnoses of catatonia and recurrent therapy-resis-
tant mood disorders had also been confirmed clinically by experienced 
psychiatrists and classified according to DSM-IV-TR.
2.3 Limitations in the titration process that was used 
In ECT, most electrons do not traverse the brain and the exact percentage of 
electrons that actually reaches the brain is not known. As we hypothesized, 
excessive shunting of electrons through the scalp and CSF in all likelihood occurs, 
but it was not possible to measure exactly the amount of shunting. The level of 
dynamic impedance is the only factor that may indirectly represent the level of 
shunting. This shunting could be due to factors as environmental temperature, 
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moisture of the air, electrode placement, electrode-skin interface, resistance of the 
patient’s hair, skin, skull, blood vessels, meninges, brain tissue and amount of CSF. 
However, we were not able to document these various factors and they, therefore, 
could not be taken into account. In other aspects, the stable treatment site, the 
experienced Rijnstate ECT team, and their consensus on how to perform ECT, may 
have adequately standardized many of the variables involved in the treatment of 
the study patients.  
Another limitation in validity and generalizability of our results is the titration 
process itself. In ECT, the ST is determined by several physical stimulus parameters, 
including pulse width, frequency, stimulus duration, and current strength. As 
other studies may have used different stimulus parameters, a comparison of our 
ST levels with those of other studies is difficult. Another difficulty in generalization 
of the estimated ST levels is the definition of adequate seizure duration in our 
study (≥ 20 seconds of motor and/or ≥ 25 seconds of EEG duration). Although this 
definition is often used internationally, it may not be comparable with other 
studies (see Chapter	2).11 Furthermore, with our used titration process, the ST levels 
were estimated very roughly in large steps of 25-100 mC. Also, our dosage 
increments during titration were accompanied by higher stimulus frequencies 
and train durations, not to mention change in pulse width at the final step in RUL 
ECT. These stimulus parameters supposedly also influenced the level of the ST.12,13 
An age-based adjustment in our titration protocol was also used in order to reduce 
the risk of unwanted subconvulsive stimulation in the mostly older patients. 
However, a truly informative ST would only have been established if an initially 
subconvulsive stimulus was followed by a stimulus which did elicit a seizure at the 
consecutive titration step.3 Our patients aged ≥ 50 years started one step higher 
(i.c., 50.4 mC) compared to the younger ones (25.2 mC).14 Consequently, the 
frequency of a lower IST was underestimated in the older patients. In our titration 
procedure, a substantial number of patients (n=64; 70%) showed adequate seizure 
activity at the first step and in these patients an overestimation of the level of the 
ST (‘floor effect’) may have occurred. Also, patients with very low STs were not 
detected with our titration procedure. This means that, for a patient with a very 
low ST (e.g., 5 mC), in whom the doubling of the threshold during the ECT course 
had taken place (e.g., 10 mC), we were not able to show this increase during the 
follow-up, as the first step in our titration protocol was 25 mC. These limitations 
make it difficult to draw conclusions about our examined ST levels. In clinical 
practice, however, these titration methods used are the best we have. 
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2.4 Limitations in the MRI data acquisition and analyses
MRI scanning of the brain serves as a non-invasive research method. The computerized 
segmentation tools facilitate reproducible estimates of the volumes of CSF, gray 
matter, white matter and WMH. In our study, some limitations were encountered. 
Firstly, the acquisition of our patients’ MRI data was fully integrated in the daily 
routine of our department of radiology in the Rijnstate Hospital, creating the 
opportunity to include very ill patients. However, our method to measure the 
thickness of scalp and skull on MRI was crude, showing an only moderate ICC 
ranging from 0.6-0.7 between two independent and experienced raters. Although 
using the mean of two raters reduced some measurement error, it cannot be 
excluded that measurement errors may have led to a reduced power in detecting a 
putative influence of scalp and skull thickness on the IST. Furthermore, the 
automatic FSL process to determine volumes of intracranial volume, CSF, gray 
and white matter and WMH, had several limitations. One such limitation may be 
that the brain extraction tool might have limited outer-brain CSF estimates, 
causing structural underestimation of the CSF volume. In some individual areas, 
the segmentation process had failed to make a correct distinction between the 
different brain tissues and CSF, and the registration processes (to correct for WMH) 
might have appointed some voxels to wrong structures, leading to slightly 
erroneous calculations of tissue volumes.
In a subgroup of our patients (n=58), we used functional MRI (fMRI), to examine 
whether the connectivity within the default-mode network (as an indication of the 
integrity of feedback circuitry within the brain and studied in epilepsy)4,5 was 
associated with the IST. Unfortunately, we were not able to establish a reliable 
default-mode network within our patient group, possibly as a result of disturbances 
during the fMRI data acquisition. Therefore, we could not examine the association 
between the IST and an indirect measurement of functional connectivity within 
the brain.     
3. Clinical implications of our study
Our results may have several clinical implications for the daily practice of ECT. The 
question arises however, as to whether the IST is indeed an important variable to 
consider in the clinical care of ECT patients. Perhaps thousands of patients are 
treated each year without any consideration of the individual IST by their treating 
psychiatrists using effective formula-based dosage methods. Having stated that, 
our study generates several recommendations for the clinical practice of ECT:
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• Clinicians can confidently use the 'fixed-dose' method in RUL and the 'half-age' 
dosing method in BL ECT, since in most of these patients the electrical doses may 
induce therapeutic seizures.
• Clinicians are advised to consider raising the stimulus dose during the ECT 
course, especially in BL treated patients who show limited clinical efficacy, 
because increasing STs during the ECT course are to be expected in these 
patients. 
• Clinicians should evaluate the necessity of electrical dose adjustments during 
the ECT course in patients who were previously treated with ECT, as ST stability 
during the ECT course may be expected. Repeated titration during the ECT 
course can help to evaluate the extent of the increase in the ST.
• In light of the expected favorable results, clinicians are advised to offer 
immediate ECT to patients with a psychotic depression and to patients who have 
had successful ECT before. 
• Clinicians are advised to taper off antipsychotics before ECT, but only if the 
clinical condition of the patient allows doing so. Our study showed some 
evidence that the use of antipsychotics is associated with an increase in cognitive 
adverse effects.
• Clinicians may decide to administer daily ECT sessions in the first week to treat 
a malignant catatonic patient with autonomic dysregulation. This frequency 
predicted a positive outcome for ECT in our retrospective study.
• In patients treated with c-ECT who experience an increase in cognitive adverse 
effects, clinicians are advised to estimate the ST again by titration and to adjust 
the electrical dose accordingly. Our retrospective study suggests a decrease of 
the ST when the time between the consecutive c-ECT sessions increases.
4. Suggestions for further research
Our results prompt further exciting research questions not only about the use of 
MRI in ECT practice, but also about the most optimal ECT dosing strategy, the 
various technical aspects, and the more basic issues of brain functioning and 
brain diseases. 
4.1 Perspectives on MRI research in ECT
Firstly, we should realize that we do not have enough scientific evidence at this 
time to recommend standard MRI evaluation for patients. This makes it difficult 
to use their individual brain characteristics in dosing strategies for ECT. More 
evidence from clinical studies is required to incorporate such an innovative 
approach in clinical practice. A pre-ECT head MRI scan (or other neuroimaging 
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technique), however, is always indicated if there is any clinical doubt about the 
existence of complicating factors in diagnosing or treating the ECT patient. For 
example, space-occupying processes, severe cerebrovascular diseases, head trauma, 
and skull damage are all clinical conditions that must be evaluated before initiating 
ECT. 
It is still a matter of debate as to whether adjusting the variable ‘volume of CSF’ to 
an ECT dosage algorithm will lead to a better outcome of mood and cognition after 
treatment. Preferably, other researchers should first replicate our estimated 
predictive value of CSF volume for the levels of IST and ST during the course. 
Subsequently, a randomized clinical trial should examine whether a dosing 
protocol, which adjusts for CSF volume as well as age, would show better outcomes 
than a protocol in which only higher age determines a higher electrical dosage. 
More prospective research should also be carried out in order to examine MRI data 
related to the clinical outcome of ECT. In our study, we did not show predictive 
values of the total volumes of CSF, gray matter, white matter and WMH for the 
clinical outcome. Yet further evaluation of these volumes in specific brain 
structures and areas may yield predictors for both the effectiveness and cognitive 
adverse effects in ECT. It would be exciting for clinicians in daily practice, if they 
could use an MRI scan to choose a more proper and individualized ECT dose, as 
well as to enhance the information they could give to their patients (and significant 
others) about the benefits and adverse effects of ECT.
4.2  Perspectives on clinical ECT dosing strategies and prediction 
of adverse effects  
As a result of our findings, it is important to explore in a randomized clinical trial 
whether a repeated dose titration method has a beneficial outcome compared to 
formula-based dosing methods. Additionally, it is essential to know whether the 
electrical dosage in those patients who were previously treated with ECT (as 
opposed to first-time treatment) can be held constant during the course with 
comparable clinical outcomes. Based on our outcome study, the important clinical 
question arises as to whether it can be confirmed using observational data, that 
continuing antipsychotics during the ECT course increases the risk for cognitive 
adverse effects. It should also be established whether bipolar patients show fewer 
cognitive adverse effects due to ECT and what might be the determinants for that 
positive effect. In bipolar patients, for example, it could be hypothesized that the 
use of lithiumcarbonate or another such mood stabilizer prior to ECT may prevent 
(or worsen) cognitive adverse effects. 
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4.3 Perspectives on technical considerations
Several technical topics for further exploration arise from the results of our 
studies. We have learned that research on the ST lacks an internationally accepted 
standard dosage titration protocol and we believe that the international ECT 
researchers should facilitate such standard. ECT devices, which are to be used in 
studies on ECT, should enable such titration protocols that allow very low dose 
administration to prevent ‘floor effects’ in the ST estimation. We have also 
established that the electrical stimulus parameters should be kept constant during 
the titration process, thereby using the same pulse width and/or frequency when 
titrating. These technical considerations should be implemented preferably in 
replication studies on the predictive value of CSF volume for IST and ST during the 
ECT course.
4.4  Perspectives on more basic issues in research of seizures  
and epilepsy
Aside from raising research questions regarding the treatment of psychiatric 
disorders, ECT can be used as a human model for seizure initiation, propagation 
and termination. With methods like fMRI and diffusion tensor imaging (DTI), 
non-invasive examination of the functional connectivity and anatomical 
connections within the human brain can occur. These variables can be related to 
the ST, seizure propagation patterns, and possibly the strength of the seizure 
termination process. This allows for further explorations, including the possibility 
to examine the feedback systems of the brain on seizure activity with fMRI. The 
amount of cerebral damage (e.g., due to WMH) in certain parts of the brain might 
be associated with connectivity patterns and neuroexcitability (e.g., higher or 
lower ST). An exploratory option to consider is whether cerebral damage may 
hamper seizure propagation through the human brain and/or the termination 
process. It is exciting to imagine that some basic research questions about human 
brain functioning and epilepsy might be examined with the help of ECT patients.
5. Concluding remarks
To conclude, our studies have revealed several exciting subject matters for further 
exploration regarding seizure thresholds in ECT. Yet, such a complex treatment as 
ECT encompasses much more than this small technical study. ECT increases the 
quality of life in these very ill (psychotic and/or suicidal) patients and is sometimes 
even life saving. Our prospective study replicated - again - high response and 
remission rates in the patients treated with ECT. Moreover, several practical 
 recommendations for clinicians can be derived from our studies. In particular, 
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suggestions were outlined regarding predictors of outcome, electrical dosage, 
session frequency and concomitant medication use. It is intended that this thesis 
should add to our knowledge about ECT and thereby also helps to improve the care 
for our patients. That’s the most exciting matter of all.
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Spannende zaken bij elektroconvulsietherapie. 
Studies naar prikkeldrempels.
Elektroconvulsietherapie (ECT) verbetert vaak het leven van patiënten die lijden 
aan ernstige, invaliderende en/of levensbedreigende psychiatrische aandoeningen 
zoals depressie en katatonie. Sinds decennia is bekend dat het effect van ECT 
afhankelijk is van de opgewekte gegeneraliseerde insultactiviteit in de hersenen. 
Het menselijk brein is echter gemaakt om cerebrale ontregeling met verspreiding 
van ongecontroleerde, overgesynchroniseerde, neuronale elektrische signalen te 
voorkomen. Daardoor ontstaat insultactiviteit alleen als de elektrische stimulus in 
staat is de zogenaamde prikkeldrempel (ST) te overstijgen. De mechanismen die 
ervoor zorgen dat een insult wordt uitgelokt, zich verspreidt en weer wordt 
onderdrukt, zijn ‘spannende’ zaken die ons meer kunnen leren over het functioneren 
van de hersenen en over de pathofysiologie van ernstige ziekten zoals depressie en 
epilepsie. In dit proefschrift onderzochten wij diverse klinische en anatomische 
eigenschappen van hoofd en hersenen bij ECT patiënten die de ST zouden kunnen 
beïnvloeden.
Vanuit de literatuur zijn er verschillende werkingsmechanismen en relevante 
technische aspecten van ECT beschreven. Er is tot op heden nog steeds discussie 
over wat de meest optimale elektrodeplaatsing, de elektrische dosering, het 
tijdsinterval tussen behandelingen en elektrische stimulus eigenschappen 
(bijvoorbeeld stroomsterkte, pulswijdte, pulsfrequentie, stimulusduur) zijn in 
relatie tot het behandeleffect en de (cognitieve) bijwerkingen. Bij ECT is het doel 
een optimale hoeveelheid neuronen te prikkelen door directe elektrische 
stimulatie. Het is hierbij noodzakelijk om de weerstand van de hoofdhuid en 
schedel te trotseren. Studies die onderzoeken hoe de stroom naar en door de 
hersenen haar weg vindt zijn schaars. Ook de mechanismen die voorwaardelijk 
zijn voor insultprovocatie, -verspreiding en -beëindiging zijn weinig onderzocht. 
In dit proefschrift worden diverse klinische en anatomische kenmerken van het 
hoofd en het brein onderzocht in relatie tot de hoogte van de ST en de effectiviteit 
van ECT bij patiënten.
Samenvatting van de belangrijkste resultaten
In deel 1 hebben we de gemiddelde ST bij ECT patiënten vastgesteld door middel 
van een meta-analyse van de internationale literatuur (hoofdstuk	2), waarbij een gewogen 
gemiddelde initiële prikkeldrempel (IST) werd berekend van 68.2 milliCoulombs 
(mC; 95%-betrouwbaarheidsinterval [95%-BI]: 63.2-73.3 mC) bij rechts unilateraal 
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(RUL) behandelde patiënten, en van 116.6 mC (95%BI: 103.7-119.4 mC) bij bilateraal 
(BL) behandelde patiënten. Hiermee toonden wij aan dat de gemiddelde IST 
spreiding bij RUL verschilde van die bij BL elektrode plaatsing. Daarbij bleek ook 
dat de spreiding van de therapeutische elektrische doses, berekend met deze 
gewogen gemiddelden, in overeenstemming was met de spreiding van de doses die 
worden toegediend bij gebruik van de zogenaamde “vaste-hoge-dosis” methode bij 
RUL en bij de “halve-leeftijd” methode bij BL ECT. 
Vervolgens onderzochten wij in de wetenschappelijke literatuur (hoofdstukken	3	en	
4) welke klinische, anatomische en/of functionele kenmerken van ECT patiënten 
waren vastgesteld of verondersteld als mogelijke voorspellers voor de IST en ST 
waarden tijdens de ECT kuur. Een hogere leeftijd, mannelijk geslacht, aanwezigheid 
van somatische comorbiditeit, het gebruik van BL elektrodeplaatsing, een toenemend 
aantal ECT-sessies, een lagere dynamische weerstand en het gebruik van bepaalde 
(psycho-)farmaca werden geassocieerd met een hogere IST. Vanuit anatomisch 
oogpunt werden de volgende kenmerken beschreven als mogelijke factoren die de 
ST zouden kunnen verhogen: een toegenomen weerstand van de hoofdhuid, 
toegenomen hoeveelheid hersenatrofie, afname van de neuronale densiteit en 
toename van het volume aan hersenvocht. Vanuit het oogpunt van functionele 
herseneigenschappen werd een afgenomen metabolisme in de prefrontale gebieden 
gesuggereerd als samenhangend met een hogere IST, alsmede toegenomen neuronale 
schade door wittestofafwijkingen (waardoor een vermindering zou kunnen 
optreden van de mate van verbintenissen binnen de hersenen), een toename van 
de gevoeligheid voor gamma-aminoboterzuur (GABA) door een hogere expressie 
van de cerebrale GABA-receptoren, en een afname van de  glutamaatconcentratie 
in de hersenen.
In deel 2 onderzochten wij, aansluitend op deze studies, in een prospectieve, 
observationele studie welke patiënt-, behandelings-, en anatomische MRI-kenmerken 
voorspellend waren voor de hoogte van de IST en de ST tijdens de ECT kuur. In onze 
studie bij 91 ECT patiënten met ernstige depressieve symptomen (hoofdstuk	 5) 
toonden wij aan dat een hogere leeftijd en BL elektrodeplaatsing onafhankelijke 
voorspellers waren van een hogere IST, maar ook van hogere ST waarden tijdens de 
ECT-kuur. Daarnaast lieten wij zien dat, als een patiënt voor het eerst in zijn/haar 
leven ECT kreeg, de ST vaker en hoger steeg dan bij patiënten die eerder een 
ECT-kuur hadden ondergaan. We definieerden vervolgens leeftijd en elektrode-
plaatsing als mogelijke confounders voor de relatie tussen anatomische kenmerken 
en IST.
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In onze MRI studie (hoofdstuk	6) toonden wij aan dat, gecorrigeerd voor leeftijd en 
geslacht, het totale volume aan hersenvocht onafhankelijk de hoogte van de IST 
voorspelde, zowel bij RUL als BL behandelde ECT patiënten. Dit was, voor zover wij 
weten, niet eerder in de literatuur beschreven. In BL toegediende ECT was dit 
verband sterker dan in RUL ECT. Bovendien voorspelde de hoeveelheid hersenvocht 
de hoogte van de ST tijdens de ECT-kuur in de RUL behandelde patiënten. Onze 
bevinding is in overeenstemming met de hypothese dat meer hersenvocht leidt tot 
meer weglekken van elektrische stroom, gepaard gaande met een zwakker en 
meer lokaal elektrisch veld dat een insult kan uitlokken. De consequentie daarvan 
is dan een hogere ST.
In een subgroep van deze patiënten (n=58) probeerden we met functionele MRI in 
rust (‘resting	state	fMRI’) te onderzoeken of er een relatie was tussen de hoogte van 
de IST en de mate van connectiviteit binnen het zogenaamde default-mode netwerk 
(als aanwijzing voor de kracht van het negatieve terugkoppelingssysteem van de 
hersenen, zoals bestudeerd in epilepsie). Helaas is dit niet gelukt, omdat we in 
onze groep geen default-mode	 netwerk konden vaststellen, mogelijk door 
verstoringen bij het verzamelen van de fMRI gegevens.
Tenslotte, onderzochten we in deel 3 bij 83 patiënten prospectief welke klinische-, 
anatomische- en behandelingskenmerken voorspellend waren voor de uitkomsten 
op de Montgomery-Åsberg Depressie Beoordelingsschaal (MADRS) en de Mini- 
Mental State Examination (MMSE) (hoofdstuk	7). Wij lieten zien dat de aanwezigheid 
van een psychotische depressie en het hebben gehad van een eerdere ECT-kuur 
voorspellend waren voor een betere eind-MADRS score. Daarnaast bleek de 
aanwezigheid van een bipolaire depressie een beter cognitief functioneren na de 
ECT-kuur te voorspellen. Het gelijktijdig gebruik van antipsychotica tijdens de 
ECT-kuur bleek daarentegen een lager cognitief functioneren na ECT te voorspellen. 
De MRI kenmerken waren geen van alle voorspellend voor de MADRS en MMSE 
scores na ECT.
In het hierboven beschreven onderzoek bestudeerden we de gebruikelijke ECT 
patiëntengroep. Dit zijn patiënten met meestal farmacotherapieresistente en/of 
psychotische depressies. In het laatste deel van dit proefschrift werden twee 
bijzondere ECT groepen in relatie tot de ST bekeken, namelijk de katatone 
patiënten en de patiënten die behandeld werden met onderhouds-ECT (c-ECT). In 
een retrospectieve studie onder 27 katatone patiënten (hoofdstuk	8) beschreven wij 
dat jongere leeftijd, autonome dysregulatie (met name koorts) aan het begin van 
de ziekteperiode, dagelijks toegediende ECT-sessies, langere insultactiviteit op het 
elektro-encefalogram (EEG) bij de laatste ECT-sessie, en minder comorbiditeit in 
186 | Chapter 11
het jaar na staken van de ECT geassocieerd waren met een betere behandeluit-
komst. Bij deze katatone patiënten was de ST vaak onverwacht hoog. Ook viel op 
dat het EEG tegelijkertijd met de conditie van de patiënt verbeterde, wat suggereert 
dat (de pathofysiologie van) katatonie de prikkeldrempel beïnvloedt.
In onze retrospectieve studie van 50 patiënten die werden behandeld met c-ECT 
(hoofdstuk	 9) lieten we zien dat een toename in het tijdsinterval tussen twee 
ECT-sessies redelijk correleerde met een toegenomen insultduur, maar niet met 
een hogere post-ictale onderdrukking van het EEG. Een kortere insultduur werd in 
de literatuur beschreven bij een hogere (boven de ST uitstijgende) elektrische 
stimulus. Dit was waarschijnlijk eerder het geval als er meer tijd tussen de sessies 
in zat, omdat de ST in de tussentijd meer kon dalen. Daarom werd bij een toename 
van het tijdsinterval tussen de ECT-sessies een afname van de ST of een verlies aan 
anticonvulsieve werking van ECT gesuggereerd. 
In het afsluitende hoofdstuk (hoofdstuk	10) wordt een opsomming gegeven van de 
belangrijkste bevindingen en daaruit voortvloeiende klinische implicaties van 
ons onderzoek:
• Clinici kunnen met vertrouwen de "vaste-dosis methode" bij RUL behandelde 
patiënten en de "halve-leeftijd" methode bij BL behandelde patiënten gebruiken, 
omdat daarmee de elektrische dosis bij de meeste patiënten een therapeutisch 
insult opwekt.
• Clinici worden geadviseerd te overwegen om tijdens de ECT kuur de stimulusdosis 
te verhogen, in ieder geval bij BL behandelde patiënten die slechts een beperkte 
verbetering vertonen, omdat bij deze patiënten steeds hogere STs tijdens de kuur 
kunnen worden verwacht.
• Clinici zouden bij patiënten die eerder ECT hebben gehad de noodzaak tot 
aanpassing van de elektrische dosis moeten evalueren tijdens de kuur, omdat bij 
deze patiënten een constante ST kan worden verwacht. Herhaalde  titratiesessies 
tijdens de ECT-kuur kunnen helpen om vast te stellen in welke mate  de ST stijgt 
tijdens de kuur.
• Clinici worden geadviseerd direct ECT aan te bieden aan psychotisch depressieve 
patiënten en aan patiënten die eerder gunstig op ECT hebben gereageerd, omdat 
deze patiënten vaak goed opknappen op ECT.
• Clinici worden geadviseerd om voor ECT de antipsychotica af te bouwen en te 
staken (indien de klinische toestand van de patiënt dit toelaat), omdat er enige 
aanwijzingen zijn dat het gebruik van antipsychotica tijdens de ECT-kuur was 
geassocieerd met meer cognitieve bijwerkingen. 
• Clinici kunnen besluiten over te gaan tot dagelijkse ECT sessies bij maligne 
katatone patiënten met autonome dysregulatie, omdat in onze retrospectieve 
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studie dagelijkse toediening geassocieerd was met een positieve uitkomst van de 
ECT.
• Clinici worden geadviseerd bij onderhouds-ECT patiënten die steeds meer 
cognitieve bijwerkingen ervaren, de ST opnieuw te bepalen met titratie en 
vervolgens de dosis hierop aan te passen, omdat onze retrospectieve studie een 
afname van de ST suggereert als het tijdsinterval tussen twee c-ECT sessies 
toeneemt.   
Tenslotte worden in dit hoofdstuk de zwakten beschreven van ons onderzoek, de 
problemen die we tegenkwamen bij de verzameling, analyse en interpretatie van 
de resultaten, en doen wij voorstellen voor verder onderzoek.




Aan de totstandkoming van dit proefschrift hebben veel mensen bijgedragen die 
ik hiervoor hartelijk wil bedanken. Bovenal geldt mijn grote waardering aan alle 
patiënten die meededen aan mijn onderzoek. Ondanks de extreem zware tijd 
waarin zij zich op dat moment bevonden, gaven zij hiervoor hun toestemming. Ik 
heb daar veel respect voor. 
In het ziekenhuis behandelen dokters patiënten nooit alleen en de zorgeenheid 
psychiatrie van Ziekenhuis Rijnstate is daarbij uniek in zijn soort. Alle verpleeg-
kundigen, vaktherapeuten, klinisch psychologen, overige paramedici, secretaresses, 
en management bedank ik hartelijk voor hun dagelijkse inzet daarbij. 
Hooggeleerde Van der Mast, promotor, beste Roos, weledelzeergeleerde Giltay, 
co-promotor, beste Erik, en weledelzeergeleerde Verwey, co-promotor, beste Bas. 
Dit dankwoord is te kort en mijn waardering voor jullie te groot om in deze beperkte 
regels genoeg dank uit te schrijven voor jullie hulp bij de totstandkoming van dit 
proefschrift.
Daarnaast bedank ik mijn maatschap van psychiaters in Rijnstate (Michael Müller, 
Joep Tuerlings, Boudewijn de Pont, Roy Derikx en - tot voor kort - Martijn Bevers), 
voor de belangrijke rol die zij hebben gespeeld in het ontstaan van dit proefschrift 
en de uitvoering van de prospectieve studie. Verder waren er tijdens dit promotie-
traject diverse mensen die me hielpen bij de organisatie, totstandkoming en/of 
publicatie van het onderzoek. Slechts enkelen kan ik hier met naam en toenaam 
bedanken: Max Stek, van wie ik de praktische toepassing van ECT leerde; Walter 
van den Broek, die mij hielp bij de allereerste opzet van het onderzoek; Nic van der 
Wee, Serge Rombouts en Nienke Pannekoek, die hielpen bij de MRI data analyses; 
Oscar Büno Heslinga, ECT-verpleegkundige in Rijnstate, die onmisbaar was bij de 
uitvoering van de prospectieve studie; Lian Roovers, epidemiologe van het weten-
schapsbureau van Rijnstate, die statistische adviezen gaf bij de eerste retrospectieve 
studies; Marijn Kroes, die zijn neurowetenschappelijke input gaf en bijdroeg aan 
het onderzoeksklimaat op onze afdeling; Bart Tonino, Marc van Driel en Gonda 
Nienhuis, en alle andere betrokken laboranten en secretaresses van de zorgeenheid 
radiologie/nucleaire geneeskunde bij Ziekenhuis Rijnstate, die zich altijd zeer 
behulpzaam opstelden bij de uitvoering van de prospectieve studie. 
Een bijzonder woord van dank is voor Lucas van Oudheusden, inmiddels psychiater 
in opleiding, en mijn paranimf. Jouw onvoorwaardelijke steun en werk met de (f)
MRI data was fantastisch. Onze cursusreis naar Montréal was een verrijking en 
levenslang memorabel. Erg veel dank, en we zien ons snel weer.
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Naast werk is er privé. Vele mensen zijn voor mij belangrijk. Slechts een paar noem 
ik hier bij naam. Allereerst Peter van den Berg, mijn voorbeeld als het gaat om het 
combineren van een drukke artsenpraktijk en het bedrijven van wetenschap. Leuk 
dat ik je al jaren ken, inmiddels samen met je gezin. We gaan vooral weer eens 
eten.
Jeroen Oldenburg, beste vriend voor het leven, mijn paranimf. Na onze gezamenlijke 
studietijd is onze hechte band altijd blijven bestaan. Mijn leven heeft vele mooie 
momenten, mede dankzij jouw aanwezigheid daarin, niet te vergeten samen 
met Birgit, Ruben en Tom. Ik ga er vanuit dat we dit nog tot hoogbejaarde leeftijd 
volhouden.  
Een mens wordt gemaakt door twee anderen. Ik ben geworden zoals ik nu ben, 
mede door de basis die werd gelegd door Han en José van Waarde, mijn ouders. 
Jullie onvoorwaardelijke steun vanaf mijn vroege jeugd en inzicht dat ik vooral 
zelf moet exploreren en ontdekken in het leven, zijn daarbij van onschatbare 
waarde. Het is niet voor niets dat jouw kunstwerk, dat je me gaf voor mijn vwo 
diploma, mijn proefschrift totaal omvat. Dit staat metafoor voor mijn bestaan in 
een veilige omgeving met jullie altijd bij me.
Een mens kan zijn wie hij is dankzij een metgezel in het leven. Frank is mijn liefste 
en dat blijft hij.  
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